

CITATION REPORT

List of articles citing

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

DOI: 10.1016/j.neuron.2011.09.010
Neuron, 2011, 72, 257-68.

Source: <https://exaly.com/paper-pdf/50356770/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2261	A hexanucleotide repeat expansion in C9ORF72 links amyotrophic lateral sclerosis and frontotemporal dementia. 2011 , 7, 595		16
2260	Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. 2011 , 7, 603-15		511
2259	FTD and ALS: genetic ties that bind. <i>Neuron</i> , 2011 , 72, 189-90	13.9	24
2258	Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. 2011 , 7, 616-30		428
2257	[Frontotemporal lobar degeneration (FTLD) concept and classification update]. 2011 , 51, 844-7		2
2256	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. <i>Neuron</i> , 2011 , 72, 245-56	13.9	3267
2255	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. 2011 , 122, 673-90		245
2254	p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. 2011 , 122, 691-702		369
2253	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. 2011 , 122, 657-71		120
2252	C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. 2011 , 122, 653-5		8
2251	Clinical phenomenology and neuroimaging correlates in ALS-FTD. 2011 , 45, 656-62		37
2250	SIGMAR1 mutations, genetic heterogeneity at the chromosome 9p locus, and the expanding etiological diversity of amyotrophic lateral sclerosis. 2011 , 70, 867-70		6
2249	New considerations in the design of clinical trials for amyotrophic lateral sclerosis. 2011 , 1, 1375-1389		29
2248	Towards unveiling the genetics of neurodegenerative diseases. 2011 , 31, 531-41		52
2247	Genetics of dementia. 2011 , 31, 449-60		37
2246	Neurogenetics: Five new things. 2011 , 1, 41-48		1
2245	Expanding ALS and FTD genetics. 2011 , 12, 616-616		

2244	A raw nerve. 2011 , 17, 1333-5	1
2243	Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies. 2011 , 12, 6980-7003	16
2242	The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry. 2011 , 6, e27985	44
2241	[Amyotrophic lateral sclerosis--diagnosis and treatment]. 2012 , 101, 907-14	1
2240	Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. 2012 , 83, 358-64	154
2239	FTD/ALS families are no longer orphaned: the C9ORF72 story. 2012 , 79, 962-4	4
2238	Detection of structural variants and indels within exome data. 2011 , 9, 176-8	93
2237	Amyotrophic lateral sclerosis, frontotemporal lobar dementia, and p62: a functional convergence?. 2012 , 79, 1526-7	5
2236	Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. 2012 , 8, e1002707	174
2235	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. 2012 , 135, 794-806	306
2234	C9ORF72 hexanucleotide repeat expansions in patients with ALS from the Coriell Cell Repository. 2012 , 79, 482-3	12
2233	Diced triplets expose neurons to RISC. 2012 , 8, e1002545	12
2232	Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration. 2012 , 2012, 908724	10
2231	Pathological roles of wild-type cu, zn-superoxide dismutase in amyotrophic lateral sclerosis. 2012 , 2012, 323261	18
2230	From Transcriptome to Noncoding RNAs: Implications in ALS Mechanism. 2012 , 2012, 278725	13
2229	Amyotrophic lateral sclerosis: update and new developments. 2012 , 2012, 1-14	56
2228	Hyperexcitability and amyotrophic lateral sclerosis. 2012 , 78, 1544-5	15
2227	Early-onset familial Alzheimer's disease (EOFAD). 2012 , 39, 436-45	126

2226	Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. 2012 , 21, 2412-9	27
2225	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. 2012 , 135, 693-708	420
2224	Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. 2012 , 6, 48	65
2223	Amyotrophic lateral sclerosis. 2012 , 25, 530-5	74
2222	Current world literature. 2012 , 25, 640-8	
2221	How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?. 2012 , 25, 689-700	136
2220	Road to the chromosome 9p-linked ALS/FTD locus. 2012 , 83, 356-7	7
2219	C9orf72 hexanucleotide repeat expansions as the causative mutation for chromosome 9p21-linked amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 69, 1159-63	16
2218	C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. 2012 , 79, 995-1001	93
2217	Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. 2012 , 78, 1519-26	47
2216	Drug discovery: Kill the messenger where it lives. 2012 , 488, 36-8	1
2215	Evidence for an oligogenic basis of amyotrophic lateral sclerosis. 2012 , 21, 3776-84	251
2214	Potential utility of biomarkers in the diagnosis and treatment of amyotrophic lateral sclerosis. 2012 , 2, 107-117	0
2213	Suicide attempt as the presenting symptom of C9orf72 dementia. 2012 , 169, 1211-3	18
2212	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. 2012 , 135, 765-83	277
2211	Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. 2012 , 79, 878-82	81
2210	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. 2012 , 135, 709-22	172
2209	Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. 2012 , 135, 652-5	51

2208	Repeat expansion in C9ORF72 in Alzheimer's disease. 2012 , 366, 283-4	142
2207	A novel TARDBP insertion/deletion mutation in the flail arm variant of amyotrophic lateral sclerosis. 2012 , 13, 465-70	11
2206	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. 2012 , 135, 736-50	340
2205	[ALS and frontotemporal dementia - case report and review of the literature]. 2012 , 80, 711-9	2
2204	Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside. 2012 , 32, 173-8	18
2203	The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. 2012 , 44, 817-28	141
2202	Analysis of European case-control studies suggests that common inherited variation in mitochondrial DNA is not involved in susceptibility to amyotrophic lateral sclerosis. 2012 , 13, 341-6	9
2201	Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. 2012 , 44, 704-8	170
2200	Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. 2012 , 17, 1277-330	50
2199	An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. 2012 , 109, 5074-9	129
2198	Frontotemporal dementia: implications for understanding Alzheimer disease. 2012 , 2, a006254	101
2197	Caenorhabditis elegans RNA-processing protein TDP-1 regulates protein homeostasis and life span. 2012 , 287, 8371-82	44
2196	Spinal cord markers in ALS: diagnostic and biomarker considerations. 2012 , 13, 407-15	39
2195	Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. 2012 , 83, 365-7	54
2194	Clinico-pathological correlations of the most common neurodegenerative dementias. 2012 , 3, 68	23
2193	Behavioral variant frontotemporal lobar degeneration with amyotrophic lateral sclerosis with a chromosome 9p21 hexanucleotide repeat. 2012 , 3, 136	5
2192	ALS and Frontotemporal Dysfunction: A Review. 2012 , 2012, 806306	48
2191	RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. 2012 , 2012, 432780	19

2190	Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. 2012 , 21, 2899-911	207
2189	How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?. 2012 , 25, 701-7	26
2188	Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. 2012 , 79, 1002-11	151
2187	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobendegeneration. 2012 , 36,	1
2186	Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. 2012 , 135, 751-64	236
2185	Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. 2012 , 135, 819-32	80
2184	Young-onset amyotrophic lateral sclerosis: historical and other observations. 2012 , 135, 2883-91	47
2183	Identification of pharmacological targets in amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways. 2012 , 13, 321-33	10
2182	Genetics and expression analysis of the specificity protein 4 gene (SP4) in patients with Alzheimer's disease and frontotemporal lobar degeneration. 2012 , 31, 537-42	6
2181	Transmission of C9orf72 hexanucleotide repeat expansions in sporadic amyotrophic lateral sclerosis: an Australian trio study. 2012 , 23, 556-9	14
2180	Ask the Experts: Translating amyotrophic lateral sclerosis genetics to the clinic: implications for the patient. 2012 , 2, 355-360	
2179	The use of next-generation sequencing in movement disorders. 2012 , 3, 75	19
2178	[Identification of a new causative gene of amyotrophic lateral sclerosis; optineurin]. 2012 , 52, 1-5	1
2177	[Frontotemporal lobar degeneration (FTLD) - changes of its concept and classification based on aggregated proteins]. 2012 , 52, 1218-20	1
2176	[Alzheimer's disease and related disorders: specificity of young onset patients, including ethical aspects]. 2012 , 10, 65-72	2
2175	Ask the Experts: Progress in diagnosing frontotemporal lobar dementia. 2012 , 2, 251-254	
2174	VALUES: a national multicenter study of regional and gender differences in frontotemporal disease in amyotrophic lateral sclerosis. 2012 , 2, 325-336	3
2173	C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. 2012 , 2, 1016	234

2172	Frontotemporal dementia in a Brazilian kindred with the c9orf72 mutation. 2012 , 69, 1149-53	32
2171	Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72. 2012 , 69, 1164-9	16
2170	Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype?. 2012 , 259, 1749-51	44
2169	Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. 2012 , 79, 2201-8	43
2168	TDP-43 and FUS/TLS yield a target-rich haul in ALS. 2012 , 15, 1467-9	7
2167	EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. 2012 , 19, 1159-79	191
2166	Endoplasmic Reticulum (ER) Stress in Amyotrophic Lateral Sclerosis (ALS). 2012 , 323-337	2
2165	Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. 2012 , 49, 258-63	131
2164	Extensive genetics of ALS: a population-based study in Italy. 2012 , 79, 1983-9	117
2163	Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients. 2012 , 13, 265-9	13
2162	Using Exome Sequencing to Reveal Mutations in TREM2 Presenting as a Frontotemporal Dementia-like Syndrome Without Bone Involvement. 2012 , 1	5
2161	Presymptomatic studies in ALS: rationale, challenges, and approach. 2012 , 79, 1732-9	63
2160	Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. 2012 , 79, 2315-20	52
2159	TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. 2013 , 33 Suppl 1, S35-45	31
2158	Recent advances in the imaging of frontotemporal dementia. 2012 , 12, 715-23	31
2157	Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. 2012 , 13, 245-50	104
2156	Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. 2012 , 488, 499-503	416
2155	Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. 2012 , 124, 733-47	91

2154	SCA6 presenting with young-onset parkinsonism without ataxia. 2012 , 27, 1067-8	9
2153	Mouse models of frontotemporal dementia. 2012 , 72, 837-49	61
2152	C9ORF72 expansion is not a significant cause of sporadic spinocerebellar ataxia. 2012 , 27, 1832-3	20
2151	The genetics and neuropathology of frontotemporal lobar degeneration. 2012 , 124, 353-72	206
2150	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. 2012 , 124, 373-82	69
2149	The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. 2012 , 124, 717-32	57
2148	Frontotemporal lobar degeneration: current knowledge and future challenges. 2012 , 259, 2278-86	31
2147	Molecular evaluation of human ubiquilin 2 gene PXX domain in familial frontotemporal dementia patients. 2012 , 259, 2488-90	2
2146	Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the c9orf72 gene. 2012 , 259, 2723-5	35
2145	Misregulated RNA processing in amyotrophic lateral sclerosis. 2012 , 1462, 3-15	124
2144	Increasing MuSK activity delays denervation and improves motor function in ALS mice. 2012 , 2, 497-502	56
2143	FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. 2012 , 2, 799-806	188
2142	Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. 2012 , 2, 789-98	103
2141	Neuroimaging in amyotrophic lateral sclerosis. 2012 , 6, 319-37	112
2140	A practical approach to molecular diagnostic testing in neuromuscular diseases. 2012 , 23, 589-608	17
2139	Association of UBQLN1 mutation with Brown-Vialetto-Van Laere syndrome but not typical ALS. 2012 , 48, 391-8	15
2138	[Which information is given to ALS patients carrying the pathogenic hexanucleotide repeat expansion of c9orf72?]. 2012 , 168, 775-7	
2137	Progranulin axis and recent developments in frontotemporal lobar degeneration. 2012 , 4, 4	14

2136	Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. 2012 , 4, 27	27
2135	Cognitive and behavioral features of c9FTD/ALS. 2012 , 4, 29	16
2134	Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 4, 30	6
2133	C9orf72 immunohistochemistry in Alzheimer's disease. 2012 , 4, 37	
2132	Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease. 2012 , 4, 38	26
2131	Neuroimaging features of C9ORF72 expansion. 2012 , 4, 45	20
2130	Treatment implications of C9ORF72. 2012 , 4, 46	9
2129	Assessment of psychiatric changes in C9ORF72 frontotemporal dementia. 2012 , 4, 49	1
2128	Motor neuron disease: the C9orf72 hexanucleotide repeat expansion in FTD and ALS. 2012 , 8, 249-50	13
2127	Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. 2012 , 13, 302-10	34
2126	Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: the Italian multicentre study. 2012 , 13, 580-4	7
2125	Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. 2012 , 31, 581-91	29
2124	ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. 2012 , 83, 730-3	52
2123	Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer's disease cerebrospinal fluid biomarkers. 2012 , 32, 19-22	25
2122	Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. 2012 , 33, 839.e1-3	28
2121	Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. 2012 , 33, 1488.e15-6	14
2120	Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. 2012 , 33, 1846.e1-4	32
2119	Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer's disease. 2012 , 33, 1846.e5-6	36

2118	ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. 2012 , 33, 1847.e15-21	24
2117	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. 2012 , 33, 1848.e15-20	63
2116	Screening for C9ORF72 repeat expansion in FTLD. 2012 , 33, 1850.e1-11	40
2115	Familial Lund frontotemporal dementia caused by C9ORF72 hexanucleotide expansion. 2012 , 33, 1850.e13-6	11
2114	High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients. 2012 , 33, 1851.e1-5	35
2113	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. 2012 , 33, 1851.e17-9	12
2112	CGG-repeat expansion in FMR1 is not associated with amyotrophic lateral sclerosis. 2012 , 33, 1852.e1-3	6
2111	Screening of the TARDBP gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. 2012 , 33, 2229.e11-2229.e18	19
2110	UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. 2012 , 33, 2230.e1-2230.e5	30
2109	A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. 2012 , 33, 2232.e11-2232.e18	47
2108	Large C9orf72 repeat expansions are not a common cause of Parkinson's disease. 2012 , 33, 2527.e1-2	39
2107	UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. 2012 , 33, 2527.e3-10	95
2106	Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. 2012 , 33, 2527.e11-6	81
2105	C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. 2012 , 33, 2528.e7-14	64
2104	Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in southern Italy. 2012 , 33, 2948.e1-2948.e10	35
2103	VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. 2012 , 33, 2950.e1-4	40
2102	Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. 2012 , 33, 2950.e5-7	72
2101	Neurodegeneration the RNA way. 2012 , 97, 173-89	68

2100	The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?. 2012 , 96, 190-207	97
2099	Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. 2012 , 122, 3063-87	324
2098	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. 2012 , 18, 1418-22	208
2097	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. 2012 , 135, 784-93	153
2096	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. 2012 , 135, 723-35	226
2095	Molecular analysis and biochemical classification of TDP-43 proteinopathy. 2012 , 135, 3380-91	75
2094	Investigation of c9orf72 in 4 neurodegenerative disorders. 2012 , 69, 1583-90	83
2093	The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice. 2012 , 123, 2080-91	27
2092	The genetics and neuropathology of amyotrophic lateral sclerosis. 2012 , 124, 339-52	299
2091	Reversal of pathology in CHMP2B-mediated frontotemporal dementia patient cells using RNA interference. 2012 , 14, 521-9	13
2090	Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients' behavioral changes than physical disability: a comparative study. 2012 , 12, 156	93
2089	Genetics of neuromuscular disorders. 2012 , 49, 33-48	48
2088	Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. 2012 , 13, 453-64	89
2087	Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. 2012 , 69, 1410-6	160
2086	Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. 2012 , 26, 841-70	91
2085	NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. 2012 , 21, 2497-502	33
2084	Genetics of frontotemporal lobar degeneration. 2012 , 3, 52	28
2083	RNA dysregulation in diseases of motor neurons. 2012 , 7, 323-52	17

2082	Advances in understanding the molecular basis of frontotemporal dementia. 2012 , 8, 423-34	306
2081	The TRK-fused gene is mutated in hereditary motor and sensory neuropathy with proximal dominant involvement. 2012 , 91, 320-9	76
2080	Losing protein in the brain: the case of progranulin. 2012 , 1476, 172-82	21
2079	Analysis of neuromuscular junctions and effects of anabolic steroid administration in the SOD1G93A mouse model of ALS. 2012 , 51, 12-21	26
2078	Pre-mRNA splicing in disease and therapeutics. 2012 , 18, 472-82	319
2077	Clinical aspects of motor neurone disease. 2012 , 40, 540-545	3
2076	Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. 2012 , 21, 297-320	31
2075	Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. 2012 , 8, 131-42	54
2074	Transplantation of mesenchymal stem cells in ALS. 2012 , 201, 333-59	23
2073	Endoplasmic reticulum stress and the ER mitochondrial calcium cycle in amyotrophic lateral sclerosis. 2012 , 13, 166-77	52
2072	Frontotemporal lobar degeneration: new understanding brings new approaches. 2012 , 22, 83-97, viii	2
2071	Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. <i>Neuron</i> , 2012 , 75, 437-50	13.9 234
2070	Montreal Cognitive Assessment (MoCA): validation study for frontotemporal dementia. 2012 , 25, 146-54	49
2069	Amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 83, 355	3
2068	Neuroprevention: a new challenge?. 2012 , 168, 796-801	5
2067	Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. 2012 , 31, 447-52	59
2066	Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. 2012 , 2, 529	148
2065	Tandem Repeat Polymorphisms. 2012 , 1-9	6

2064	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. 2011 , 13, 38-50	450
2063	Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. 2012 , 7, 53	52
2062	Neuromuscular effects of G93A-SOD1 expression in zebrafish. 2012 , 7, 44	46
2061	Does a loss of TDP-43 function cause neurodegeneration?. 2012 , 7, 27	68
2060	Mutational analysis of familial and sporadic amyotrophic lateral sclerosis with OPTN mutations in Japanese population. 2012 , 13, 562-6	16
2059	Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. 2012 , 4, 41	73
2058	Dystrophic neurites express C9orf72 in Alzheimer's disease brains. 2012 , 4, 33	18
2057	Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis. 2012 , 7, e32479	40
2056	A high-density genome-wide association screen of sporadic ALS in US veterans. 2012 , 7, e32768	44
2055	Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. 2012 , 7, e35333	41
2054	A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. 2012 , 7, e37885	106
2053	Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. 2012 , 7, e39216	155
2052	Genome wide assessment of young onset Parkinson's disease from Finland. 2012 , 7, e41859	25
2051	Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. 2012 , 7, e43993	139
2050	ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. 2012 , 7, e42956	34
2049	Widespread structural and functional connectivity changes in amyotrophic lateral sclerosis: insights from advanced neuroimaging research. 2012 , 2012, 473538	16
2048	Discovery of Novel DENN Proteins: Implications for the Evolution of Eukaryotic Intracellular Membrane Structures and Human Disease. 2012 , 3, 283	187
2047	Molecular Mechanisms in Amyotrophic Lateral Sclerosis: The Role of Angiogenin, a Secreted RNase. 2012 , 6, 167	26

2046	Conjugal amyotrophic lateral sclerosis. 2012 , 25, 31-3	4
2045	Amyotrophic lateral sclerosis and other disorders of the lower motor neuron. 136-147	
2044	Parkinson's Disease. 215-226	
2043	Amyotrophic Lateral Sclerosis. 273-283	
2042	18 Amyotrophe Lateralsklerose (Motoneuronerkrankungen). 2012 ,	
2041	Typical and atypical stem cells in the brain, vitamin C effect and neuropathology. 2012 , 45, 243-56	15
2040	RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. 2012 , 3, 265-85	36
2039	Investigation. 2012 , 107-137	
2038	'Costa da Morte' ataxia is spinocerebellar ataxia 36: clinical and genetic characterization. 2012 , 135, 1423-35	56
2037	New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration. 2012 , 12, 502-10	21
2036	Psychosis, C9ORF72 and dementia with Lewy bodies. 2012 , 83, 1031-2	43
2035	Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. 2012 , 79, 66-72	94
2034	The expansions of ALS. 2012 , 79, 842-3	0
2033	Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder. 2012 , 27, 1068-9	13
2032	C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. 2012 , 27, 1072-4	39
2031	Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice. 2012 , 4, 730-42	102
2030	The non-fluent/agrammatic variant of primary progressive aphasia. 2012 , 11, 545-55	147
2029	The gigatonne gap in China's carbon dioxide inventories. 2012 , 2, 672-675	395

2028	Genetics of dementia: update and guidelines for the clinician. 2012 , 159B, 628-43	33
2027	C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. 2012 , 69, 1154-8	77
2026	Exom-Sequenzierung zur Identifizierung von Krankheitsgenen. 2012 , 24, 4-11	2
2025	Recent advances in the genetics of the ALS-FTLD complex. 2012 , 12, 243-50	45
2024	TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. 2012 , 124, 285-91	18
2023	Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. 2012 , 123, 825-39	148
2022	Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. 2012 , 123, 807-23	43
2021	Ubiquilin immunoreactivity in cytoplasmic and nuclear inclusions in synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease. 2012 , 124, 149-51	32
2020	Genetic testing in neurological diseases. 2012 , 259, 1249-54	5
2019	Clinical phenotypes and genetic biomarkers of FTLD. 2012 , 119, 851-60	16
2018	New drugs for ALS: how do we get there?. 2012 , 233, 112-7	7
2017	Coupling biomarkers and drug action for neurodegenerative disease therapies: does the nose know?: Commentary on Sattler et al.: human nasal olfactory epithelium as a dynamic marker for CNS therapy development. 2012 , 235, 508-12	
2016	Stem cell therapy in amyotrophic lateral sclerosis. 2012 , 2, 58-63	1
2015	Using human pluripotent stem cells to study post-transcriptional mechanisms of neurodegenerative diseases. 2012 , 1462, 129-38	4
2014	The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. 2012 , 1462, 61-80	450
2013	FUS-related proteinopathies: lessons from animal models. 2012 , 1462, 44-60	49
2012	Progranulin: an emerging target for FTLD therapies. 2012 , 1462, 118-28	33
2011	RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. 2012 , 1462, 100-11	69

2010	RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome. 2012 , 1462, 112-7	34
2009	Rodent models of TDP-43: recent advances. 2012 , 1462, 26-39	89
2008	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. 2012 , 11, 54-65	489
2007	Neuromuscular diseases: advances in therapy and diagnosis. 2012 , 11, 15-7	3
2006	What is repeated in ALS and FTL. 2012 , 11, 25-7	2
2005	Erratum. 2012 , 11, 27	2
2004	Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. 2012 , 11, 232-40	349
2003	Mutation in C9orf72 changes the boundaries of ALS and FTD. 2012 , 11, 205-7	3
2002	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. 2012 , 11, 323-30	830
2001	C9orf72 repeat expansions in patients with ALS and FTD. 2012 , 11, 297-8	40
2000	Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. 2012 , 48, 124-31	24
1999	Yeast as a model eukaryote in toxinology: a functional genomics approach to studying the molecular basis of action of pharmacologically active molecules. 2012 , 60, 558-71	7
1998	Neuropathology and omics in motor neuron diseases. 2012 , 32, 458-62	13
1997	An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. 2012 , 32, 505-14	99
1996	Ultrastructure of ubiquitin-positive, TDP-43-negative neuronal inclusions in cerebral cortex of C9ORF72-linked frontotemporal lobar degeneration/amyotrophic lateral sclerosis. 2012 , 32, 679-81	5
1995	RNA-binding proteins involved in RNA localization and their implications in neuronal diseases. 2012 , 35, 1818-36	33
1994	UBQLN2/P62 cellular recycling pathways in amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 45, 157-62	39
1993	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. 2012 , 123, 409-17	127

1992	Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. 2013 , 33, 122-33	38
1991	Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation. 2013 , 8, 12	40
1990	Altered microRNA expression profile in Amyotrophic Lateral Sclerosis: a role in the regulation of NFL mRNA levels. 2013 , 6, 26	103
1989	The C9ORF72 mutation brings more answers and more questions. 2013 , 5, 7	3
1988	Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. 2013 , 70, 4729-45	54
1987	New therapy options for amyotrophic lateral sclerosis. 2013 , 14, 1907-17	14
1986	Tertiary structural elements determine the extent and specificity of messenger RNA editing. 2013 , 4, 2232	36
1985	Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: a new target of disease mechanisms. 2013 , 10, 722-33	50
1984	Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. 2013 , 126, 385-99	261
1983	c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. 2013 , 17, 991-5	14
1982	Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. 2013 , 70, 1268-76	46
1981	Spinal cord: motor neuron diseases. 2013 , 31, 219-39	15
1980	Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. 2013 , 65, 509-527	208
1979	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. 2013 , 1, 36	19
1978	Promoter DNA methylation regulates progranulin expression and is altered in FTLD. 2013 , 1, 16	35
1977	Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?. 2013 , 260, 1155-7	34
1976	Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995-2009. 2013 , 260, 572-9	33
1975	Immune-mediated mechanisms in the pathoprogession of amyotrophic lateral sclerosis. 2013 , 8, 888-99	201

1974	Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. <i>Neuron</i> , 2013 , 79, 416-389	1038
1973	The genetics of Parkinson's disease: progress and therapeutic implications. 2013 , 28, 14-23	248
1972	Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. 2013 , 2, 8	37
1971	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. 2013 , 126, 401-9	119
1970	Sporadic ALS with compound heterozygous mutations in the SQSTM1 gene. 2013 , 126, 453-9	27
1969	Protein aggregation in amyotrophic lateral sclerosis. 2013 , 125, 777-94	347
1968	Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. 2013 , 125, 523-33	18
1967	Altered ribostasis: RNA-protein granules in degenerative disorders. 2013 , 154, 727-36	423
1966	Sirtuin deacetylases in neurodegenerative diseases of aging. 2013 , 23, 746-58	149
1965	FDG PET and the genetics of dementia. 2013 , 1, 235-246	2
1964	Motor Neuron Disease. 2013 , 1-22	3
1963	C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. 2013 , 70, 742-5	18
1962	Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. 2013 , 92, 345-53	242
1961	Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. 2013 , 5, 1178-86	334
1960	Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat. 2013 , 34, 2234.e1-7	18
1959	Polymorphic variation as a driver of differential neuropeptide gene expression. 2013 , 47, 395-400	8
1958	Next generation sequencing for neurological diseases: new hope or new hype?. 2013 , 115, 948-53	19
1957	Frontotemporal lobar degeneration: diversity of FTLD lesions. 2013 , 169, 786-92	4

1956	Analysis of the C9orf72 hexanucleotide repeat expansion in Korean patients with familial and sporadic amyotrophic lateral sclerosis. 2013 , 34, 1311.e7-9	56
1955	C9ORF72 repeat expansions not detected in a group of patients with schizophrenia. 2013 , 34, 1309.e9-10	21
1954	Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. 2013 , 126, 881-93	342
1953	TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. 2013 , 34, 812-26	171
1952	Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. 2013 , 24, 499-507	39
1951	FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTL. 2013 , 91, 1343-54	27
1950	Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. 2013 , 34, 1311.e1-2	30
1949	A novel optineurin truncating mutation and three glaucoma-associated missense variants in patients with familial amyotrophic lateral sclerosis in Germany. 2013 , 34, 1516.e9-15	42
1948	Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. 2013 , 70, 1411-7	87
1947	RNA and splicing regulation in neurodegeneration. 2013 , 56, 404-5	1
1946	Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. 2013 , 116, 561-75	28
1945	Amyotrophic lateral sclerosis: an update on recent genetic insights. 2013 , 260, 2917-27	50
1944	Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. 2013 , 83, 408-16	78
1943	Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. 2013 , 5, 208ra149	488
1942	The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. 2013 , 16, 1725-7	58
1941	Retroviruses and amyotrophic lateral sclerosis. 2013 , 99, 180-7	93
1940	Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. 2013 , 140, 4982-7	334
1939	Exome sequencing: how to understand it. 2013 , 13, 399-407	6

1938	Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. 2013 ,	3
1937	Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?. 2013 , 14, 487-93	21
1936	Proteopathic Seeds and Neurodegenerative Diseases. 2013 ,	4
1935	RNA dysfunction and aggregopathy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum. 2013 , 136, 1345-60	69
1934	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. 2013 , 12, 978-88	200
1933	Behavioral and language variants of frontotemporal dementia: a review of key symptoms. 2013 , 115, 2405-10	22
1932	Emerging drug targets in amyotrophic lateral sclerosis. 2013 , 1, 5-20	4
1931	Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. 2013 , 110, 89-101	35
1930	Genetische Diagnostik der amyotrophen Lateralsklerose. 2013 , 25, 352-357	1
1929	Genetic factors in frontotemporal dementia: A review. 2013 , 5, 113-130	2
1928	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. 2013 , 1, 68	131
1927	Expanded G4C2 repeats linked to C9ORF72 ALS and FTD form length-dependent RNA foci, sequester RNA binding proteins and are neurotoxic. 2013 , 8, O14	78
1926	Idiopathic Parkinson's disease phenotype related to C9ORF72 repeat expansions: contribution of the neuropsychological assessment. 2013 , 6, 343	5
1925	Pathological assessments for the presence of hexanucleotide repeat expansions in C9ORF72 in Alzheimer's disease. 2013 , 1, 50	10
1924	Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. 2013 , 34, 899-903	25
1923	Frontotemporale dementie en de psychiatrische differentiaaldiagnose: twee gevalsbeschrijvingen en de rationale van de maat Ontstaan Frontaal syndroom (LOF)-studie 2013 , 1, 72-79	
1922	Calcium-dependent protein folding in amyotrophic lateral sclerosis. 2013 , 54, 132-43	43
1921	C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. 2013 , 77, 351-63	60

1920	Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences. 2013 , 169, 793-8	19
1919	Controversies and priorities in amyotrophic lateral sclerosis. 2013 , 12, 310-22	377
1918	The next-generation sequencing revolution and its impact on genomics. 2013 , 155, 27-38	655
1917	RNA toxicity in human disease and animal models: from the uncovering of a new mechanism to the development of promising therapies. 2013 , 1832, 1390-409	51
1916	Amyotrophic lateral sclerosis: Problems and prospects. 2013 , 74, 309-16	104
1915	ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease. 2013 , 19, 295-301	11
1914	Cellular toxicity induced by the 26-kDa fragment and amyotrophic lateral sclerosis-associated mutant forms of TAR DNA-binding protein 43 in human embryonic stem cell-derived motor neurons. 2013 , 1, 24-31	1
1913	Advances in catheter-ablation treatment of AF. 2013 , 10, 63-4	6
1912	Motoneuronal and muscle-selective removal of ALS-related misfolded proteins. 2013 , 41, 1598-604	27
1911	Schizophrenia and frontotemporal dementia: shared causation?. 2013 , 25, 168-77	22
1910	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. 2013 , 34, 636-9	45
1909	Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. 2013 , 34, 248-62	24
1908	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. 2013 , 34, 357.e7-19	53
1907	Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. 2013 , 34, 1519.e5-1260	
1906	Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. 2013 , 84, 1161-70	167
1905	A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. 2013 , 34, 363-73	208
1904	Detection of a novel frameshift mutation and regions with homozygosity within ARHGAP28 gene in familial amyotrophic lateral sclerosis. 2013 , 14, 444-51	27
1903	Dementia and neuroimaging. 2013 , 260, 685-91	11

1902	C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. 2013 , 80, 366-70	76
1901	Progress in frontotemporal dementia research. 2013 , 28, 15-23	11
1900	Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLN, PSP, and CBS. 2013 , 19, 15-20	65
1899	Mixed tau, TDP-43 and p62 pathology in FTLN associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. 2013 , 125, 303-10	63
1898	Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. 2013 , 19, 198-201	35
1897	Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. 2013 , 125, 111-20	213
1896	Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. 2013 , 125, 289-302	75
1895	Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders. 2013 , 125, 173-85	34
1894	Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. 2013 , 260, 85-92	19
1893	The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLN/ALS. 2013 , 339, 1335-8	879
1892	Motor neuron disease in 2012: Novel causal genes and disease modifiers. 2013 , 9, 63-4	22
1891	Electrodiagnosis of motor neuron disease. 2013 , 24, 139-51	15
1890	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. 2013 , 136, 385-91	128
1889	Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. <i>Neuron</i> , 2013 , 77, 639-46	13.9 783
1888	Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. 2013 , 34, 79-82	71
1887	A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. 2013 , 47, 260-70	48
1886	Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. 2013 , 7, 123-35	27
1885	Association studies indicate that protein disulfide isomerase is a risk factor in amyotrophic lateral sclerosis. 2013 , 58, 81-6	40

1884	Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. 2013 , 55, 64-75		97
1883	RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. <i>Neuron</i> , 2013 , 80, 415-28	13.9	650
1882	Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. 2013 , 34, 2890.e7-2890.e12		28
1881	C9orf72-associated FTD/ALS: when less is more. <i>Neuron</i> , 2013 , 80, 257-8	13.9	3
1880	Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. 2013 , 74, 384-91		94
1879	Investigation of C9orf72 repeat expansions in Parkinson's disease. 2013 , 34, 1710.e7-9		21
1878	Madras motor neuron disease (MMND) is distinct from the riboflavin transporter genetic defects that cause Brown-Vialetto-Van Laere syndrome. 2013 , 334, 119-22		10
1877	Genetic ablation of phospholipase C delta 1 increases survival in SOD1(G93A) mice. 2013 , 60, 11-7		15
1876	Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. 2013 , 84, 467-72		106
1875	Pathophysiological insights into ALS with C9ORF72 expansions. 2013 , 84, 931-5		80
1874	Mutation analysis and immunopathological studies of PFN1 in familial and sporadic amyotrophic lateral sclerosis. 2013 , 34, 2235.e7-10		15
1873	Identification of mutation in NPC2 by exome sequencing results in diagnosis of Niemann-Pick disease type C. 2013 , 110, 139-44		14
1872	Translational proteomics in Alzheimer's disease and related disorders. 2013 , 46, 480-6		17
1871	Screening for rare variants in the coding region of ALS-associated genes at 9p21.2 and 19p13.3. 2013 , 34, 1518.e5-7		12
1870	ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. 2013 , 34, 2236.e5-8		26
1869	A novel phosphorylation site mutation in profilin 1 revealed in a large screen of US, Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia cohorts. 2013 , 34, 1708.e1-6		61
1868	Neural substrates of episodic memory dysfunction in behavioural variant frontotemporal dementia with and without C9ORF72 expansions. 2013 , 2, 836-43		28
1867	C9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment. 2013 , 34, 1712.e1-7		57

1866	Refining the clinical presentation of the C9ORF72 hexanucleotide repeat expansion. 2013 , 74, 320		
1865	Presymptomatic studies in genetic frontotemporal dementia. 2013 , 169, 820-4		33
1864	The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations. 2013 , 335, 26-35		20
1863	Modeling human disease with pluripotent stem cells: from genome association to function. 2013 , 12, 656-68		149
1862	Clinical neurogenetics: amyotrophic lateral sclerosis. 2013 , 31, 929-50		29
1861	Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. 2013 , 34, 1516.e1-8		25
1860	Mechanisms of granulin deficiency: lessons from cellular and animal models. 2013 , 47, 337-60		49
1859	Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. 2013 , 23, 121-8		148
1858	RANTing about C9orf72. <i>Neuron</i> , 2013 , 77, 597-8	13.9	19
1857	Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. 2013 , 125, 511-22		170
1856	Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. 2013 , 14, 452-6		2
1855	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. 2013 , 125, 413-23		250
1854	Parkinson disease is not associated with C9ORF72 repeat expansions. 2013 , 34, 1519.e1-2		34
1853	The changing scene of amyotrophic lateral sclerosis. 2013 , 14, 248-64		716
1852	Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration. 2013 , 21, 1260-5		6
1851	Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. 2013 , 83, 279-83		115
1850	The unstable repeats--three evolving faces of neurological disease. <i>Neuron</i> , 2013 , 77, 825-43	13.9	151
1849	Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis. 2013 , 123, 366-74		25

1848	Overexpression of human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse embryonic motor neurons. 2013 , 247, 91-100	31
1847	VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration. 2013 , 70, 1763-78	114
1846	Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosis. 2013 , 47, 629-31	6
1845	Mitochondrial Medicine. 2013 , 1-153	5
1844	Rodent models of amyotrophic lateral sclerosis. 2013 , 1832, 1421-36	119
1843	A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. 2013 , 12, 713-26	231
1842	Expanded complexity of unstable repeat diseases. 2013 , 39, 164-75	14
1841	Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. 2013 , 34, 2234.e13-9	54
1840	Widening Spectrum of Prions Causing Neurodegenerative Diseases. 2013 , 1-17	1
1839	Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. 2013 , 35, 106-17	43
1838	Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLN cohort. 2013 , 70, 365-73	77
1837	Current insights into the C9orf72 repeat expansion diseases of the FTLN/ALS spectrum. 2013 , 36, 450-9	129
1836	The wobbler mouse, an ALS animal model. 2013 , 288, 207-29	66
1835	Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. 2013 , 74, 20-38	588
1834	The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. 2013 , 34, 2541-7	50
1833	Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. 2013 , 32, 1917-26	123
1832	Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. 2013 , 74, 180-7	238
1831	Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration. 2013 , 56, 475-86	95

1830	Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. 2013 , 16, 780-9	156
1829	Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. 2013 , 34, 1837-45	14
1828	CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. <i>Neuron</i> , 2013 , 78, 440-55	13.9 327
1827	RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a review. 2013 , 47, 330-8	17
1826	Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. 2013 , 92, 981-9	211
1825	RNA-mediated toxicity in neurodegenerative disease. 2013 , 56, 406-19	70
1824	Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. 2013 , 21, 1486-96	35
1823	Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. 2013 , 126, 859-79	248
1822	Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. 2013 , 126, 829-44	392
1821	Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. 2013 , 126, 895-905	217
1820	C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. 2013 , 126, 845-57	225
1819	Making sense of the antisense transcripts in C9FTD/ALS. 2013 , 126, 785-7	3
1818	Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72. 2013 , 14, 172-6	44
1817	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. 2013 , 25, 210-20	11
1816	Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. 2013 , 84, 766-73	99
1815	Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. 2013 , 41, 118-30	469
1814	Genetic and epigenetic studies of amyotrophic lateral sclerosis. 2013 , 14 Suppl 1, 44-52	21
1813	[Genetics of amyotrophic lateral sclerosis]. 2013 , 84, 1213-9	4

1812	Progressive amnesic dementia, hippocampal sclerosis, and mutation in C9ORF72. 2013 , 126, 545-54	22
1811	Neuroscience. RNA that gets RAN in neurodegeneration. 2013 , 339, 1282-3	8
1810	A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. 2014 , 7, 73-81	43
1809	Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. 2013 , 70, 78-84	257
1808	Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice. 2013 , 154, 4695-706	19
1807	C9ORF72 transcription in a frontotemporal dementia case with two expanded alleles. 2013 , 81, 1719-21	24
1806	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. 2013 , 81, 1332-41	75
1805	Bildgebende Verfahren bei amyotropher Lateralsklerose und frontotemporaler Demenz. 2013 , 44, 145-153	
1804	[Diagnostics and therapy for amyotrophic lateral sclerosis]. 2013 , 81, 592-603; quiz 604	4
1803	Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. 2013 , 110, 7778-83	255
1802	Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. 2013 , 21, 237-9	25
1801	The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. 2013 , 21, 102-8	159
1800	Homozygosity analysis in amyotrophic lateral sclerosis. 2013 , 21, 1429-35	12
1799	Neuroimaging in neurodegenerative dementias. 2012 , 32, 347-60	15
1798	Repeat-associated non-ATG (RAN) translation in neurological disease. 2013 , 22, R45-51	125
1797	Innate immunity and neuroinflammation. 2013 , 2013, 342931	104
1796	Enlarging the clinical spectrum associated with C9orf 72 repeat expansions: findings in an Italian cohort of patients with parkinsonian syndromes and relevance for genetic counselling. 2013 , 14, 479-80	11
1795	Peer recommendations on how to improve clinical research, and Conference wrap-up. 2013 , 14 Suppl 1, 67-73	1

1794	Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72. 2013 , 84, 79-87	46
1793	C9orf72 repeat expansions are not detected in Chinese patients with familial ALS. 2013 , 14, 630-1	19
1792	Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. 2013 , 80, 458-63	65
1791	Detection of slipped-DNAs at the trinucleotide repeats of the myotonic dystrophy type I disease locus in patient tissues. 2013 , 9, e1003866	45
1790	Clinical variability and female penetrance in X-linked familial FTD/ALS caused by a P506S mutation in UBQLN2. 2013 , 14, 615-9	26
1789	Clinical and electrophysiologic variability in amyotrophic lateral sclerosis within a kindred harboring the C9ORF72 repeat expansion. 2013 , 14, 132-7	7
1788	The role of s-nitrosylation and s-glutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration. 2013 , 2013, 797914	44
1787	THEME 8 HUMAN CELL BIOLOGY AND PATHOLOGY. 2013 , 14, 166-176	
1786	The G4 genome. 2013 , 9, e1003468	366
1785	Multiparametric MRI study of ALS stratified for the C9orf72 genotype. 2013 , 81, 361-9	129
1784	Blink rate in ALS. 2013 , 14, 291-3	6
1783	Profilin-1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia. 2013 , 14, 463-9	23
1782	Frontotemporal dementia, Parkinsonism and lower motor neuron involvement in a patient with C9ORF72 expansion. 2013 , 14, 66-9	12
1781	No GGGGCC-hexanucleotide repeat expansion in C9ORF72 in parkinsonism patients in Sweden. 2013 , 14, 26-9	24
1780	Parental age and the risk of amyotrophic lateral sclerosis. 2013 , 14, 224-7	1
1779	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2013 , 14, 1-63	4
1778	Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. 2013 , 26, 466-72	18
1777	Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: a detailed clinical cohort. 2013 , 26, 146-54	56

1776	Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. 2013 , 27, 302-9	37
1775	Distinct roles for Toll and autophagy pathways in double-stranded RNA toxicity in a Drosophila model of expanded repeat neurodegenerative diseases. 2013 , 22, 2811-9	19
1774	Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. 2013 , 4, 295-310	176
1773	Tardbp1 splicing rescues motor neuron and axonal development in a mutant tardbp zebrafish. 2013 , 22, 2376-86	26
1772	Ubiquilin 2 mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia. 2013 , 84, 183-7	58
1771	ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. 2013 , 22, 3690-704	103
1770	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. 2013 , 110, E4530-9	420
1769	Comparison of 2 diagnostic criteria for the behavioral variant of frontotemporal dementia. 2013 , 28, 469-76	10
1768	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTL-ALS spectrum disorders. 2013 , 22, R77-87	111
1767	The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. 2013 , 29, 499-503	270
1766	Rapidly progressive frontotemporal dementia and bulbar amyotrophic lateral sclerosis in Portuguese patients with C9orf72 mutation. 2013 , 14, 70-2	11
1765	C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. 2013 , 110, E4385-92	50
1764	C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study. 2013 , 81, 808-11	49
1763	Programmed Cells from Basic Neuroscience to Therapy. 2013 ,	
1762	Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. 2013 , 84, 163-9	112
1761	Lifetime physical activity and the risk of amyotrophic lateral sclerosis. 2013 , 84, 976-81	98
1760	Comment: double mutants of frontotemporal dementia genes--Simple co-occurrence?. 2013 , 81, 1338	3
1759	The genetics of dementia. 2013 , 33, 417-22	3

1758	RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. 2013 , 110, E4968-77	538
1757	Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTL-D-TDP. 2013 , 81, 1945-52	78
1756	The FTL-D risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. 2014 , 33, 450-67	92
1755	Plasma progranulin levels in cortical dementia phenotypes with asymmetric perisylvian atrophy. 2013 , 20, 1319-24	4
1754	Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation. 2013 , 39, 562-71	13
1753	The involvement of the cerebellum in amyotrophic lateral sclerosis. 2013 , 14, 507-15	54
1752	TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. 2013 , 126, 781-91	57
1751	A rare motor neuron deleterious missense mutation in the DPYSL3 (CRMP4) gene is associated with ALS. 2013 , 34, 953-60	26
1750	CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. 2013 , 74, 39-52	75
1749	Optineurin and amyotrophic lateral sclerosis. 2013 , 13, 528-32	29
1748	What is the key player in TDP-43 pathology in ALS: Disappearance from the nucleus or inclusion formation in the cytoplasm?. 2013 , 1, 11-17	5
1747	Abnormal RNA structures (RNA foci) containing a penta-nucleotide repeat (UGGAA) _n in the Purkinje cell nucleus is associated with spinocerebellar ataxia type 31 pathogenesis. 2013 , 33, 600-11	42
1746	Genomic editing opens new avenues for zebrafish as a model for neurodegeneration. 2013 , 127, 461-70	46
1745	C9ORF72 expansion in a family with bipolar disorder. 2013 , 15, 326-32	50
1744	Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting. 2013 , 39, 335-47	8
1743	Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. 2013 , 280, 4348-70	131
1742	Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. 2013 , 84, 398-401	56
1741	The disease-associated r(GGGGCC) _n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. 2013 , 288, 9860-9866	230

1740	The epidemiology of frontotemporal dementia. 2013 , 25, 130-7	280
1739	Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. 2013 , 80, 814-23	71
1738	Yeast genetic screen reveals novel therapeutic strategy for ALS. 2013 , 1, e24420	17
1737	Molecular biomarkers of neurodegeneration. 2013 , 13, 845-61	23
1736	ALS antisense oligonucleotides. 2013 , 6, 1210-1210	
1735	Toxic RNA as a driver of disease in a common form of ALS and dementia. 2013 , 110, 7533-4	8
1734	Frontal lobe dementia, motor neuron disease, and clinical and neuropathological criteria. 2013 , 84, 713-4	11
1733	Highly efficient targeted mutagenesis in mice using TALENs. 2013 , 195, 703-13	54
1732	C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. 2013 , 70, 736-41	77
1731	Amyotrophic lateral sclerosis descriptive studies: not only rates and frequencies. 2013 , 41, 62-3	
1730	[Amyotrophic lateral sclerosis: update on etiological treatment]. 2013 , 68, 93-106	1
1729	Wild-type but not mutant SOD1 transgenic astrocytes promote the efficient generation of motor neuron progenitors from mouse embryonic stem cells. 2013 , 14, 126	4
1728	Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a <i>Drosophila</i> model of amyotrophic lateral sclerosis. 2013 , 6, 721-33	58
1727	Barriers to novel therapeutics in amyotrophic lateral sclerosis. 2013 , 3, 525-537	
1726	[C9orf72 in Japanese amyotrophic lateral sclerosis (ALS)]. 2013 , 53, 1074-6	5
1725	Neurodegenerative disorders. 23-71	
1724	Neuropathology of frontotemporal lobar degeneration: a review. 2013 , 7, 19-26	16
1723	SOD1 aggregation and ALS: role of metallation states and disulfide status. 2012 , 12, 2560-72	70

1722	Clinical Characteristics of C9ORF72-Linked Frontotemporal Lobar Degeneration. 2013 , 3, 251-62	23
1721	Hippocampal sclerosis dementia: An amnesic variant of frontotemporal degeneration. 2013 , 7, 83-87	10
1720	Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9. 2013 , 35, 455-62	15
1719	C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patients. 2013 , 8, e56899	51
1718	Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1. 2013 , 8, e61210	13
1717	Credibility analysis of putative disease-causing genes using bioinformatics. 2013 , 8, e64899	8
1716	Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. 2013 , 8, e65235	72
1715	Can ALS-associated C9orf72 repeat expansions be diagnosed on a blood DNA test alone?. 2013 , 8, e70007	16
1714	De novo mutations in ataxin-2 gene and ALS risk. 2013 , 8, e70560	21
1713	Altered intracellular localization of SOD1 in leukocytes from patients with sporadic amyotrophic lateral sclerosis. 2013 , 8, e75916	25
1712	Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in <i>C. elegans</i> . 2013 , 8, e83450	135
1711	Neuromuscular Disease: A Case-Based Approach. 23-28	
1710	Structural disorder and the loss of RNA homeostasis in aging and neurodegenerative disease. 2013 , 4, 149	4
1709	C9orf72 mutation is rare in Alzheimer's disease, Parkinson's disease, and essential tremor in China. 2013 , 7, 164	30
1708	Differential autophagy power in the spinal cord and muscle of transgenic ALS mice. 2013 , 7, 234	42
1707	An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. 2013 , 7, 253	147
1706	GroupICA dual regression analysis of resting state networks in a behavioral variant of frontotemporal dementia. 2013 , 7, 461	54
1705	RNA pathogenesis via Toll-like receptor-activated inflammation in expanded repeat neurodegenerative diseases. 2013 , 6, 25	10

1704	Antisense gene silencing: therapy for neurodegenerative disorders?. 2013 , 4, 457-84	10
1703	Antisense therapy in neurology. 2013 , 3, 144-76	50
1702	C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study. 2014 , 38, 799-808	33
1701	Behavioural-variant frontotemporal dementia: an update. 2013 , 7, 10-18	17
1700	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. 2013 , 5, 6	69
1699	Delusion of Pregnancy: A Case Revisited. 2013 , 27, 293-294	20
1698	Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach. 2013 , 2013, 538765	8
1697	Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective. 2013 , 2013, 208245	4
1696	Genetics of ALS and Correlations Between Genotype and Phenotype in ALS [A Focus on Italian Population]. 2013 ,	3
1695	Other Dementias. 2013 ,	
1694	[Overlapping features of frontotemporal dementia and amyotrophic lateral sclerosis]. 2014 , 142, 867-79	8
1693	Frontotemporal dementia and primary progressive aphasia, a review. 2014 , 10, 1045-55	35
1692	A case of logopenic primary progressive aphasia with C9ORF72 expansion and cortical florbetapir binding. 2014 , 42, 413-20	13
1691	A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects. 2014 , 9, e85962	15
1690	Spectrum of cognitive impairment in Korean ALS patients without known genetic mutations. 2014 , 9, e87163	32
1689	Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS--a systematic review and meta-analysis of observational studies. 2014 , 9, e105534	21
1688	Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. 2014 , 9, e105632	60
1687	Worming forward: amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in <i>Caenorhabditis elegans</i> . 2014 , 5, 85	43

1686	Therapeutic and diagnostic challenges for frontotemporal dementia. 2014 , 6, 204	16
1685	Rac1 at the crossroad of actin dynamics and neuroinflammation in Amyotrophic Lateral Sclerosis. 2014 , 8, 279	31
1684	The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. 2014 , 8, 282	20
1683	Elevated mRNA-levels of distinct mitochondrial and plasma membrane Ca(2+) transporters in individual hypoglossal motor neurons of endstage SOD1 transgenic mice. 2014 , 8, 353	14
1682	RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis. 2014 , 8, 431	20
1681	Motoneuron firing in amyotrophic lateral sclerosis (ALS). 2014 , 8, 719	24
1680	Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. 2014 , 6, 57	52
1679	iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development. 2014 , 3, 1124-45	5
1678	Incomplete penetrance of the C9ORF72 hexanucleotide repeat expansions: frequency in a cohort of geriatric non-demented subjects. 2014 , 39, 19-22	26
1677	Neuronal death and rescue: neurotrophic factors and anti-apoptotic mechanisms. 255-273	
1676	. 2014 ,	2
1675	Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta-analysis. 2015 , 43, 325-34	5
1674	Towards understanding RNA-mediated neurological disorders. 2014 , 41, 473-84	13
1673	Deciphering genetic interactions between ALS genes using <i>C. elegans</i> . 2014 , 3, e29047	2
1672	Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. 2014 , 111, 829-32	231
1671	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. 2014 , 261, 2085-92	7
1670	Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. 2014 , 111, 3620-5	293
1669	C9orf72 expansion as a possible genetic cause of Huntington disease phenocopy syndrome. 2014 , 261, 1917-21	27

1668	Early onset frontotemporal dementia with psychiatric presentation due to the C9ORF72 hexanucleotide repeat expansion: a case report. 2014 , 14, 228	7
1667	C9orf72 FTL/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. 2014 , 128, 485-503	217
1666	A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. 2014 , 15, 226-34	24
1665	"Undifferentiated schizophrenia" revisited. 2014 , 26, E62-3	9
1664	PTEN regulates AMPA receptor-mediated cell viability in iPS-derived motor neurons. 2014 , 5, e1096	19
1663	Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis. 2014 , 15, 148-50	39
1662	Theme 10 in vivo experimental models. 2014 , 15 Suppl 1, 179-96	
1661	Current concepts in the classification and diagnosis of frontotemporal lobar degenerations: a practical approach. 2014 , 138, 132-8	10
1660	Hereditary spastic paraplegia is not associated with C9ORF72 repeat expansions in a Danish cohort. 2014 , 52, 77-9	4
1659	Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. 2014 , 82, 149-55	79
1658	Tale of two diseases: amyotrophic lateral sclerosis and frontotemporal dementia. 2014 , 62, 347-51	12
1657	Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. 2014 , 10, e1004704	39
1656	Use of <i>Caenorhabditis elegans</i> as a model to study Alzheimer's disease and other neurodegenerative diseases. 2014 , 5, 279	158
1655	Hypermethylation of the CpG-island near the C9orf72 GGG repeat expansion in FTL/ALS patients. 2014 , 23, 5630-7	68
1654	Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis. 2014 , 2014, 467560	27
1653	Theme 7 genetics. 2014 , 15 Suppl 1, 141-51	
1652	Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. 2014 , 2014, 947513	33
1651	The neurogenetics of atypical parkinsonian disorders. 2014 , 34, 217-24	13

1650	Clinicopathologic report of ocular involvement in ALS patients with C9orf72 mutation. 2014 , 15, 569-80	19
1649	The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. 2014 , 4, 223-39	45
1648	Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype. 2014 , 29, 964-71	9
1647	Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. 2014 , 83, e19-26	93
1646	Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. 2014 , 137, 2040-51	207
1645	Heterogeneous nuclear ribonucleoproteins in amyotrophic lateral sclerosis: what do we know?. 2014 , 9, 173-185	1
1644	Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. 2014 , 4, e005528	20
1643	Genetik und Neurochemische Biomarker bei Amyotropher Lateralsklerose und Frontotemporaler Lobe Degeneration. 2014 , 41, 239-247	5
1642	Fishing for causes and cures of motor neuron disorders. 2014 , 7, 799-809	47
1641	TDP-43 suppresses CGG repeat-induced neurotoxicity through interactions with HnRNP A2/B1. 2014 , 23, 5036-51	49
1640	Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. <i>Neuron</i> , 2014 , 84, 1213-25	13-9 340
1639	The non-cell-autonomous component of ALS: new in vitro models and future challenges. 2014 , 42, 1270-4	14
1638	Brain 18 F-FDG and 11 C-PiB PET findings in two siblings with FTD/ALS associated with the C9ORF72 repeat expansion. 2014 , 20, 150-7	12
1637	The GGGGCC repeat expansion in C9ORF72 in a case with discordant clinical and FDG-PET findings: PET trumps syndrome. 2014 , 20, 110-20	13
1636	Animal Models for Neurodegenerative Disorders. 2014 , 39-56	1
1635	Global investigation and meta-analysis of the C9orf72 (G4C2) _n repeat in Parkinson disease. 2014 , 83, 1906-13	49
1634	The genetics of primary progressive aphasia. 2014 , 28, 941-947	10
1633	Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients. 2014 , 35, 2882.e13-2882.e15	23

1632	Deep proteomic evaluation of primary and cell line motoneuron disease models delineates major differences in neuronal characteristics. 2014 , 13, 3410-20	40
1631	Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. 2014 , 137, 3047-60	102
1630	C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. 2014 , 16, 448-9	26
1629	C9ORF72 repeat expansion is not a significant cause of late onset cerebellar ataxia syndrome. 2014 , 347, 322-4	10
1628	A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. 2014 , 40, 502-13	31
1627	Inferring short tandem repeat variation from paired-end short reads. 2014 , 42, e16	42
1626	Clinical variability and additional mutations in amyotrophic lateral sclerosis patients with p.N352S mutations in TARDBP. 2014 , 40, 356-8	1
1625	Neuroimmunology of Amyotrophic Lateral Sclerosis. 2014 , 185-209	
1624	tRNA-derived G-quadruplex protects motor neurons. 2014 , 111, 18108-9	1
1623	Amyotrophic Lateral Sclerosis. 2014 , 639-654	
1622	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. 2014 , 128, 505-24	227
1621	Genetic validation of a therapeutic target in a mouse model of ALS. 2014 , 6, 248ra104	21
1620	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. 2014 , 9, 38	51
1619	Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. 2014 , 2, 70	91
1618	A common gene expression signature in Huntington's disease patient brain regions. 2014 , 7, 60	34
1617	A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD. 2014 , 2, 166	22
1616	Immunoreactivity of valosin-containing protein in sporadic amyotrophic lateral sclerosis and in a case of its novel mutant. 2014 , 2, 172	31
1615	C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function?. 2014 , 27, 515-23	55

1614	Genetics in degenerative dementia: current status and applicability. 2014 , 28, 199-205	12
1613	The evidence for symptomatic treatments in amyotrophic lateral sclerosis. 2014 , 27, 524-31	33
1612	Novel TARDBP sequence variant and C9ORF72 repeat expansion in a family with frontotemporal dementia. 2014 , 28, 190-3	16
1611	Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72. 2014 , 73, 837-45	34
1610	Frontotemporal lobar degeneration: current perspectives. 2014 , 10, 297-310	79
1609	Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration: Imaging. 2014 , 159-178	
1608	ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. 2014 , 8, 252	185
1607	Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. 2014 , 71, 1123-34	53
1606	Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. 2014 , 71, 771-4	53
1605	Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. 2014 , 71, 442-8	58
1604	Lack of c9orf72 repeat expansion in taiwanese patients with mixed neurodegenerative disorders. 2014 , 5, 59	13
1603	Microglia centered pathogenesis in ALS: insights in cell interconnectivity. 2014 , 8, 117	134
1602	Frontotemporal lobar degeneration: a clinical approach. 2014 , 34, 189-201	58
1601	C9orf72 repeat expansions in rapid eye movement sleep behaviour disorder. 2014 , 41, 759-62	14
1600	Rapid detection of expanded short tandem repeats in personal genomics using hybrid sequencing. 2014 , 30, 815-22	50
1599	Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia. 2014 , 71, 775-81	24
1598	Cortical degeneration in frontotemporal lobar degeneration with TDP-43 proteinopathy caused by progranulin gene mutation. 2014 , 124, 894-903	3
1597	ALS and other motor neuron diseases. 2014 , 20, 1185-207	28

1596	ALS-FTD complex disorder due to C9ORF72 gene mutation: description of first Polish family. 2014 , 72, 64-71	1
1595	Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?. 2014 , 4, 417-37	11
1594	TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC) _n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. 2014 , 289, 4653-9	145
1593	No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. 2014 , 40, 844-54	17
1592	Endoplasmic reticulum stress is accompanied by activation of NF- κ B in amyotrophic lateral sclerosis. 2014 , 270, 29-36	37
1591	Diagnosis and management of behavioral variant frontotemporal dementia. 2014 , 75, 574-81	69
1590	FXN GAA repeat expansions in amyotrophic lateral sclerosis. 2014 , 21, 1319-22	
1589	Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia. 2014 , 35, 1213.e13-7	28
1588	Genetics of dementia. 2014 , 383, 828-40	179
1587	The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. 2014 , 141, 40-54	91
1586	The multifaceted role of glial cells in amyotrophic lateral sclerosis. 2014 , 71, 287-97	61
1585	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. 2014 , 22, 735-40	22
1584	Roles of Multiple Types of Autophagy in Neurodegenerative Diseases. 2014 , 61-68	
1583	C9ORF72 mutations in neurodegenerative diseases. 2014 , 49, 386-98	19
1582	The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. 2014 , 41, 844-52	76
1581	Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection. 2014 , 127, 243-56	22
1580	Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis. 2014 , 49, 966-83	15
1579	Amyotrophic lateral sclerosis and skeletal muscle: an update. 2014 , 49, 984-90	51

1578	Neurodegenerative diseases: G-quadruplex poses quadruple threat. 2014 , 507, 175-7	26
1577	Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. 2014 , 1842, 1295-301	79
1576	C9orf72 nucleotide repeat structures initiate molecular cascades of disease. 2014 , 507, 195-200	630
1575	Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. 2014 , 71, 999-1015	71
1574	The neuropathology associated with repeat expansions in the C9ORF72 gene. 2014 , 127, 347-57	135
1573	The C9ORF72 expansion mutation: gene structure, phenotypic and diagnostic issues. 2014 , 127, 319-32	38
1572	Searching for Grendel: origin and global spread of the C9ORF72 repeat expansion. 2014 , 127, 391-6	25
1571	The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. 2014 , 127, 333-45	124
1570	C9ORF72: grabbing a tiger by the tail. 2014 , 127, 311-8	1
1569	TMEM106B: a strong FTLN disease modifier. 2014 , 127, 419-22	18
1568	Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. 2014 , 127, 451-8	56
1567	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. 2014 , 127, 407-18	97
1566	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). 2014 , 127, 423-439	183
1565	Mechanisms of toxicity in C9FTLD/ALS. 2014 , 127, 359-76	114
1564	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. 2014 , 127, 397-406	108
1563	Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia. 2014 , 127, 377-89	39
1562	SIRT1 in neurodevelopment and brain senescence. <i>Neuron</i> , 2014 , 81, 471-83	13.9 291
1561	Motoneuron disease. 2014 , 220, 411-41	8

1560	Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. 2014 , 14, 781-95		300
1559	Folding of the RNA recognition motif (RRM) domains of the amyotrophic lateral sclerosis (ALS)-linked protein TDP-43 reveals an intermediate state. 2014 , 289, 8264-76		28
1558	Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. 2014 , 49, 786-803		56
1557	Neurotrophic Factors. 2014 ,		24
1556	Oligonucleotide-based therapy for neurodegenerative diseases. 2014 , 1584, 116-28		30
1555	Neurodegenerative Diseases. 2014 ,		2
1554	Dementia in Clinical Practice: A Neurological Perspective. 2014 ,		20
1553	Dissection of genetic factors associated with amyotrophic lateral sclerosis. 2014 , 262 Pt B, 91-101		116
1552	Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. <i>Neuron</i> , 2014 , 82, 295-307	13.9	116
1551	Repeat expansion in C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. 2014 , 35, 267.e1-7		27
1550	Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. 2014 , 23, R47-53		48
1549	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. 2014 , 128, 525-41		138
1548	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. 2014 , 23, 749-54		84
1547	Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. 2014 , 57, 2755-72		70
1546	Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. 2014 , 50, 721-32		45
1545	Progranulin in neurodegenerative disease. 2014 , 37, 388-98		119
1544	C9ORF72 familial motor neuron disease - frontotemporal dementia associated with lung adenocarcinoma and anti-Ma2/Ta antibodies: a chance association?. 2014 , 21, e31-3		5
1543	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. 2014 , 51, 419-24		96

1542	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. 2014 , 35, 2421.e13-7	62
1541	Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. 2014 , 35, 1499-509	51
1540	Increased expression of microRNA-29a in ALS mice: functional analysis of its inhibition. 2014 , 53, 231-41	41
1539	Familial frontotemporal dementia associated with C9orf72 repeat expansion and dysplastic gangliocytoma. 2014 , 35, 444.e11-4	1
1538	Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. 2014 , 127, 151-73	36
1537	Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. 2014 , 262 Pt B, 75-83	63
1536	Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?. 2014 , 20, 25-35	27
1535	Amyotrophic Lateral Sclerosis. 2014 , 395-423	3
1534	Dementia in 2013: frontotemporal lobar degeneration-building on breakthroughs. 2014 , 10, 70-2	20
1533	State of play in amyotrophic lateral sclerosis genetics. 2014 , 17, 17-23	1018
1532	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. 2014 , 23, 2220-31	95
1531	Gene and protein therapies utilizing VEGF for ALS. 2014 , 141, 261-71	36
1530	Tracking the progression of social cognition in neurodegenerative disorders. 2014 , 85, 1076-83	64
1529	C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. 2014 , 23, 3579-95	330
1528	Additional resources and the default mode network: Evidence of increased connectivity and decreased white matter integrity in amyotrophic lateral sclerosis. 2014 , 15, 537-45	23
1527	Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. 2014 , 34, 15587-600	91
1526	Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability?. 2014 , 224, 45-51	28
1525	Microarray gene and miRNA expression studies: looking for new therapeutic targets for frontotemporal lobar degeneration. 2014 , 75, 366-71	3

1524	Repeat-associated non-AUG translation and its impact in neurodegenerative disease. 2014 , 11, 721-31	31
1523	Tools and talk: an evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis. 2014 , 49, 469-77	31
1522	Neuronal RNA-binding proteins in health and disease. 2014 , 5, 565-76	24
1521	The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. 2014 , 28, 30-40	38
1520	ALS-related misfolded protein management in motor neurons and muscle cells. 2014 , 79, 70-8	23
1519	Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis. 2014 , 10, 1256-71	84
1518	Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS. <i>Neuron</i> , 2014 , 84, 241-3	13.9 13
1517	Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. 2014 , 262 Pt B, 121-6	61
1516	Parkinsonian syndrome in familial frontotemporal dementia. 2014 , 20, 957-64	62
1515	Genetic architecture of ALS in Sardinia. 2014 , 35, 2882.e7-2882.e12	48
1514	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. 2014 , 137, 2938-50	67
1513	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. 2014 , 85, 684-91	47
1512	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. 2014 , 42, 6591-602	41
1511	Biological metals and metal-targeting compounds in major neurodegenerative diseases. 2014 , 43, 6727-49	336
1510	Systems Biology of RNA Binding Proteins. 2014 ,	3
1509	C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. 2014 , 345, 1192-1194	454
1508	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. 2014 , 23, 1916-22	14
1507	Cell Biology. Clogging information flow in ALS. 2014 , 345, 1118-9	12

1506	Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. 2014 , 35, 2884.e1-2884.e4	80
1505	C9ORF72 repeat expansion: a genetic mutation associated with Amyotrophic Lateral Sclerosis. 2014 , 4, 161-167	
1504	Mitochondrial oxidative phosphorylation transcriptome alterations in human amyotrophic lateral sclerosis spinal cord and blood. 2014 , 16, 714-26	23
1503	Imaging frontotemporal lobar degeneration. 2014 , 14, 489	33
1502	Significance and limitation of the pathological classification of TDP-43 proteinopathy. 2014 , 34, 578-88	20
1501	The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease. 2014 , 369,	133
1500	Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). 2014 , 262 Pt B, 138-51	39
1499	Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. <i>Neuron</i> , 2014 , 83, 1043-50	13.9 232
1498	Heritability in frontotemporal dementia: more missing pieces?. 2014 , 261, 2170-7	27
1497	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. 2014 , 35, 2657.e13-2657.e19	
1496	Patterns of microglial cell activation in frontotemporal lobar degeneration. 2014 , 40, 686-96	50
1495	miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. 2014 , 15, 243-53	76
1494	The phenotypic variability of amyotrophic lateral sclerosis. 2014 , 10, 661-70	331
1493	RNA binding proteins: a common denominator of neuronal function and dysfunction. 2014 , 30, 610-26	27
1492	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. 2014 , 6, 1	110
1491	Treatment of frontotemporal dementia. 2014 , 16, 319	45
1490	Identical twins with the C9orf72 repeat expansion are discordant for ALS. 2014 , 83, 1476-8	39
1489	C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. 2014 , 76, 120-33	61

1488	FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion. 2014 , 128, 597-604	20
1487	Amyotrophic lateral sclerosis in a patient with a family history of huntington disease: genetic counseling challenges. 2014 , 23, 725-33	9
1486	Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. 2014 , 34, 8021-31	118
1485	C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. 2014 , 82, 292-9	152
1484	Movement Disorders in Dementias. 2014 ,	2
1483	Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?. 2014 , 171, 2191-205	68
1482	Genome-wide association study combining pathway analysis for typical sporadic amyotrophic lateral sclerosis in Chinese Han populations. 2014 , 35, 1778.e9-1778.e23	36
1481	Assessment of Parkinson's disease risk loci in Greece. 2014 , 35, 442.e9-442.e16	12
1480	Frontotemporal dementia and its subtypes: a genome-wide association study. 2014 , 13, 686-99	207
1479	A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. 2014 , 137, 2329-45	292
1478	Analysis of the C9orf72 gene in spinal muscular atrophy patients. 2014 , 15, 563-8	2
1477	RNA-binding proteins in neurological diseases. 2014 , 57, 432-44	45
1476	A novel small molecule HSP90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo. 2014 , 19, 421-35	19
1475	Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery. 2014 , 23, 955-63	10
1474	Atlas of Neuromuscular Diseases. 2014 ,	2
1473	Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. 2014 , 345, 1139-45	418
1472	Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. 2014 , 35, 2658.e1-2658.e5	27
1471	Cortical thinning and its relation to cognition in amyotrophic lateral sclerosis. 2014 , 35, 240-6	59

1470	Discovery of 1,3,4-oxidiazole scaffold compounds as inhibitors of superoxide dismutase expression. 2014 , 24, 1532-7	11
1469	RNA-protein interactions in unstable microsatellite diseases. 2014 , 1584, 3-14	43
1468	Identification of C9orf72 repeat expansions in patients with amyotrophic lateral sclerosis and frontotemporal dementia in mainland China. 2014 , 35, 936.e19-22	45
1467	RNA metabolism in ALS: when normal processes become pathological. 2014 , 15, 321-36	45
1466	Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2014 , 35, 2421.e1-2421.e12	37
1465	Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. 2014 , 35, 2419.e17-21	16
1464	Analysis of the hexanucleotide repeat expansion and founder haplotype at C9ORF72 in an Irish psychosis case-control sample. 2014 , 35, 1510.e1-5	15
1463	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. 2014 , 35, 1473-82	38
1462	The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. 2014 , 1584, 28-38	55
1461	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. 2014 , 35, 408-17	29
1460	C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation. 2014 , 35, 1780.e13-7	2
1459	Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis. 2014 , 35, 936.e1-4	13
1458	De novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. 2014 , 35, 1513.e7-11	19
1457	C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. 2014 , 35, 1214.e7-1214.e10	44
1456	Familial benign frontotemporal deterioration with C9ORF72 hexanucleotide expansion. 2014 , 10, S284-9	15
1455	Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. 2014 , 35, 1214.e1-6	43
1454	PGRN haploinsufficiency increased Wnt5a signaling in peripheral cells from frontotemporal lobar degeneration-progranulin mutation carriers. 2014 , 35, 886-98	20
1453	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. 2014 , 35, 1779.e5-1779.e13	19

1452	Screening for frontal lobe and general cognitive impairment in patients with amyotrophic lateral sclerosis. 2014 , 336, 191-6	39
1451	Extensive molecular genetic survey of Taiwanese patients with amyotrophic lateral sclerosis. 2014 , 35, 2423.e1-6	40
1450	Identification of a novel missense (C7W) mutation of SOD1 in a large familial amyotrophic lateral sclerosis pedigree. 2014 , 35, 725.e11-5	6
1449	C9orf72 repeat expansions are restricted to the ALS-FTD spectrum. 2014 , 35, 936.e13-7	24
1448	Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. 2014 , 29, 827-30	20
1447	C9ORF72 in dementia with Lewy bodies. 2014 , 85, 1435-6	11
1446	A roadmap for genetic testing in ALS. 2014 , 85, 476	3
1445	Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. 2014 , 71, 331-9	112
1444	Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. 2014 , 26, 6-15	90
1443	Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. 2014 , 262 Pt B, 84-90	70
1442	C9orf72; abnormal RNA expression is the key. 2014 , 262 Pt B, 102-10	13
1441	Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. 2014 , 37, 433-42	150
1440	Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. 2014 , 340, 5-12	35
1439	UBQLN2 mutations are not a frequent cause of amyotrophic lateral sclerosis in Ireland. 2014 , 35, 267.e9-11	6
1438	?????????????????????. 2014 , 117, 1423-1430	
1437	Stem cell transplantation in neurological diseases: improving effectiveness in animal models. 2014 , 2, 17	23
1436	The role of miRNA in motor neuron disease. 2014 , 8, 15	40
1435	The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. 2014 , 8, 147	83

1434	Phenotypic variability associated with the C9ORF72 hexanucleotide repeat expansion: a sporadic case of frontotemporal lobar degeneration with prodromal hyposmia and predominant semantic deficits. 2014 , 40, 849-55	5
1433	Epigenetic modifications of the C9ORF72 gene: a potential biomarker of disease?. 2014 , 9, 123-126	
1432	Astrocyte toxicity in motor neuron disease: progress and future hopes. 2014 , 9, 149-161	
1431	Molecular network analysis suggests a logical hypothesis for the pathological role of c9orf72 in amyotrophic lateral sclerosis/frontotemporal dementia. 2014 , 6, 69-78	24
1430	Presymptomatic electrophysiological tests predict clinical onset and survival in SOD1(G93A) ALS mice. 2014 , 50, 943-9	11
1429	Genetica delle demenze degenerative. 2015 , 15, 1-9	
1428	Novel animal models of GARS-associated neuropathy by overexpression of mutant GARS using an adenoviral vector. 2015 , 19, 359-364	
1427	Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. 2015 , 78, 568-83	100
1426	Accumulation of dipeptide repeat proteins predates that of TDP-43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. 2015 , 41, 601-12	53
1425	C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. 2015 , 78, 426-38	189
1424	Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). 2015 , 41, 578-97	56
1423	Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. 2015 , 41, 858-81	130
1422	Theme 14 Therapeutic Strategies. 2015 , 16 Suppl 1, 227-49	
1421	Topology of a G-quadruplex DNA formed by C9orf72 hexanucleotide repeats associated with ALS and FTD. 2015 , 5, 16673	48
1420	G4-associated human diseases. 2015 , 16, 910-22	200
1419	Genetic Counseling: Preconception, Prenatal, and Perinatal. 2015 , 1-67	
1418	The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis. 2016 , 49, 875-85	20
1417	The Role of Regulatory T Cells and Microglia in Amyotrophic Lateral Sclerosis. 2015 , 235-249	

1416	Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. 2015 , 1,	21
1415	Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. 2015 ,	0
1414	Screening for C9orf72 Expansion Mutation in Serbian Patients with Early-Onset Dementia. 2015 , 40, 358-65	3
1413	Theme 9 Genetics. 2015 , 16 Suppl 1, 160-75	
1412	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. 2015 , 29, 353-6	7
1411	Amyotrophic lateral sclerosis models derived from human embryonic stem cells with different superoxide dismutase 1 mutations exhibit differential drug responses. 2015 , 15, 459-468	11
1410	Frontotemporale Demenz: vorwiegend Verhaltens- und Sprachstörungen. 2015 , 16, 42-50	2
1409	The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. 2015 , 4, 5	30
1408	C9ORF72 expression and cellular localization over mouse development. 2015 , 3, 59	18
1407	Bioinformatics Data Mining Approach Suggests Coexpression of AGTPBP1 with an ALS-linked Gene C9orf72. 2015 , 7, 15-26	6
1406	Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis. 2015 , 44, 49-56	9
1405	Lack of C9orf72 expansion in 406 sporadic and familial cases of idiopathic dystonia in Japan. 2015 , 30, 1430-1	1
1404	Histone deacetylases (HDACs) in frontotemporal lobar degeneration. 2015 , 41, 245-57	8
1403	Promising Targets for the Treatment of Neurodegenerative Diseases. 2015 , 98, 492-501	17
1402	Phenotypic and molecular analyses of primary lateral sclerosis. 2015 , 1, e3	38
1401	Rodent Models of Amyotrophic Lateral Sclerosis. 2015 , 69, 5.67.1-5.67.21	150
1400	Acute Traumatic Brain Injury Does Not Exacerbate Amyotrophic Lateral Sclerosis in the SOD1 (G93A) Rat Model. 2015 , 2,	7
1399	. 2015 ,	1

1398	The genetic basis of amyotrophic lateral sclerosis: recent breakthroughs. 2015 , 327	10
1397	and the FTD-ALS spectrum: A systematic review of neuroimaging studies. 2015 , 9, 413-421	8
1396	Pattern of Respiratory Deterioration in Sporadic Amyotrophic Lateral Sclerosis According to Onset Lesion by Using Respiratory Function Tests. 2015 , 24, 351-7	5
1395	The Genetics of Monogenic Frontotemporal Dementia. 2015 , 9, 219-229	28
1394	New perspectives in the search for reliable biomarkers in Alzheimer disease. 2015 , 29, 51-65	3
1393	Amyotrophic lateral sclerosis: clinical perspectives. 2015 , 19	1
1392	C9orf72-related disorders: expanding the clinical and genetic spectrum of neurodegenerative diseases. 2015 , 73, 246-56	19
1391	Autophagy and Neurodegeneration: Insights from a Cultured Cell Model of ALS. 2015 , 4, 354-86	55
1390	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. 2015 , 7, 171	75
1389	ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. 2015 , 7, 205	13
1388	Executive Dysfunctions and Event-Related Brain Potentials in Patients with Amyotrophic Lateral Sclerosis. 2015 , 7, 225	15
1387	Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling. 2015 , 9, 203	51
1386	Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. 2015 , 9, 410	25
1385	ALS Patient Stem Cells for Unveiling Disease Signatures of Motoneuron Susceptibility: Perspectives on the Deadly Mitochondria, ER Stress and Calcium Triad. 2015 , 9, 448	28
1384	Golgi fragmentation in amyotrophic lateral sclerosis, an overview of possible triggers and consequences. 2015 , 9, 400	35
1383	Golgi Fragmentation in ALS Motor Neurons. New Mechanisms Targeting Microtubules, Tethers, and Transport Vesicles. 2015 , 9, 448	42
1382	Neurodegeneration and Dementia. 2015 , 398-406	
1381	DNA secondary structure at chromosomal fragile sites in human disease. 2015 , 16, 60-70	37

1380	A comprehensive library of familial human amyotrophic lateral sclerosis induced pluripotent stem cells. 2015 , 10, e0118266	33
1379	Genotype-property patient-phenotype relations suggest that proteome exhaustion can cause amyotrophic lateral sclerosis. 2015 , 10, e0118649	16
1378	Microstructural changes across different clinical milestones of disease in amyotrophic lateral sclerosis. 2015 , 10, e0119045	26
1377	Analysis of the GGGGCC Repeat Expansions of the C9orf72 Gene in SCA3/MJD Patients from China. 2015 , 10, e0130336	6
1376	Risk factors for amyotrophic lateral sclerosis. 2015 , 7, 181-93	204
1375	Resveratrol: A Focus on Several Neurodegenerative Diseases. 2015 , 2015, 392169	100
1374	The building process of the functional paraspeckle with long non-coding RNAs. 2015 , 7, 1-47	32
1373	When the Good Turns Bad. 2015 , 259-272	
1372	Clinical and genetic basis of familial amyotrophic lateral sclerosis. 2015 , 73, 1026-37	18
1371	Dementia in motor neuron disease: Reviewing the role of MRI in diagnosis. 2015 , 9, 369-379	2
1370	Frontotemporal Lobar Degeneration. 2015 , 57-66	1
1369	What does imaging reveal about the pathology of amyotrophic lateral sclerosis?. 2015 , 15, 45	48
1368	Jump from pre-mutation to pathologic expansion in C9orf72. 2015 , 96, 962-70	41
1367	C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence. 2015 , 84, 1622-30	55
1366	Genetics of ALS. 2015 , 385-409	
1365	Slowly progressive frontotemporal lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. 2015 , 21, 85-9	26
1364	Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. 2015 , 72, 49-57	27
1363	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. 2015 , 130, 363-72	53

1362	No abnormal hexanucleotide repeat expansion of C9ORF72 in Japanese schizophrenia patients. 2015 , 122, 731-2	10
1361	Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis. 2015 , 12, 340-51	23
1360	Diseases of Motor Neurons and Neuromuscular Junctions. 2015 , 165-197	
1359	mRNA metabolism and neuronal disease. 2015 , 589, 1598-606	16
1358	Evaluation of Skin Fibroblasts from Amyotrophic Lateral Sclerosis Patients for the Rapid Study of Pathological Features. 2015 , 28, 138-46	21
1357	C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis. 2015 , 10, e0127376	74
1356	Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions. 2015 , 28, 99-107	29
1355	Iron is a specific cofactor for distinct oxidation- and aggregation-dependent A β toxicity mechanisms in a Drosophila model. 2015 , 8, 657-67	19
1354	The Genetic Workup for Congenital Structural Heart Disease: From Clinical to Genetic Evaluation. 238-256	1
1353	Circulating microRNAs in Disease Diagnostics and their Potential Biological Relevance. 2015 ,	7
1352	Reply: Is CHCHD10 Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?. 2015 , 138, e386	3
1351	Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. 2015 , 24, 6198-212	44
1350	Inhibitory dysfunction in amyotrophic lateral sclerosis: future therapeutic opportunities. 2015 , 5, 511-25	11
1349	Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. 2015 , 5, e007069	21
1348	Polyalanine expansions drive a shift into β helical clusters without amyloid-fibril formation. 2015 , 22, 1008-15	29
1347	Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. 2015 , 22, 1505-1511	17
1346	Molecular basis of ALS and FTD: implications for translational studies. 2015 , 66, 285-90	7
1345	Circulating microRNAs in Neurodegenerative Diseases. 2015 , 106, 151-169	18

1344	Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. 2015 , 36, 546.e1-7	41
1343	Amyotrophic Lateral Sclerosis: Review. 2015 , 35, 469-76	41
1342	Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. 2015 , 74, 359-76	51
1341	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. 2015 , 129, 469-91	165
1340	Human glial progenitor engraftment and gene expression is independent of the ALS environment. 2015 , 264, 188-99	18
1339	Identification and computational analysis of gene regulatory elements. 2015 , 2015, pdb.top083642	4
1338	High Caloric Diets in Amyotrophic Lateral Sclerosis. 2015 , 355-361	
1337	Biomarkers: a new approach to behavioural variant frontotemporal dementia. 2015 , 30, 50-61	1
1336	Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72-a cautionary note. 2015 , 36, 1224-6	9
1335	Analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. 2015 , 36, 1221.e1-6	32
1334	TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. 2015 , 12, 352-63	176
1333	DNA damage in neurodegenerative diseases. 2015 , 776, 84-97	111
1332	Endocannabinoids and amyotrophic lateral sclerosis. 2015 , 99-123	8
1331	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. 2015 , 14, 291-301	165
1330	Amyotrophic Lateral Sclerosis and Dementia. 2015 , 23-34	1
1329	Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. 2015 , 36, 1223.e1-2	19
1328	The distinct genetic pattern of ALS in Turkey and novel mutations. 2015 , 36, 1764.e9-1764.e18	65
1327	VCP mutations are not a major cause of familial amyotrophic lateral sclerosis in the UK. 2015 , 349, 209-13	9

1326	Small deletion in C9orf72 hides a proportion of expansion carriers in FTL. 2015 , 36, 1601.e1-5	17
1325	Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?. 2015 , 126, 1288-94	12
1324	Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. 2015 , 24, 2426-41	161
1323	Functional roles of alternative splicing factors in human disease. 2015 , 6, 311-26	89
1322	Diagnosis and treatment of chorea syndromes. 2015 , 15, 514	56
1321	Repeat instability during DNA repair: Insights from model systems. 2015 , 50, 142-67	112
1320	Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia. 2015 , 4, 16-24	51
1319	Frontotemporal dementia: a bridge between dementia and neuromuscular disease. 2015 , 1338, 71-93	86
1318	Use of biomarkers in ALS drug development and clinical trials. 2015 , 1607, 94-107	31
1317	Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing. 2015 , 21, 599-615	22
1316	PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. 2015 , 24, 1741-54	49
1315	Emerging role of RNADNA hybrids in C9orf72-linked neurodegeneration. 2015 , 14, 526-32	22
1314	R-loops highlight the nucleus in ALS. 2015 , 6, 23-9	31
1313	Multiple system atrophy: the application of genetics in understanding etiology. 2015 , 25, 19-36	15
1312	A fruitful endeavor: modeling ALS in the fruit fly. 2015 , 1607, 47-74	64
1311	Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. 2015 , 22, 745-52	86
1310	The C9orf72 repeat expansion itself is methylated in ALS and FTL. 2015 , 129, 715-27	101
1309	No evidence of association between polymorphisms in four genes and sporadic amyotrophic lateral sclerosis in Han Chinese. 2015 , 16, 245-8	2

1308	The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis. 2015 , 12, 326-39	39
1307	Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future. 2015 , 26, 161-81	3
1306	Dementia: An Overview of Risk Factors. 2015 , 187-198	4
1305	Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: broadening the clinical and neuropsychological phenotype. 2015 , 16, 8-15	7
1304	A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. 2015 , 16, 490-6	4
1303	ACTH (Acthar Gel) Reduces Toxic SOD1 Protein Linked to Amyotrophic Lateral Sclerosis in Transgenic Mice: A Novel Observation. 2015 , 10, e0125638	1
1302	FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. 2015 , 130, 525-35	101
1301	Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS). 2015 , 1628, 343-350	33
1300	The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. 2015 , 130, 315-31	212
1299	Genetics of Mendelian Forms of Parkinson's Disease. 2015 , 3-18	1
1298	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. 2015 , 130, 537-55	125
1297	Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. 2015 , 49, 182-7	34
1296	Lack of relationship between the P413L chromogranin B variant and a SALS Italian cohort. 2015 , 568, 186-9	4
1295	The Big Bluff of Amyotrophic Lateral Sclerosis Diagnosis: The Role of Neurodegenerative Disease Mimics. 2015 , 15, 313-21	6
1294	Frontotemporal lobar dementia and amyotrophic lateral sclerosis associated with c9orf72 expansion. 2015 , 171, 475-81	6
1293	Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?. 2015 , 5, 93-5	2
1292	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. 2015 , 271, 241-50	19
1291	In silico analysis of SIGMAR1 variant (rs4879809) segregating in a consanguineous Pakistani family showing amyotrophic lateral sclerosis without frontotemporal lobar dementia. 2015 , 16, 299-306	33

1290	Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. 2015 , 133, 1-26	76
1289	Profiling of ubiquitination pathway genes in peripheral cells from patients with frontotemporal dementia due to C9ORF72 and GRN mutations. 2015 , 16, 1385-94	9
1288	Cognitive Profile of C9orf72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. 2015 , 15, 59	11
1287	Mutation analysis of C9orf72 in patients with corticobasal syndrome. 2015 , 36, 2905.e1-5	11
1286	Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. 2015 , 18, 1175-82	235
1285	Frontotemporal Dementia. 2015 , 779-791	1
1284	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. 2015 , 36, 2904.e13-26	34
1283	C9ORF72 hexanucleotide repeat expansion in ALS patients from the Central European Russia population. 2015 , 36, 2908.e5-9	8
1282	Six SQSTM1 mutations in a Chinese amyotrophic lateral sclerosis cohort. 2015 , 16, 378-84	20
1281	Neuroimaging features in C9orf72 and TARDBP double mutation with FTD phenotype. 2015 , 21, 529-34	7
1280	Environmental Factors and Amyotrophic Lateral Sclerosis. 2015 , 329-353	
1279	Guanine tetrads: an IRMPD spectroscopy, energy resolved SORI-CID, and computational study of M(9-ethylguanine)(4)(+) (M = Li, Na, K, Rb, Cs) in the gas phase. 2015 , 17, 25778-85	26
1278	The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross-sectional comparison of established screening tools in a German-Swiss population. 2015 , 16, 16-23	86
1277	p62/SQSTM1 analysis in frontotemporal lobar degeneration. 2015 , 36, 1603.e5-9	10
1276	Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population. 2015 , 36, 1601.e17-20	8
1275	Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. 2015 , 267, 115-22	30
1274	Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death. 2015 , 130, 86-120	128
1273	Site promiscuity of coliphage HK022 integrase as a tool for gene therapy. 2015 , 22, 521-7	3

1272	Semantic deficits in amyotrophic lateral sclerosis. 2015 , 16, 46-53	31
1271	Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. 2015 , 11, 266-79	145
1270	Motor neuron disease-frontotemporal dementia: a clinical continuum. 2015 , 15, 509-22	41
1269	Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. 2015 , 11, 1277-85	59
1268	The Repeat Expansion Diseases: The dark side of DNA repair. 2015 , 32, 96-105	46
1267	Letter to the Editor on a paper by Hsiao C-T, Tsai P-C, Liao Y-C, Lee Y-C, Soong B-W. C9ORF72 repeat expansion is not a significant cause of late-onset cerebellar ataxia syndrome. <i>J Neurol Sci</i> 2014;347:322-324. 2015 , 351, 196-197	1
1266	Stratified gene expression analysis identifies major amyotrophic lateral sclerosis genes. 2015 , 36, 2006.e1-9	14
1265	Intermediate-length polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese patients with amyotrophic lateral sclerosis. 2015 , 36, 1603.e11-4	12
1264	Genetic Variation of MT-ND Genes in Frontotemporal Lobar Degeneration: Biochemical Phenotype-Genotype Correlation. 2015 , 15, 70-80	1
1263	Neuropsychiatric symptoms and survival in amyotrophic lateral sclerosis: a missing link?. 2015 , 5, 89-91	3
1262	Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. 2015 , 16, 86-91	47
1261	Complexities of Genetic Counseling for ALS: A Case of Two Siblings with Discordant Genetic Test Results. 2015 , 24, 553-7	9
1260	Amyotrophic Lateral Sclerosis: An Aging-Related Disease. 2015 , 4, 142-153	14
1259	Heme activation by DNA: isoguanine pentaplexes, but not quadruplexes, bind heme and enhance its oxidative activity. 2015 , 43, 4191-201	26
1258	TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. 2015 , 3, 15	29
1257	Applications of Cas9 as an RNA-programmed RNA-binding protein. 2015 , 37, 732-9	27
1256	Patient-derived olfactory mucosa for study of the non-neuronal contribution to amyotrophic lateral sclerosis pathology. 2015 , 19, 1284-95	5
1255	G-quadruplexes: Emerging roles in neurodegenerative diseases and the non-coding transcriptome. 2015 , 589, 1653-68	145

1254	Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. 2015 , 130, 63-75	118
1253	The Role of Neuroimaging in Amyotrophic Lateral Sclerosis. 2015 , 787-797	
1252	Movement Disorder Genetics. 2015 ,	
1251	Current developments in gene therapy for amyotrophic lateral sclerosis. 2015 , 15, 935-47	25
1250	Amyotrophic Lateral Sclerosis. 2015 , 163-182	
1249	Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. 2015 , 348, 1151-4	279
1248	Proteome-wide analysis of neural stem cell differentiation to facilitate transition to cell replacement therapies. 2015 , 12, 83-95	4
1247	Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. 2015 , 39, 287-93	15
1246	Nuclear accumulation of mRNAs underlies G4C2-repeat-induced translational repression in a cellular model of C9orf72 ALS. 2015 , 128, 1787-99	85
1245	Amyotrophic lateral sclerosis as a spatiotemporal mislocalization disease: location, location, location. 2015 , 315, 23-71	8
1244	Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. 2015 , 24, 3529-44	42
1243	Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. 2015 , 130, 49-61	49
1242	The dual roles of immunity in ALS: injury overrides protection. 2015 , 77, 1-12	49
1241	FTD and ALS--translating mouse studies into clinical trials. 2015 , 11, 360-6	55
1240	A network of RNA and protein interactions in Fronto Temporal Dementia. 2015 , 8, 9	20
1239	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. 2015 , 130, 77-92	222
1238	Emerging mechanisms of molecular pathology in ALS. 2015 , 125, 1767-79	167
1237	Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases. 2015 , 74, 380-7	26

1236	Impaired cognitive flexibility in amyotrophic lateral sclerosis. 2015 , 28, 17-26	18
1235	Autophagosome dynamics in neurodegeneration at a glance. 2015 , 128, 1259-67	97
1234	Lifting the veil: how to use clinical neuropsychology to assess dementia. 2015 , 86, 1216-24	13
1233	Focal Cortical Degenerations. 2015 , 707-711	
1232	Rab8, POSH, and TAK1 regulate synaptic growth in a Drosophila model of frontotemporal dementia. 2015 , 208, 931-47	54
1231	Motor neuron dysfunctions in the frontotemporal lobar degeneration spectrum: a clinical and neurophysiological study. 2015 , 351, 72-77	14
1230	Defects in optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis. 2015 , 24, 3830-46	56
1229	The frontotemporal dementias. 2015 , 38, 193-209	10
1228	Young-onset dementia epidemiology applied to neuropsychiatry practice. 2015 , 38, 233-48	10
1227	Increased anxiety-like behavior and selective learning impairments are concomitant to loss of hippocampal interneurons in the presymptomatic SOD1(G93A) ALS mouse model. 2015 , 523, 1622-38	23
1226	Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. 2015 , 78, 684-92	52
1225	Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). 2015 , 31, 263-73	88
1224	Dual Role of Autophagy in Neurodegenerative Diseases: The Case of Amyotrophic Lateral Sclerosis. 2015 , 63-78	2
1223	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. 2015 , 36, 2906.e1-5	10
1222	Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. 2015 , 231, 213-31	23
1221	Endocannabinoids. 2015 ,	13
1220	Vapb/Amyotrophic lateral sclerosis 8 knock-in mice display slowly progressive motor behavior defects accompanying ER stress and autophagic response. 2015 , 24, 6515-29	34
1219	Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. <i>Neuron</i> , 2015 , 87, 1207-1214	13.9 149

1218	Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. 2015 , 33, 855-76	151
1217	Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. 2015 , 3, 36	61
1216	A perspective on stem cell modeling of amyotrophic lateral sclerosis. 2015 , 14, 3679-88	15
1215	DNA Replication Dynamics of the GGGGCC Repeat of the C9orf72 Gene. 2015 , 290, 28953-62	17
1214	Theme 11 ALS Pathogenesis and Neurotoxicity. 2015 , 16 Suppl 1, 186-205	
1213	Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport. 2015 , 11, 670-2	11
1212	Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. 2015 , 85, 1780-8	50
1211	Neurodegenerative Disorders as Systemic Diseases. 2015 ,	1
1210	Experimental approaches for elucidating co-agonist regulation of NMDA receptor in motor neurons: Therapeutic implications for amyotrophic lateral sclerosis (ALS). 2015 , 116, 2-6	10
1209	RNautophagy/DNautophagy possesses selectivity for RNA/DNA substrates. 2015 , 43, 6439-49	26
1208	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. 2015 , 23, 1056-66	18
1207	Frontotemporal dementia. 2015 , 386, 1672-82	471
1206	A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression. 2015 , 11, 1133-43	17
1205	Solution structure of a DNA quadruplex containing ALS and FTD related GGGGCC repeat stabilized by 8-bromodeoxyguanosine substitution. 2015 , 43, 8590-600	48
1204	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). 2015 , 82, 445-454	27
1203	Biomarker for Amyotrophic Lateral Sclerosis. 2015 , 1031-1052	
1202	Neurogenetic disorders in the Basque population. 2015 , 79, 57-75	4
1201	Oral Presentations. 2015 , 41, 8-29	

1200	Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. 2015 , 12, 793-806	85
1199	Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. 2015 , 16, 497-505	61
1198	Genetic variation and the de novo assembly of human genomes. 2015 , 16, 627-40	242
1197	Quadruplex formation by both G-rich and C-rich DNA strands of the C9orf72 (GGGGCC)8(GGCCCC)8 repeat: effect of CpG methylation. 2015 , 43, 10055-64	52
1196	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. 2015 , 130, 863-76	81
1195	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLT-DTP and ALS. 2015 , 130, 661-78	47
1194	Drosophila as an In Vivo Model for Human Neurodegenerative Disease. 2015 , 201, 377-402	172
1193	Genetik neurodegenerativer Erkrankungen. 2015 , 42, 385-392	1
1192	Genetics of Frontotemporal Dementia. 2015 , 75-105	
1191	C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis. 2015 , 36, 2660.e1-8	40
1190	Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. 2015 , 6, 5999	186
1189	Decade in review-dementia: a decade of discovery and disappointment in dementia research. 2015 , 11, 613-4	3
1188	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population. 2015 , 262, 2498-503	23
1187	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: the TARDBP Ala382Thr mutation and C9orf72 expansion. 2015 , 357, 229-34	4
1186	How many biomarkers to discriminate neurodegenerative dementia?. 2015 , 52, 314-26	14
1185	De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. 2015 , 36, 3117.e1-3117.e6	48
1184	Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. 2015 , 4, 13	46
1183	Closing the tau loop: the missing tau mutation. 2015 , 138, 3100-9	29

1182	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. 2015 , 525, 56-61	642
1181	GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. 2015 , 525, 129-33	540
1180	Neurodegeneration: Problems at the nuclear pore. 2015 , 525, 36-7	12
1179	Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. 2015 , 18, 1226-9	411
1178	A 30-unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP-43 inclusions and clinical disease. 2015 , 130, 599-601	27
1177	Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis. 2015 , 33, 787-805	28
1176	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. 2015 , 130, 559-73	72
1175	Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. 2015 , 130, 845-61	155
1174	A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. 2015 , 10, 1099-118	20
1173	Cortical Function in Asymptomatic Carriers and Patients With C9orf72 Amyotrophic Lateral Sclerosis. 2015 , 72, 1268-74	59
1172	Prevalence of neurogenetic disorders in the North of England. 2015 , 85, 1195-201	18
1171	Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. 2015 , 3, 38	66
1170	Familial Amyotrophic Lateral Sclerosis. 2015 , 33, 807-30	76
1169	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. 2015 , 85, 1283-92	20
1168	Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. 2015 , 85, 2116-25	119
1167	C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. <i>Neuron</i> , 2015 , 88, 892-901	13.9 201
1166	Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. <i>Neuron</i> , 2015 , 88, 902-909	13.9 183
1165	Epidemiology and molecular mechanism of frontotemporal lobar degeneration/amyotrophic lateral sclerosis with repeat expansion mutation in C9orf72. 2015 , 29, 85-94	14

1164	Session 1 - joint opening session. 2015 , 16 Suppl 1, 1-62	3
1163	Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. 2015 , 24, 3133-42	74
1162	Fundamentals of Neurodegeneration and Protein Misfolding Disorders. 2015 ,	3
1161	Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. 2015 , 24, 1682-90	48
1160	Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion. 2015 , 86, 986-95	36
1159	C9ORF72 hexanucleotide repeat expansions are a frequent cause of Huntington disease phenocopies in the Greek population. 2015 , 36, 547.e13-6	26
1158	Role of Inflammation in Neurodegenerative Diseases. 2015 , 380-395	2
1157	MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis. 2015 , 56, 102-12	38
1156	Amyotrophic Lateral Sclerosis. 2015 , 1033-1050	
1155	Clinical Subtypes of Frontotemporal Dementia. 2015 , 30, 653-61	16
1154	Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. 2015 , 86, 168-73	188
1153	Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases. 2015 , 32, 212-28	27
1152	Biomarkers: a new approach to behavioural variant frontotemporal dementia. 2015 , 30, 50-61	13
1151	Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. 2015 , 41, 201-26	45
1150	Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art. 2015 , 41, 109-34	34
1149	Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survival. 2015 , 37, 55-70	48
1148	Biomarker development for C9orf72 repeat expansion in ALS. 2015 , 1607, 26-35	19
1147	Sporadic and hereditary amyotrophic lateral sclerosis (ALS). 2015 , 1852, 679-84	126

1146	Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control. 2015 , 1607, 36-46	54
1145	Opposing roles of p38 and JNK in a Drosophila model of TDP-43 proteinopathy reveal oxidative stress and innate immunity as pathogenic components of neurodegeneration. 2015 , 24, 757-72	43
1144	Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. 2015 , 24, 1630-45	111
1143	Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. 2015 , 129, 39-52	98
1142	Characterization of DNA G-quadruplex species forming from C9ORF72 G4C2-expanded repeats associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2015 , 36, 1091-6	53
1141	Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS. 2015 , 36, 1130-9	41
1140	ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis. 2015 , 1607, 1-14	18
1139	Induced pluripotent stem cells from ALS patients for disease modeling. 2015 , 1607, 15-25	44
1138	Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. 2015 , 21, 543-7	1
1137	The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?. 2015 , 1617, 155-73	59
1136	Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins. 2015 , 24, 740-56	44
1135	Sequencing technologies and tools for short tandem repeat variation detection. 2015 , 16, 193-204	18
1134	Functional overlap and divergence between ALS and bvFTD. 2015 , 36, 413-23	51
1133	Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges. 2015 , 1607, 75-93	107
1132	Amyotrophic Lateral Sclerosis. 2015 , 262-280	2
1131	PET Imaging in ALS. 2016 ,	2
1130	Overview of Motor Neuron Disorders. 2016 ,	
1129	Tiny microRNAs Fine-Tune Amyotrophic Lateral Sclerosis Regulation. 2016 ,	

1128	Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS. 2016 , 25, 233-240	80
1127	A Novel Loss-of-Function GRN Mutation p.(Tyr229*): Clinical and Neuropathological Features. 2017 , 55, 1167-1174	5
1126	Geneticsof frontotemporal dementia and related disorders. 185-196	
1125	Frontotemporal Dementia in Amyotrophic Lateral Sclerosis: From Rarity to Reality?. 2016 , 8, 6534	3
1124	Esclerosis lateral amiotrřica: actualizaciř. 2016 , 29,	1
1123	Primary progressive aphasia: conceptual evolution and challenges. 2016 , 9	6
1122	The Association between C9orf72 Repeats and Risk of Alzheimer’s Disease and Amyotrophic Lateral Sclerosis: A Meta-Analysis. 2016 , 2016, 5731734	11
1121	The Use of Stem Cells to Model Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: From Basic Research to Regenerative Medicine. 2016 , 2016, 9279516	15
1120	Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: effects of genetic, demographic and neuropathological variables. 2016 , 54, 137-48	6
1119	Editorial: Repetitive Structures in Biological Sequences: Algorithms and Applications. 2016 , 4, 66	
1118	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. 2016 , 8, 10	13
1117	Impaired Autophagy and Defective Mitochondrial Function: Converging Paths on the Road to Motor Neuron Degeneration. 2016 , 10, 44	30
1116	A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease. 2016 , 10, 204	29
1115	C9orf72’s Interaction with Rab GTPases-Modulation of Membrane Traffic and Autophagy. 2016 , 10, 228	21
1114	Rare Variants in Neurodegeneration Associated Genes Revealed by Targeted Panel Sequencing in a German ALS Cohort. 2016 , 9, 92	30
1113	Forward Genetic Screen in Suggests F57A10.2 and acp-4 As Suppressors of C9ORF72 Related Phenotypes. 2016 , 9, 113	13
1112	Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. 2016 , 6, 142-9	31
1111	The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. 2016 , 4, 51	175

1110	Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. 2016 , 12, e1006443	115
1109	Mutation Frequency of the Major Frontotemporal Dementia Genes, MAPT, GRN and C9ORF72 in a Turkish Cohort of Dementia Patients. 2016 , 11, e0162592	16
1108	DNA Methylation in Neurodegenerative Diseases. 2016 , 401-415	4
1107	The genetics of amyotrophic lateral sclerosis: current insights. 2016 , 6, 49-64	41
1106	Sequencing-based diagnostics for pediatric genetic diseases: progress and potential. 2016 , 16, 987-99	22
1105	The C9ORF72 expansion sizes in patients with psychosis: a population-based study on the Northern Finland Birth Cohort 1966. 2016 , 26, 92-4	10
1104	Review: Induced pluripotent stem cell models of frontotemporal dementia. 2016 , 42, 497-520	7
1103	From the Bench. 2016 , 16, 29-30	
1102	The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal Variants. 2016 , 37, 877-83	10
1101	Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. 2016 , 138 Suppl 1, 54-70	167
1100	Motor function and behaviour across the ALS-FTD spectrum. 2016 , 133, 367-72	16
1099	Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: a systematic neuropathological review. 2016 , 42, 547-60	27
1098	Oligogenic inheritance of optineurin (OPTN) and C9ORF72 mutations in ALS highlights localisation of OPTN in the TDP-43-negative inclusions of C9ORF72-ALS. 2016 , 36, 125-34	27
1097	Structural brain correlates of cognitive and behavioral impairment in MND. 2016 , 37, 1614-26	64
1096	Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions. 2016 , 42, 377-89	5
1095	Cortical hyperexcitability in patients with C9ORF72 mutations: Relationship to phenotype. 2016 , 54, 264-9	19
1094	Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update. 2016 , 53, 842-9	8
1093	Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated loci. 2016 , 2, e71	5

1092	New In Vitro Models to Study Amyotrophic Lateral Sclerosis. 2016 , 26, 258-65	14
1091	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. 2016 , 31, 436-57	148
1090	TDP-43 binds and transports G-quadruplex-containing mRNAs into neurites for local translation. 2016 , 21, 466-81	61
1089	Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients. 2016 , 30, 3461-3473	39
1088	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions. 2016 , 79, 295-305	21
1087	Old versus New Mechanisms in the Pathogenesis of ALS. 2016 , 26, 276-86	37
1086	Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts. 2016 , 10, 453-62	9
1085	Sessions 1 - 11. 2016 , 17, 1-80	1
1084	Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. 2016 , 6, 37968	52
1083	A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy. 2016 , 53, 475-85	9
1082	A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. 2016 , 2, e1601167	144
1081	The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. 2016 , 35, 1656-76	237
1080	Historical introduction to FTD. 1-14	
1079	Overview of frontotemporal dementia and its relationship to other neurodegenerative disorders. 15-29	1
1078	Clinical phenotypes. 30-43	1
1077	Primary progressive aphasia. 55-67	2
1076	The FTD-ALS spectrum. 68-81	1
1075	Neuropathology of frontotemporal dementia and related disorders. 165-184	1

1074	Functional disability and the impact of frontotemporal dementia in everyday life. 211-228	
1073	Anti-sense DNA d(GGCCCC)n expansions in C9ORF72 form i-motifs and protonated hairpins. 2015 , 5, 17944	53
1072	Influence of cigarette smoking on ALS outcome: a population-based study. 2016 , 87, 1229-1233	27
1071	Paving the road for the study of epigenetics in neurodegenerative diseases. 2016 , 132, 483-5	5
1070	Gene expression profiles and protein-protein interaction networks in amyotrophic lateral sclerosis patients with C9orf72 mutation. 2016 , 11, 148	28
1069	Bidirectional Transcriptional Inhibition as Therapy for ALS/FTD Caused by Repeat Expansion in C9orf72. <i>Neuron</i> , 2016 , 92, 1160-1163	13.9 14
1068	An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. 2016 , 6, 39490	26
1067	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. 2016 , 51, 277-91	13
1066	Quantitative Assessment of Eye Phenotypes for Functional Genetic Studies Using <i>Drosophila melanogaster</i> . 2016 , 6, 1427-37	29
1065	Motor neuron disease: biomarker development for an expanding cerebral syndrome. 2016 , 16, s60-s65	4
1064	Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis. 2016 , 6, 39297	11
1063	Lost & found: C9ORF72 and the autophagy pathway in ALS/FTD. 2016 , 35, 1251-3	7
1062	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. 2017 , 55, 973-979	17
1061	Recent advances in genetics of chorea. 2016 , 29, 486-95	22
1060	Longitudinal imaging in mutation carriers: Relationship to phenotype. 2016 , 12, 1035-1043	49
1059	C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. 2016 , 6, 23204	162
1058	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. 2017 , 55, 585-595	30
1057	The ONDRISeg panel: custom-designed next-generation sequencing of genes related to neurodegeneration. 2016 , 1, 16032	17

1056	Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation. 2016 , 4, 74	15
1055	Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. 2016 , 1647, 65-78	89
1054	Analysis of RNA metabolism in peripheral WBCs of TDP-43 KI mice identifies novel biomarkers of ALS. 2016 , 106, 12-22	3
1053	Recent advances in amyotrophic lateral sclerosis. 2016 , 263, 1241-54	55
1052	Modeling ALS with motor neurons derived from human induced pluripotent stem cells. 2016 , 19, 542-53	174
1051	Inhibition of long non-coding RNA IGF2AS has profound effect on inducing neuronal growth and protecting local-anesthetic induced neurotoxicity in dorsal root ganglion neurons. 2016 , 82, 298-303	19
1050	ALS: A bucket of genes, environment, metabolism and unknown ingredients. 2016 , 142, 104-129	124
1049	Characterization of an FTL-DDB family with the coexistence of SQSTM1 mutation and hexanucleotide (GGGGGG) repeat expansion in C9orf72 gene. 2016 , 40, 191.e1-191.e8	9
1048	PET-CT and PET-MRI in Neurology. 2016 ,	2
1047	A novel 10-base pair insertion mutation in exon 5 of the SOD1 gene in a Chinese family with amyotrophic lateral sclerosis. 2016 , 45, 212.e1-212.e4	3
1046	Stress granules at the intersection of autophagy and ALS. 2016 , 1649, 189-200	68
1045	Genotype-phenotype correlations of amyotrophic lateral sclerosis. 2016 , 5, 3	43
1044	No Change in Executive Performance in ALS Patients: A Longitudinal Neuropsychological Study. 2016 , 16, 184-91	29
1043	Protein folding alterations in amyotrophic lateral sclerosis. 2016 , 1648, 633-649	65
1042	RAN translation-What makes it run?. 2016 , 1647, 30-42	68
1041	Proteostasis impairment in ALS. 2016 , 1648, 571-579	49
1040	There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. 2016 , 1647, 19-29	103
1039	The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. 2016 , 17, 383-95	127

1038	C9ORF72-ALS/FTD: Transgenic Mice Make a Come-BAC. <i>Neuron</i> , 2016 , 90, 427-31	13.9	14
1037	Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. 2016 , 25, 2681-2697		38
1036	C9orf72 isoforms in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. 2016 , 1647, 43-49		31
1035	Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy. 2016 , 66, 127-42		10
1034	Axonal transport defects are a common phenotype in Drosophila models of ALS. 2016 , 25, 2378-2392		70
1033	C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. <i>Neuron</i> , 2016 , 90, 521-34	13.9	218
1032	Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. <i>Neuron</i> , 2016 , 90, 535-50	13.9	331
1031	ALS: Recent Developments from Genetics Studies. 2016 , 16, 59		45
1030	Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs. 2016 , 11, 1720-8		98
1029	Nucleocytoplasmic transport in C9orf72-mediated ALS/FTD. 2016 , 7, 132-7		18
1028	Frontotemporale Lobendegeneration [Prägnanztypen, Diagnosekriterien und Therapieansätze]. 2016 , 10, 179-190		2
1027	Impaired protein degradation in FTLD and related disorders. 2016 , 32, 122-139		47
1026	Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. 2016 , 132, 175-196		80
1025	Depression in amyotrophic lateral sclerosis. 2016 , 86, 2271-7		39
1024	Serum metal evaluation in a small cohort of Amyotrophic Lateral Sclerosis patients reveals high levels of thiophylic species. 2016 , 2,		3
1023	Abnormal d-Serine Metabolism in Amyotrophic Lateral Sclerosis. 2016 , 137-149		2
1022	Identification of a novel loss-of-function C9orf72 splice site mutation in a patient with amyotrophic lateral sclerosis. 2016 , 47, 219.e1-219.e5		15
1021	Mechanisms of Dendrite Degeneration in Amyotrophic Lateral Sclerosis. 2016 , 545-579		

1020	Cell-to-Cell Transmission of Dipeptide Repeat Proteins Linked to C9orf72-ALS/FTD. 2016 , 17, 645-652	120
1019	Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study. 2016 , 12, 460-5	31
1018	Recent Advances in Stem Cells. 2016 ,	1
1017	Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. 2016 , 4, 99	71
1016	Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. 2016 , 113, E6496-E6505	102
1015	Frontotemporal dementia. 2016 , 49-63	2
1014	Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. <i>Neuron</i> , 2016 , 92, 383-391	13.9 220
1013	The epidemiology of amyotrophic lateral sclerosis. 2016 , 138, 225-38	126
1012	DEMENCIA FRONTOTEMPORAL, CMO HA RESURGIDO SU DIAGNOSTICO. 2016 , 27, 309-318	1
1011	C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. 2016 , 19, 1610-1618	87
1010	Pathophysiological and diagnostic implications of cortical dysfunction in ALS. 2016 , 12, 651-661	119
1009	Pluripotent Stem Cells for Modeling Motor Neuron Diseases. 2016 , 85-100	
1008	Dynamic expression of the mouse orthologue of the human amyotrophic lateral sclerosis associated gene C9orf72 during central nervous system development and neuronal differentiation. 2016 , 229, 871-891	4
1007	The role of the FTD-ALS associated C9orf72 expansion in suicide victims. 2016 , 17, 589-592	3
1006	MRS in Motor Neuron Diseases. 2016 , 121-150	
1005	Clinical aspects of motor neurone disease. 2016 , 44, 552-556	11
1004	Therapy and clinical trials in frontotemporal dementia: past, present, and future. 2016 , 138 Suppl 1, 211-21	76
1003	Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. 2016 , 87, 1024-30	49

1002	Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. 2016 , 22, 769-783	80
1001	Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials. 2016 , 39, 124-35	4
1000	Prion-like propagation as a pathogenic principle in frontotemporal dementia. 2016 , 138 Suppl 1, 163-83	42
999	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. 2016 , 353, 708-12	92
998	NEURODEGENERATION. One target for amyotrophic lateral sclerosis therapy?. 2016 , 353, 647-8	1
997	Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation. 2016 , 95, 168-78	37
996	C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. 2016 , 34, 2063-78	133
995	Dysregulated axonal RNA translation in amyotrophic lateral sclerosis. 2016 , 7, 589-603	21
994	Genetics of FTL: overview and what else we can expect from genetic studies. 2016 , 138 Suppl 1, 32-53	89
993	Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions. 2016 , 138 Suppl 1, 145-62	54
992	Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia. 2016 , 138 Suppl 1, 134-44	35
991	The clinical spectrum of sporadic and familial forms of frontotemporal dementia. 2016 , 138 Suppl 1, 6-31	78
990	Charting Frontotemporal Dementia: From Genes to Networks. 2016 , 26, 16-27	7
989	Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. 2016 ,	0
988	C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. 2016 , 27, 3040-3051	114
987	What we know about TMEM106B in neurodegeneration. 2016 , 132, 639-651	59
986	D-Amino Acids. 2016 ,	6
985	Chromatin Landscape and Epigenetic Signatures in Neurological Disorders. 2016 , 519-537	1

984	Supportive and symptomatic management of amyotrophic lateral sclerosis. 2016 , 12, 526-38	73
983	Structural insight into C9orf72 hexanucleotide repeat expansions: Towards new therapeutic targets in FTD-ALS. 2016 , 100, 11-20	17
982	Dementia and Cognitive Impairment. 2016 , 289-336	4
981	Genetics of Frontotemporal Dementia. 2016 , 16, 107	72
980	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. 2016 , 3, 623-36	163
979	Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases. 2016 , 44, 9050-9070	31
978	Familial Amyotrophic Lateral Sclerosis-linked Mutations in Profilin 1 Exacerbate TDP-43-induced Degeneration in the Retina of <i>Drosophila melanogaster</i> through an Increase in the Cytoplasmic Localization of TDP-43. 2016 , 291, 23464-23476	13
977	Amyotrophic lateral sclerosis: moving towards a new classification system. 2016 , 15, 1182-94	221
976	Common and Divergent Mechanisms in Developmental Neuronal Remodeling and Dying Back Neurodegeneration. 2016 , 26, R628-R639	42
975	Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia. 2016 , 533-546	1
974	Amyotrophic Lateral Sclerosis 1 and Many Diseases. 2016 , 685-712	2
973	Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population. 2016 , 61, 1003-1008	20
972	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. 2016 , 48, 1043-8	328
971	Pure cerebellar ataxia linked to large C9orf72 repeat expansion. 2016 , 17, 301-3	14
970	Potential new complication in drug therapy development for amyotrophic lateral sclerosis. 2016 , 16, 1397-1405	13
969	Role of FET proteins in neurodegenerative disorders. 2016 , 13, 1089-1102	53
968	Decoding ALS: from genes to mechanism. 2016 , 539, 197-206	1040
967	<i>Drosophila</i> screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. 2016 , 6, 20877	179

966	From animal models to human disease: a genetic approach for personalized medicine in ALS. 2016 , 4, 70	87
965	C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. 2016 , 167, 774-788.e17	402
964	Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. 2016 , 167, 789-802.e12	235
963	Impaired set-shifting in amyotrophic lateral sclerosis: An event-related potential study of executive function. 2016 , 30, 120-134	32
962	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. 2016 , 7, 11253	126
961	TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. 2016 , 6, 33996	38
960	Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis. 2016 , 25, 4771-4786	11
959	Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. 2016 , 139, 3202-3216	90
958	Modelling C9orf72 dipeptide repeat proteins of a physiologically relevant size. 2016 , 25, 5069-5082	19
957	Diversity of Cognitive Phenotypes Associated with C9ORF72 Hexanucleotide Expansion. 2016 , 52, 25-31	
956	Pathophysiology and animal models of frontotemporal dementia. 197-210	
955	Pharmacologic therapy for FTD and related disorders. 243-261	1
954	Diagnostic Distortions: A Case Report of Progressive Apraxia of Speech. 2016 , 53, 79-83	5
953	C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. 2016 , 16, 370-2	7
952	Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype. 2016 , 4, 122	9
951	Unstable repeat expansion in major psychiatric disorders: two decades on, is dynamic DNA back on the menu?. 2016 , 26, 156-65	4
950	New ALS-Related Genes Expand the Spectrum Paradigm of Amyotrophic Lateral Sclerosis. 2016 , 26, 266-75	23
949	Mitochondrial Dysfunction in Neurodegenerative Disorders. 2016 ,	2

948	ALS and FTD: an epigenetic perspective. 2016 , 132, 487-502	51
947	Defining the spectrum of frontotemporal dementias associated with TARDBP mutations. 2016 , 2, e80	41
946	Periodic power spectrum with applications in detection of latent periodicities in DNA sequences. 2016 , 73, 1053-1079	8
945	Hypo- and Hyper-Assembly Diseases of RNA-Protein Complexes. 2016 , 22, 615-628	53
944	Inside out: the role of nucleocytoplasmic transport in ALS and FTL. 2016 , 132, 159-173	81
943	C9ORF72 G4C2-repeat expansion and frontotemporal dementia first reported case in Argentina. 2016 , 22, 281-4	3
942	Delineating the relationship between amyotrophic lateral sclerosis and frontotemporal dementia: Sequence and structure-based predictions. 2016 , 1862, 1742-54	19
941	A transgenic mouse expressing CHMP2Bintron5 mutant in neurons develops histological and behavioural features of amyotrophic lateral sclerosis and frontotemporal dementia. 2016 , 25, 3341-3360	23
940	Simple animal models for amyotrophic lateral sclerosis drug discovery. 2016 , 11, 797-804	12
939	Variants within the SP110 nuclear body protein modify risk of canine degenerative myelopathy. 2016 , 113, E3091-100	25
938	Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. 2016 , 73, 812-20	40
937	C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. 2016 , 4, 37	39
936	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. 2016 , 4, 47	96
935	Further development of biomarkers in amyotrophic lateral sclerosis. 2016 , 16, 853-68	8
934	Mitochondria, the Synapse, and Neurodegeneration. 2016 , 219-239	1
933	Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. 2016 , 30, 218-224	25
932	Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. 2016 , 35, 1276-97	250
931	Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. 2016 , 17, 1669-82	13

930	GBA-associated parkinsonism and dementia: beyond β -synucleinopathies?. 2016 , 23, 520-6	6
929	In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. 2016 , 221, 1387-402	26
928	Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases. 2016 , 24, 271-6	1
927	A genome-wide association study on amyotrophic lateral sclerosis in the Taiwanese Han population. 2016 , 10, 597-611	8
926	Vulnerability of microRNA biogenesis in FTD-ALS. 2016 , 1647, 105-111	27
925	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. 2016 , 41, 16-26	8
924	In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells. 2016 , 73, 3-12	16
923	SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. 2016 , 60, 95-104	79
922	Unstable repeat expansions in neurodegenerative diseases: nucleocytoplasmic transport emerges on the scene. 2016 , 39, 174-83	24
921	The 'Omics' of Amyotrophic Lateral Sclerosis. 2016 , 22, 53-67	25
920	Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. 2016 , 39, 219.e1-8	42
919	Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis. 2016 , 38, 217.e15-217.e22	31
918	Cognitive impairment in amyotrophic lateral sclerosis, clues from the SOD1 mouse. 2016 , 60, 12-25	11
917	The role of CHMP2B in autophagy and frontotemporal dementia. 2016 , 1649, 151-157	28
916	C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. 2016 , 19, 668-677	201
915	The Glycine-Alanine Dipeptide Repeat from C9orf72 Hexanucleotide Expansions Forms Toxic Amyloids Possessing Cell-to-Cell Transmission Properties. 2016 , 291, 4903-11	52
914	ALS biomarkers for therapy development: State of the field and future directions. 2016 , 53, 169-82	64
913	Maturation and electrophysiological properties of human pluripotent stem cell-derived oligodendrocytes. 2016 , 34, 1040-53	50

912	Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases. 2016 , 156, 1-13	21
911	Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. 2016 , 42, 242-54	48
910	C9orf72 is required for proper macrophage and microglial function in mice. 2016 , 351, 1324-9	334
909	A look into the future of ALS research. 2016 , 21, 939-49	16
908	Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. 2016 , 30, 227-43	29
907	Parkinsonism, movement disorders and genetics in frontotemporal dementia. 2016 , 12, 175-85	80
906	To Dement or Not to Dement, That Is the Question. 2016 , 73, 383-4	
905	G-quadruplex formation of oligonucleotides containing ALS and FTD related GGGGCC repeat. 2016 , 10, 222-237	5
904	C9ORF72 repeat expansion is not detected in sporadic ataxia patients in mainland China. 2016 , 361, 181-3	1
903	Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking. 2016 , 18, 174-88	140
902	Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. 2016 , 263, 558-74	30
901	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. 2016 , 132, 391-411	77
900	Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred. 2016 , 17, 245-8	5
899	The frontotemporal dementia-motor neuron disease continuum. 2016 , 388, 919-31	191
898	Syntactic comprehension deficits across the FTD-ALS continuum. 2016 , 41, 11-18	21
897	Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. 2016 , 121, 918-925	12
896	Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. 2016 , 4, 18	34
895	Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. 2016 , 25, 1803-13	102

894	Analysis of C9orf72 in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Argentina. 2016 , 40, 192.e13-192.e15	17
893	Disturbance of proteasomal and autophagic protein degradation pathways by amyotrophic lateral sclerosis-linked mutations in ubiquilin 2. 2016 , 472, 324-31	56
892	Endocytic membrane trafficking and neurodegenerative disease. 2016 , 73, 1529-45	99
891	[Amyotrophic lateral sclerosis. Multisystem degeneration]. 2016 , 87, 179-88	13
890	C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. 2016 , 277, 171-177	16
889	An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. 2016 , 36, 99-106	54
888	Methylation of C9orf72 expansion reduces RNA foci formation and dipeptide-repeat proteins expression in cells. 2016 , 612, 204-209	20
887	Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. 2016 , 71, 34-45	54
886	Progranulin mutation analysis: Identification of one novel mutation in exon 12 associated with frontotemporal dementia. 2016 , 39, 218.e1-3	5
885	Preferential PPAR- β activation reduces neuroinflammation, and blocks neurodegeneration in vivo. 2016 , 25, 317-27	49
884	Left hand dystonia as a recurring feature of a family carrying C9ORF72 mutation. 2016 , 87, 793-5	3
883	Translational potential of astrocytes in brain disorders. 2016 , 144, 188-205	72
882	Reverse engineering human neurodegenerative disease using pluripotent stem cell technology. 2016 , 1638, 30-41	15
881	Purinergic contribution to amyotrophic lateral sclerosis. 2016 , 104, 180-93	44
880	MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis. 2016 , 139, 86-100	28
879	Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells. 2016 , 56, 123-40	49
878	Iron and Neurodegeneration: Is Ferritinophagy the Link?. 2016 , 53, 5542-74	62
877	The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. 2016 , 21, 1112-24	154

876	Cognitive and Behavioral Symptoms in ALS/FTD: Detection, Differentiation, and Progression. 2016 , 29, 3-10	20
875	CHCHD10 Pro34Ser is not a highly penetrant pathogenic variant for amyotrophic lateral sclerosis and frontotemporal dementia. 2016 , 139, e9	7
874	Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. 2015 , 17, 85-92	25
873	C9orf72 mutations may be rare in frontotemporal lobar degeneration patients in India. 2015 , 17, 151-3	5
872	Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. 2016 , 31, 229-45	67
871	Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?. 2016 , 22, 161-7	2
870	Mitochondria and endoplasmic reticulum crosstalk in amyotrophic lateral sclerosis. 2016 , 90, 35-42	53
869	Psychosis associated with expansions in the C9orf72 gene: the influence of a 10 base pair gene deletion. 2016 , 87, 562-3	9
868	Spinocerebellar ataxia 36 (SCA36): «Costa da Morte ataxia». 2017 , 32, 386-393	4
867	The Role of Long Noncoding RNAs in Neurodegenerative Diseases. 2017 , 54, 2012-2021	108
866	Modeling ALS and FTD with iPSC-derived neurons. 2017 , 1656, 88-97	37
865	Executive dysfunction affects word list recall performance: Evidence from amyotrophic lateral sclerosis and other neurodegenerative diseases. 2017 , 11, 74-90	13
864	Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP-43 subcellular distribution. 2017 , 43, 133-153	18
863	Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis. 2017 , 112, 346-364	18
862	Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis. 2017 , 97, 103-113	26
861	C9ORF72 Regulates Stress Granule Formation and Its Deficiency Impairs Stress Granule Assembly, Hypersensitizing Cells to Stress. 2017 , 54, 3062-3077	58
860	Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis. 2017 , 54, 3189-3194	14
859	Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. 2017 , 27, 723-736	76

858	Fused in Sarcoma Neuropathology in Neurodegenerative Disease. 2017 , 7,	10
857	Phase to Phase with TDP-43. 2017 , 56, 809-823	47
856	HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort. 2017 , 373, 124-128	10
855	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. 2017 , 51, 177.e9-177.e16	43
854	Linking amyotrophic lateral sclerosis and spinal muscular atrophy through RNA-transcriptome homeostasis: a genomics perspective. 2017 , 141, 12-30	14
853	Pathology of Neurodegenerative Diseases. 2017 , 9,	360
852	Biological Spectrum of Amyotrophic Lateral Sclerosis Prions. 2017 , 7,	16
851	Widespread temporo-occipital lobe dysfunction in amyotrophic lateral sclerosis. 2017 , 7, 40252	25
850	Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. 2017 , 1, CD011776	23
849	Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis. 2017 , 53, 195.e1-195.e5	15
848	The neuropathological signature of bulbar-onset ALS: A systematic review. 2017 , 75, 378-392	26
847	The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. 2017 , 92, 259-266	33
846	A PR plug for the nuclear pore in amyotrophic lateral sclerosis. 2017 , 114, 1445-1447	5
845	Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. 2017 , 53, 194.e1-194.e8	34
844	Toxic PR poly-dipeptides encoded by the repeat expansion block nuclear import and export. 2017 , 114, E1111-E1117	142
843	Diagnosis of Spinocerebellar Ataxias Caused by Trinucleotide Repeat Expansions. 2017 , 92, 9.30.1-9.30.22	1
842	Amyotrophic Lateral Sclerosis. 2017 , 493-502	2
841	Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. 2017 , 54, 145-154	57

840	DNA repair and mutations during quiescence in yeast. 2017 , 17,		15
839	Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. 2017 , 12, 6		43
838	c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA. 2017 , 24, 141-148		22
837	C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism. 2017 , 32, 158-162		12
836	Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome. <i>Neuron</i> , 2017 , 93, 331-347	13.9	131
835	Frontotemporal dementia. 143-155		
834	A genomic view of short tandem repeats. 2017 , 44, 9-16		50
833	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. 2017 , 88, 281		25
832	Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. <i>Neuron</i> , 2017 , 93, 1015-1034	13.9	596
831	Psychiatric Presentations of C9orf72 Mutation: What Are the Diagnostic Implications for Clinicians?. 2017 , 29, 195-205		38
830	Tdp-43 cryptic exons are highly variable between cell types. 2017 , 12, 13		37
829	Potential multisystem degeneration in Asidan patients. 2017 , 373, 216-222		3
828	The identification of a novel isoform of EphA4 and ITS expression in SOD1 mice. 2017 , 347, 11-21		5
827	Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function. 2017 , 292, 5089-5100		35
826	Regulation of DENND3, the exchange factor for the small GTPase Rab12 through an intramolecular interaction. 2017 , 292, 7274-7282		9
825	Genetic Counseling Dilemmas for a Patient with Sporadic Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration & Parkinson's Disease. 2017 , 26, 442-446		3
824	C9orf72 hexanucleotide repeat expansions are not a common cause of obsessive-compulsive disorder. 2017 , 375, 71-72		2
823	Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: Frequency of abnormality and effect on survival. 2017 , 376, 16-23		34

822	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. 2017 , 13, 858-869	18
821	C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease. 2017 , 18, 267-276	36
820	Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). 2017 , 55, 123-131	74
819	Frontotemporal Dementia. 2017 , 35, 339-374	177
818	Interactions of pathological proteins in neurodegenerative diseases. 2017 , 134, 187-205	193
817	Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. 2017 , 13, 1280-1303	50
816	Frontotemporal dementia. 2017 , 199-249	1
815	C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration?. 2017 , 378, 49-51	2
814	References. 2017 , 301-354	
813	Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis. 2017 , 137-160	
812	Progranulin, lysosomal regulation and neurodegenerative disease. 2017 , 18, 325-333	114
811	Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. 2017 , 134, 241-254	70
810	Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. 2017 , 133, 863-885	145
809	Next Generation Sequencing Based Clinical Molecular Diagnosis of Human Genetic Disorders. 2017 ,	0
808	Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. 2017 , 16, 505-512	428
807	The roles of the nuclear pore complex in cellular dysfunction, aging and disease. 2017 , 68, 72-84	66
806	RNA metabolism in neurodegenerative disease. 2017 , 10, 509-518	78
805	Modelling amyotrophic lateral sclerosis: progress and possibilities. 2017 , 10, 537-549	110

804	Frontotemporal dementia as a comorbidity to idiopathic normal pressure hydrocephalus (iNPH): a short review of literature and an unusual case. 2017 , 14, 10	12
803	Bidirectional nucleolar dysfunction in C9orf72 frontotemporal lobar degeneration. 2017 , 5, 29	36
802	Targeting RNA G-Quadruplexes for Potential Therapeutic Applications. 2017 , 177-206	2
801	Endothelial and Astrocytic Support by Human Bone Marrow Stem Cell Grafts into Symptomatic ALS Mice towards Blood-Spinal Cord Barrier Repair. 2017 , 7, 884	28
800	The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. 2017 , 26, 2882-2896	74
799	Protein sequestration as a normal function of long noncoding RNAs and a pathogenic mechanism of RNAs containing nucleotide repeat expansions. 2017 , 136, 1247-1263	14
798	C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis. 2017 , 56, 211.e9-211.e14	7
797	Reappraisal of TDP-43 pathology in FTL-D subtypes. 2017 , 134, 79-96	66
796	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. 2017 , 140, 1784-1791	31
795	DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients. 2017 , 134, 271-279	26
794	Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders. 2017 , 136, 1215-1235	11
793	ALS and frontotemporal dementia belong to a common disease spectrum. 2017 , 173, 273-279	37
792	Optineurin in amyotrophic lateral sclerosis: Multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms. 2017 , 154, 1-20	52
791	Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients. 2017 , 19, 2244-2256	60
790	Neuropsychological Profile in the C9ORF72 Associated Behavioral Variant Frontotemporal Dementia. 2017 , 58, 479-489	8
789	Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. 2017 , 264, 1426-1433	22
788	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. 2017 , 134, 255-269	57
787	The Applications and Challenges of Next-Generation Sequencing in Diagnosing Neuromuscular Disorders. 2017 , 177-200	2

786	Age-related penetrance of the C9orf72 repeat expansion. 2017 , 7, 2116	61
785	Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. 2017 , 82, 139-146	58
784	Brain white matter demyelinating lesions and amyotrophic lateral sclerosis in a patient with C9orf72 hexanucleotide repeat expansion. 2017 , 17, 1-4	1
783	The evolving genetic risk for sporadic ALS. 2017 , 89, 226-233	28
782	Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy. 2017 , 95, 705-718	13
781	Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges. 2017 , 39, 190-198	33
780	New routes in frontotemporal dementia drug discovery. 2017 , 12, 659-671	5
779	Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells. 2017 , 27, 518-524	8
778	The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms. 2017 , 28, 725-738	10
777	Amyotrophic lateral sclerosis. 2017 , 390, 2084-2098	499
776	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. 2017 , 140, 887-897	94
775	Viral delivery of hexanucleotide repeat expansions in mice leads to repeat-length-dependent neuropathology and behavioural deficits. 2017 , 10, 859-868	17
774	RNA phase transitions in repeat expansion disorders. 2017 , 546, 243-247	406
773	Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. 2017 , 18, 611-623	49
772	Autophagy in neuroinflammatory diseases. 2017 , 16, 856-874	34
771	Structural and functional brain signatures of C9orf72 in motor neuron disease. 2017 , 57, 206-219	35
770	Spinocerebellar ataxia 36 (SCA36): <i>Costa da Morte ataxia</i> 2017 , 32, 386-393	2
769	C9orf72 mutations do not influence the tau signature of amyotrophic lateral sclerosis with cognitive impairment (ALSci). 2017 , 18, 549-554	2

768	Genetics of Amyotrophic Lateral Sclerosis. 2017 , 43-59	2
767	Molecular Mechanisms of Amyotrophic Lateral Sclerosis. 2017 , 61-99	3
766	Examining the language and behavioural profile in FTD and ALS-FTD. 2017 , 88, 675-680	35
765	Disease progression in mutation carriers. 2017 , 89, 234-241	21
764	Genetic models of C9orf72: what is toxic?. 2017 , 44, 92-101	41
763	New developments in RAN translation: insights from multiple diseases. 2017 , 44, 125-134	62
762	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. 2017 , 26, 1732-1746	41
761	Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. 2021 , 154, 105360	27
760	Roles of non-canonical structures of nucleic acids in cancer and neurodegenerative diseases. 2021 , 49, 7839-7855	5
759	Mortality among family members of patients with amyotrophic lateral sclerosis - a Swedish register-based study. 2021 , 1-10	
758	Generation, quality control, and analysis of the first genomically humanised knock-in mice for the ALS/FTD genes SOD1, TARDBP (TDP-43), and FUS.	
757	Mitostasis, Calcium and Free Radicals in Health, Aging and Neurodegeneration. 2021 , 11,	11
756	Blood-based Biomarkers for Amyotrophic Lateral Sclerosis. 105-120	0
755	Genome-wide contribution of common Short-Tandem Repeats to Parkinson Disease genetic risk.	0
754	Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities. 2021 , 14, 713031	3
753	RNA Is a Double-Edged Sword in ALS Pathogenesis. 2021 , 15, 708181	3
752	Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases. 2021 , 15, 668500	3
751	Amyotrophic Lateral Sclerosis (ALS): Stressed by Dysfunctional Mitochondria-Endoplasmic Reticulum Contacts (MERCs). 2021 , 10,	7

750	Nanosopic investigation of C9orf72 poly-GA oligomers on nuclear membrane disruption by a photoinducible platform. 2021 , 4,	
749	FTLD Patient-Derived Fibroblasts Show Defective Mitochondrial Function and Accumulation of p62. 2021 , 58, 5438-5458	1
748	TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. 2021 , 22,	4
747	Assessment of Immunological Potential of Glial Restricted Progenitor Graft In Vivo-Is Immunosuppression Mandatory?. 2021 , 10,	3
746	Motor neuron disease beginning with frontotemporal dementia: clinical features and progression. 2021 , 22, 508-516	1
745	Chemical Biology of Double Helical and Non-Double Helical Nucleic Acids: To B or Not To B, That Is the Question 2021 , 94, 1970-1998	6
744	Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing. 2021 , 11,	3
743	Prion-Like Proteins in Phase Separation and Their Link to Disease. 2021 , 11,	3
742	Genetic and epigenetic disease modifiers in an Italian family expressing ALS, FTD or PD clinical phenotypes. 2021 , 1-7	0
741	NDST3 deacetylates α -tubulin and suppresses V-ATPase assembly and lysosomal acidification. 2021 , 40, e107204	4
740	Ligand-induced native G-quadruplex stabilization impairs transcription initiation. 2021 , 31, 1546-1560	5
739	Imaging and Quantifying Neuronal Autophagy to Determine the Autophagy Contribution to Neuronal and Dendritic Morphogenesis. 2022 , 115-133	
738	Nuclear export and translation of circular repeat-containing intronic RNA in C9ORF72-ALS/FTD. 2021 , 12, 4908	10
737	Genotype-phenotype correlations in a chinese population with familial amyotrophic lateral sclerosis. 2021 , 1-11	0
736	SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis. 2021 , 16, 53	2
735	Splicing factor proline and glutamine rich intron retention, reduced expression and aggregate formation are pathological features of amyotrophic lateral sclerosis. 2021 , 47, 990-1003	3
734	Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. 2021 ,	4
733	Bipolar disorder and frontotemporal dementia: A systematic review. 2021 , 144, 433-447	0

732	Exploring the alternative: Fish, flies and worms as preclinical models for ALS. 2021 , 759, 136041	2
731	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. 2021 , 1-7	0
730	Analysis of Heritability Across the Clinical Phenotypes of Frontotemporal Dementia and the Frequency of the C9ORF72 in a Colombian Population. 2021 , 12, 681595	0
729	Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. 2021 , 127, 958-978	2
728	Linkage of Alzheimer disease families with Puerto Rican ancestry identifies a chromosome 9 locus. 2021 , 104, 115.e1-115.e7	0
727	Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis. 2021 , 10,	5
726	-GC Intermediate Repeats and Parkinson's Disease; A Data-Driven Hypothesis. 2021 , 12,	2
725	Therapeutic Potential of Polyphenols in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. 2021 , 10,	5
724	Picking the arginine lock on PQLC2 cycling. 2021 , 118,	
723	Plasma NFL levels and longitudinal change rates in and -associated diseases: from tailored references to clinical applications. 2021 , 92, 1278-1288	2
722	Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease. 2021 , 434, 167220	2
721	Advances in the genetic classification of amyotrophic lateral sclerosis. 2021 ,	4
720	Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. 2021 , 759, 136039	6
719	The RNA helicase DHX36-G4R1 modulates C9orf72 GGGGCC hexanucleotide repeat-associated translation. 2021 , 297, 100914	3
718	Measuring and Interpreting Nuclear Transport in Neurodegenerative Disease-The Example of C9orf72 ALS. 2021 , 22,	2
717	Translation of the poly(GR) frame in C9ORF72-ALS/FTD is regulated by cis-elements involved in alternative splicing. 2021 , 105, 327-332	2
716	Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics?. 2021 , 22,	1
715	NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. 2021 , 173, 125-141	4

7 ¹⁴	Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions. 2021 , 100, 151179	2
7 ¹³	ZNF598 co-translationally titrates poly(GR) protein implicated in the pathogenesis of C9ORF72-associated ALS/FTD. 2021 , 49, 11294-11311	2
7 ¹²	The nuclear ubiquitin ligase adaptor SPOP is a conserved regulator of C9orf72 dipeptide toxicity. 2021 , 118,	
7 ¹¹	Genetic variants in progranulin upstream open reading frames increase downstream protein expression. 2021 , 110, 113-113	
7 ¹⁰	Integrative genetic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes.	0
7 ⁰⁹	RNA Deregulation in Amyotrophic Lateral Sclerosis: The Noncoding Perspective. 2021 , 22,	5
7 ⁰⁸	Alternative polyadenylation: An enigma of transcript length variation in health and disease. 2021 , e1692	2
7 ⁰⁷	Two coexisting pseudo-mirror heteromolecular telomeric G-quadruplexes in opposite loop progressions differentially recognized by a low equivalent of Thioflavin T. 2021 , 49, 10717-10734	0
7 ⁰⁶	Novel insights into the relationship between cerebellum and dementia: A narrative review as a toolkit for clinicians. 2021 , 70, 101389	2
7 ⁰⁵	Gene Therapy Overexpressing Neuregulin 1 Type I in Combination With Neuregulin 1 Type III Promotes Functional Improvement in the SOD1 ALS Mice. 2021 , 12, 693309	1
7 ⁰⁴	Phase separation and toxicity of C9orf72 poly(PR) depends on alternate distribution of arginine. 2021 , 220,	2
7 ⁰³	Genotyping and Plasma/Cerebrospinal Fluid Profiling of a Cohort of Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Patients. 2021 , 11,	0
7 ⁰²	Elucidating the Role of Cerebellar Synaptic Dysfunction in C9orf72-ALS/FTD - a Systematic Review and Meta-Analysis. 2021 , 1	0
7 ⁰¹	Interactome screening of C9orf72 dipeptide repeats reveals VCP sequestration and functional impairment by polyGA. 2021 ,	3
7 ⁰⁰	All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. 2021 , 10,	2
699	Development of a specific live-cell assay for native autophagic flux. 2021 , 297, 101003	2
698	A Novel Genetic Marker for the C9orf72 Repeat Expansion in the Finnish Population. 2021 , 83, 1325-1332	1
697	Repeat Expansion Affects the Proteome of Primary Skin Fibroblasts in ALS. 2021 , 22,	1

696	Uncovering the impact of noncoding variants in neurodegenerative brain diseases. 2021,	1
695	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. 2021, 11, 451	0
694	Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis. 2021, 22,	4
693	Porphyryns ameliorate spinocerebellar ataxia type 36 GGCCTG repeat expansion-mediated cytotoxicity. 2021, 171, 92-102	2
692	The porphyrin TMPyP4 inhibits elongation during the noncanonical translation of the FTLN/ALS-associated GGGGCC repeat in the C9orf72 gene. 2021, 297, 101120	1
691	Frequency of frontotemporal dementia-related gene variants in Turkey. 2021, 106, 332.e1-332.e11	
690	NEAT1 lncRNA and amyotrophic lateral sclerosis. 2021, 150, 105175	0
689	Investigating RFC1 expansions in sporadic amyotrophic lateral sclerosis. 2021, 430, 118061	0
688	Younger-Onset Dementias: Behavioral Neurology/Brain Diseases/Healthy & Pathological Aging. 2022, 88-96	
687	MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches. 2022, 17, 728-740	2
686	Fluid Biomarkers of Frontotemporal Lobar Degeneration. 2021, 1281, 123-139	1
685	Motor Neuron Diseases. 2021, 820-841.e5	
684	Genetics of frontotemporal dementia. 2021, 3-16	
683	Phylogenetic analysis of microRNA biomarkers for amyotrophic lateral sclerosis. 2021, 45, 547-561	1
682	Unravelling the clinical spectrum and the role of repeat length in repeat expansions. 2021, 92, 502-509	6
681	Knowledge assessment and psychological impact of genetic counseling in people at risk for familial FTD. 2021, 13, e12225	1
680	Enhanced detection of nucleotide repeat mRNA with hybridization chain reaction.	0
679	Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy. 2021, 19-47	

678	Impaired recognition of disgust in amyotrophic lateral sclerosis is related to basal ganglia involvement. 2021 , 32, 102803	0
677	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. 2021 , 144, 2798-2811	2
676	Molecular Genetics of Frontotemporal Dementia.	2
675	Early life metal dysregulation in amyotrophic lateral sclerosis. 2020 , 7, 872-882	11
674	Amyotrophic Lateral Sclerosis: Genotypes and Phenotypes. 2014 , 179-192	1
673	Neurotrophic Therapy for ALS/MND. 2014 , 1755-1785	1
672	RNA-binding protein misregulation in microsatellite expansion disorders. 2014 , 825, 353-88	21
671	Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. 2014 , 825, 303-52	44
670	RNA Granules and Their Role in Neurodegenerative Diseases. 2019 , 1203, 195-245	10
669	Astrocytes in Motor Neuron Diseases. 2019 , 1175, 227-272	12
668	Encyclopedia of Geropsychology. 2016 , 1-17	3
667	Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders. 2017 , 54, 4466-4476	24
666	Neurodegenerative Diseases and RNA-Mediated Toxicity. 2018 , 441-475	2
665	Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36. <i>Neuron</i> , 2020 , 107, 292-305.e6	13.9 25
664	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. 2012 , 2012, 170-172	10
663	Exome sequencing to identify de novo mutations in sporadic ALS trios. 2013 , 16, 851-5	112
662	Targeting RNA structures in diseases with small molecules. 2020 , 64, 955-966	6
661	Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD. 2020 , 4, 293-305	13

660	Neuropathology of primary lateral sclerosis. 2020 , 21, 47-51	2
659	Emerging drug targets in amyotrophic lateral sclerosis.	1
658	PQLC2 recruits the C9orf72 complex to lysosomes in response to cationic amino acid starvation. 2020 , 219,	22
657	The microglial component of amyotrophic lateral sclerosis. 2020 , 143, 3526-3539	21
656	Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. 2020 , 143, 3603-3618	6
655	Intricacies of aetiology in intrafamilial degenerative disease. 2020 , 2, fcaa120	3
654	CRISPR-Cas9 targeted deletion of the C9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived iPS cells.	4
653	Detection of long repeat expansions from PCR-free whole-genome sequence data.	6
652	CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9orf72 dipeptide repeat protein toxicity.	1
651	Project MinE: study design and pilot analyses of a large-scale whole genome sequencing study in amyotrophic lateral sclerosis.	1
650	Machine learning suggests polygenic contribution to cognitive dysfunction in amyotrophic lateral sclerosis.	1
649	miRNA biomarkers for diagnosis of ALS and FTD, developed by a nonlinear machine learning approach.	2
648	Structure of the lysosomal SCARF (L-SCARF) complex, an Arf GAP haploinsufficient in ALS and FTD.	0
647	Gene expression imputation provides insight into the genetic architecture of frontotemporal dementia.	0
646	Receptor-like role for PQLC2 amino acid transporter in the lysosomal sensing of cationic amino acids.	0
645	Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types.	0
644	Resting State Functional Connectivity is Decreased Globally Across the C9orf72 Mutation Spectrum.	1
643	Activated iPSC-microglia from C9orf72 ALS/FTD patients exhibit endosomal-lysosomal dysfunction.	4

642	SFPQ intron retention, reduced expression and aggregate formation in central nervous system tissue are pathological features of amyotrophic lateral sclerosis.	1
641	Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition.	1
640	Generalized displacement of DNA- and RNA-binding factors mediates the toxicity of arginine-rich cell-penetrating peptides.	3
639	Altered BOLD signal variation in Alzheimer's disease and frontotemporal dementia.	1
638	Repeat expansion and methylation state analysis with nanopore sequencing.	3
637	Implementation of an antibody characterization process: Application to the major ALS/FTD disease gene C9ORF72.	2
636	Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia.	2
635	C9orf72 Dipeptide Repeats Inhibit UPF1-Mediated RNA Decay Independent of Stress Granule Formation.	1
634	Small molecule inhibition of PIKFYVE kinase rescues gain- and loss-of-function C9ORF72 ALS/FTD disease processes in vivo.	4
633	Sema3A Facilitates a Retrograde Death Signal via CRMP4-Dynein Complex Formation in ALS Motor Axons.	1
632	C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility.	7
631	ExpansionHunter Denovo: A computational method for locating known and novel repeat expansions in short-read sequencing data.	1
630	Neurodegenerative disorder masquerading as psychosis in a forensic psychiatry setting. 2014 , 2014,	2
629	An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. 2019 , 4,	8
628	TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. 2019 , 129, 3578-3593	14
627	Frontotemporal Dementias. 2016 , 22, 464-89	29
626	Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2017 , 23, 1332-1359	22
625	and the Care of the Patient With ALS or FTD: Progress and Recommendations After 10 Years. 2021 , 7, e542	5

624	Nuclear pore complexes in development and tissue homeostasis. 2020 , 147,	13
623	The C9orf72 expansion is associated with accelerated respiratory function decline in a large Amyotrophic Lateral Sclerosis cohort. 2019 , 2, 23	4
622	Unstable Repeat Expansion in Neurodegenerative Dementias: Mechanisms of Disease. 2012 , 11, 1	1
621	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. 2012 , 11, 38	2
620	LSM12-EPAC1 defines a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient. 2020 , 18, e3001002	4
619	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. 2017 , 13, e1007045	19
618	Daf-2 signaling modifies mutant SOD1 toxicity in <i>C. elegans</i> . 2012 , 7, e33494	30
617	Genetic overlap between apparently sporadic motor neuron diseases. 2012 , 7, e48983	48
616	RNA-Seq profiling of spinal cord motor neurons from a presymptomatic SOD1 ALS mouse. 2013 , 8, e53575	46
615	Characterization of FUS mutations in amyotrophic lateral sclerosis using RNA-Seq. 2013 , 8, e60788	16
614	RNP2 of RNA recognition motif 1 plays a central role in the aberrant modification of TDP-43. 2013 , 8, e66966	4
613	Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. 2013 , 8, e76055	91
612	Voxel-based MRI intensitometry reveals extent of cerebral white matter pathology in amyotrophic lateral sclerosis. 2014 , 9, e104894	16
611	G-quadruplex structures formed by expanded hexanucleotide repeat RNA and DNA from the neurodegenerative disease-linked C9orf72 gene efficiently sequester and activate heme. 2014 , 9, e106449	40
610	Computational and functional characterization of Angiogenin mutations, and correlation with amyotrophic lateral sclerosis. 2014 , 9, e111963	12
609	The Phenotype of the C9ORF72 Expansion Carriers According to Revised Criteria for bvFTD. 2015 , 10, e0131817	24
608	Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis. 2016 , 11, e0161816	38
607	Distinct C9orf72-Associated Dipeptide Repeat Structures Correlate with Neuronal Toxicity. 2016 , 11, e0165084	24

606	Elucidation of Relevant Neuroinflammation Mechanisms Using Gene Expression Profiling in Patients with Amyotrophic Lateral Sclerosis. 2016 , 11, e0165290	14
605	Neurotrophic effects of progranulin in vivo in reversing motor neuron defects caused by over or under expression of TDP-43 or FUS. 2017 , 12, e0174784	14
604	-Associated Arginine-Rich Dipeptide Repeat Proteins Reduce the Number of Golgi Outposts and Dendritic Branches in Drosophila Neurons. 2020 , 43, 821-830	5
603	New perspective on parkinsonism in frontotemporal lobar degeneration. 2013 , 6, 1-8	21
602	Progranulin deficiency induces overactivation of WNT5A expression via TNF- α /NF- κ B pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers. 2016 , 41, 225-39	24
601	The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded Inhibits the Proteasome. 2017 , 4,	37
600	The RNA exosome complex degrades expanded hexanucleotide repeat RNA in C9orf72 FTL/ALS. 2020 , 39, e102700	7
599	G-Quadruplexes act as sequence-dependent protein chaperones. 2020 , 21, e49735	7
598	Loss of TMEM106B potentiates lysosomal and FTL/ALS-like pathology in progranulin-deficient mice. 2020 , 21, e50241	17
597	The emerging role of minor intron splicing in neurological disorders. 2018 , 2, 40-54	17
596	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene.	2
595	Protective Effects of the Caffeine Against Neurodegenerative Diseases. 2019 , 26, 5137-5151	12
594	Dysfunctional Autophagy and Endolysosomal System in Neurodegenerative Diseases: Relevance and Therapeutic Options. 2020 , 14, 602116	13
593	Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity. 2020 , 11, 569661	3
592	Structural Diversity of Sense and Antisense RNA Hexanucleotide Repeats Associated with ALS and FTL/ALS. 2020 , 25,	8
591	Modeling neuromuscular junctions in vitro: A review of the current progress employing human induced pluripotent stem cells. 2018 , 2, 91-118	3
590	Mislocalization, aggregation formation and defect in proteolysis in ALS. 2016 , 3, 246-268	1
589	Genome-wide association studies in neurology. 2014 , 2, 124	18

588	Toward precision medicine in amyotrophic lateral sclerosis. 2016 , 4, 27	8
587	La accesibilidad de los portales web de las universidades p�blicas andaluzas. 2017 , 40, 169	6
586	Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway?. 2017 , 12, 1052-1061	30
585	The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis. 2020 , 15, 2186-2194	7
584	The 5'UTR untranslated Region of the C9orf72 mRNA Exhibits a Phylogenetic Alignment to the Cis-Aconitase Iron-Responsive Element; Novel Therapies for Amyotrophic Lateral Sclerosis. 2016 , 07, 15-26	7
583	Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules. 2017 , 9, 187-202	12
582	Diagnosis and management of amyotrophic lateral sclerosis. 2015 , 58, 131	3
581	Screening for the C9ORF72 expansion in Greek Huntington Disease phenocopies and controls and meta-analysis of current data. 2020 , 10, 5	2
580	Quo vadis motor neuron disease?. 2016 , 6, 56-64	8
579	GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. 2015 , 4, e08881	69
578	The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. 2016 , 5,	157
577	Suppression of RNA repeat-induced neurotoxicity by the ALS-associated RNA-binding protein Zfp106. 2017 , 6,	29
576	A matter of balance. 2018 , 7,	4
575	Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis. 2019 , 8,	49
574	Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. 2019 , 8,	20
573	arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. 2020 , 9,	46
572	TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. 2020 , 9,	17
571	Cytosolic calcium regulates cytoplasmic accumulation of TDP-43 through Calpain-A and Importin B. 2020 , 9,	6

570	A comparative bioinformatic analysis of. 2018 , 6, e4391	9
569	C9orf72, a protein associated with amyotrophic lateral sclerosis (ALS) is a guanine nucleotide exchange factor. 2018 , 6, e5815	31
568	msRepDB: a comprehensive repetitive sequence database of over 80 000 species. 2021 ,	0
567	Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. 2021 , 15, 742065	17
566	Loss of C9orf72 perturbs the Ran-GTPase gradient and generates compositionally diverse cytoplasmic Importin β 1 granules in motor and cortical neurons in vivo.	
565	Reduction of oxidative stress suppresses poly-GR-mediated toxicity in zebrafish embryos. 2021 , 14,	1
564	Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions.	
563	p53 Transactivation Domain Mediates Binding and Phase Separation with Poly-PR/GR. 2021 , 22,	1
562	C9orf72-derived poly-GA DPRs undergo endocytic uptake in iNPC-derived astrocytes and spread to motor neurons.	
561	Modeling -Related Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in. 2021 , 15, 770937	1
560	Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. 2021 , 22,	9
559	Biofluid Biomarkers of Amyotrophic Lateral Sclerosis. 2022 , 263-306	
558	A <i>C. elegans</i> model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation. 2021 , 12, 6025	5
557	Coactivation of GSK3 β and IGF-1 Attenuates Amyotrophic Lateral Sclerosis Nerve Fiber Cytopathies in SOD1 Mutant Patient-Derived Motor Neurons. 2021 , 10,	0
556	Protein clearance strategies for disease intervention. 2021 , 1	1
555	Aging of the Human Neuromuscular System: Patient Vignettes. 55-80	
554	Aging of the Human Neuromuscular System: Clinical Considerations. 33-54	
553	Toward a Personalized Approach in Amyotrophic Lateral Sclerosis: New Developments in Diagnosis, Genetics, Pathogenesis and Therapies. 2013 , 205-233	

552 De la maladie de Pick aux dñences fronto-temporales. **2012**, 196, 431-443

551 Potential of Stem Cell-Derived Motor Neurons for Modeling Amyotrophic Lateral Sclerosis (ALS). **2013**, 75-91

550 Amyotrophic Lateral Sclerosis. **2013**,

549 Developing a consortium for ALS clinical research: the Canadian ALS Research Network. **2013**, 3, 1113-1117 1

548 Neurotoxicity and ALS: Insights into Pathogenesis. **2014**, 1435-1456

547 Amyotrophic Lateral Sclerosis: A Glial Perspective. **2014**, 231-263

546 Investigation. **2014**, 203-248

545 Biomarker for Amyotrophic Lateral Sclerosis. **2014**, 1-18

544 Antioxidants and Anti-Inflammatory Drugs in the Treatment of Motor Neuron Disease. **2014**, 3167-3194

543 Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes. **2014**, 93-109

542 Excitotoxicity and Amyotrophic Lateral Sclerosis. **2014**, 1209-1222 0

541 Motor Neuron Diseases. **2014**, 283-290

540 Movement Disorders in Frontotemporal Dementia. **2014**, 141-153

539 Genetics of Dementia with Lewy Bodies. **2015**, 65-74

538 Genetic Risk Factors for Neurodegenerative Diseases. **2015**, 117-134

537 Introduction. **2015**, 1-28

536 Hexanucleotide Repeat Expansion in C9ORF72 Is Not Detected in the Treatment-Resistant Schizophrenia Patients of Chinese Han. **2015**, 10, e0145347

535 ĩ Boynuz Tutulumuyla Giden Hastalıklar. 62-0

534 Antisense Oligonucleotides for Amyotrophic Lateral Sclerosis. **2016**, 99-109

533 Encyclopedia of Signaling Molecules. **2016**, 1-9

532 Neurodegenerative Disorders. **2016**, 261-276

531 Neuroimaging in Amyotrophic Lateral Sclerosis. **2016**, 231-246

530 Rehabilitation in Chorea. **2017**, 105-113

529 Frontotemporal Dementia and Parkinsonism. **2017**,

528 Frontotemporal Dementia. **2017**, 141-175

527 RNA Gelation in Repeat Expansion Disorders.

526 Inherited Neuromuscular Disease. 1-10

525 Frontotemporal Dementia (FTD). **2017**, 917-933

524 Cryptography for genetic material.

523 Deciphering the molecular logic of ALS using model organisms: "A family affair.". **2017**, 4, 1-3

1

522 Long-read sequencing technology indicates genome-wide effects of non-B DNA on polymerization speed and error rate.

521 Poly(GP) proteins: a potential pharmacodynamic marker in ALS and FTD. **2017**, 5, 504

520 Prion-Like Propagation in Neurodegenerative Diseases. **2018**, 189-242

519 An Intramolecular Salt Bridge Linking TDP43's RNA Recognition Motifs Dictates RNA Binding and TDP43-Dependent Neurodegeneration.

1

518 Amyotrophic Lateral Sclerosis and Other TDP-43 Proteinopathies. **2018**, 99-115

517 Encyclopedia of Signaling Molecules. **2018**, 2407-2415

- 516 Autosomal Dominant Frontotemporal Lobar Degeneration: From Genotype to Phenotype. **2018**, 123-145
- 515 Investigation. **2018**, 207-240
- 514 Molecular Genetics of Parkinsonism. 1-16
- 513 Long-read sequencing across the C9orf72 CGGGCC repeat expansion: implications for clinical use and genetic discovery efforts in human disease. 1
- 512 Loss of CREST leads to neuroinflammatory responses and ALS-like motor defects in mice.
- 511 Characterization of a human-specific tandem repeat associated with bipolar disorder and schizophrenia.
- 510 Axon-seq decodes the motor axon transcriptome and its modulation in response to ALS.
- 509 Risk Factors in Amyotrophic Lateral Sclerosis. **2019**, 47-59 1
- 508 SMCR8 negatively regulates AKT and MTORC1 signaling to modulate lysosome biogenesis and tissue homeostasis.
- 507 Protective Role of Glial Heat Shock Proteins in Amyotrophic Lateral Sclerosis. **2019**, 169-185
- 506 Amyotrophic Lateral Sclerosis. **2019**, 322-346 1
- 505 CHAPTER 7: Targeting Toxic Repeats. **2019**, 126-150
- 504 Amyotrophic Lateral Sclerosis-Like Motor Impairment in Prion Diseases. **2019**, 10, 15-29
- 503 Systematic analysis of dark and camouflaged genes: disease-relevant genes hiding in plain sight.
- 502 Evolving Methods in Defining the Role of RNA in RNP Assembly. **2019**, 39-55
- 501 Understanding the Pathogenicity of Noncoding RNA Expansion-Associated Neurodegenerative Disorders. **2019**, 335-371
- 500 A quantitative model of human neurodegenerative diseases involving protein aggregation.
- 499 A multi-omic analysis of optineurin proteinopathy in a yeast model suggests the involvement of lipid metabolism in Amyotrophic Lateral Sclerosis.

- 498 PQLC2 signals lysosomal cationic amino acid abundance to the C9orf72 complex. 0
- 497 Nucleocytoplasmic Proteomic Analysis Uncovers eRF1 and Nonsense Mediated Decay as Modifiers of ALS C9orf72 Toxicity.
- 496 Salience network atrophy links neuron type-specific pathobiology to loss of empathy in frontotemporal dementia.
- 495 Arginine valency in C9ORF72 dipolypeptides mediates promiscuous proteome binding that stalls ribosomes, disable actin cytoskeleton assembly and impairs arginine methylation of endogenous proteins.
- 494 Tau Accumulation via Reduced BAG3-mediated Autophagy Is Required for GGGGCC Repeat Expansion-Induced Neurodegeneration.
- 493 Genome sequencing for early-onset dementia: high diagnostic yield and frequent observation of multiple contributory alleles. 1
- 492 Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72.
- 491 C9orf72-associated arginine-rich dipeptide repeats induce RNA-dependent accumulation of Staufen in nucleus.
- 490 Uncovering active modulators of native macroautophagy through novel high-content screens.
- 489 A qualitative study of the preparedness of practitioners to care for people with motor neurone disease in their homes. **2019**, 29, 38-44
- 488 C9orf72 arginine-rich dipeptide repeat proteins disrupt importin β mediated nuclear import. 0
- 487 A 54-Year-Old Man with Progressive Lower Limb Weakness and CK Elevation. **2020**, 233-241
- 486 Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. 1
- 485 Genetic contributions to sporadic frontotemporal dementia. **2020**, 71-88
- 484 Inclusion bodies formed by polyglutamine and poly(glycine-alanine) are enriched with distinct proteomes but converge in proteins that are risk factors for disease and involved in protein degradation.
- 483 Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity. 2
- 482 Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice. 0
- 481 The carboxyl-termini of RAN translated GGGGCC nucleotide repeat expansions modulate toxicity in models of ALS/FTD. 1

480 TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS.

479 A *C. elegans* model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation.

478 G-quadruplex-forming sequences as potential drivers of genetic diversity in primate protein coding genes.

477 Ribosome inhibition by C9ORF72-ALS/FTD-associated poly-PR and poly-GR proteins revealed by cryo-EM. 2

476 Social and affective neuroscience: an Australian perspective. **2020**, 15, 965-980

475 Effect of G4C2-Repeat Expansions on the Motion of Lysosomes Inside Neurites..

474 Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis. **2021**,

3

473 Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(GC) repeat expansion in vitro and in vivo ALS models. **2021**, 13, eabd5991

6

472 Clinical and pathological phenotypes in dementia. **2020**, 147-164

471 Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice. **2021**, 29, 3900-3918

4

470 Who and Why? Requests for Presymptomatic Genetic Testing for Amyotrophic Lateral Sclerosis/Frontotemporal Dementia vs Huntington Disease. **2021**, 7, e538

1

469 Canadian Pioneers of Amyotrophic Lateral Sclerosis: A Brief History. **2021**, 48, 708-714

1

468 Comparison of Phenotypic Characteristics and Prognosis Between Black and White Patients in a Tertiary ALS Clinic. **2021**, 96, e840-e844

1

467 Effects of Dissolved Gases on the Amyloid Fibril Morphology. **2021**, 37, 516-523

0

466 Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. **2021**, 13, e12595

3

465 Amyotrophic lateral sclerosis (ALS) and the endocrine system: Are there any further ties to be explored?. **2021**, 1, 100024

0

464 TDP-43 and neurodegenerative diseases. **2022**, 1-26

463 Gene regulation by antisense transcription: A focus on neurological and cancer diseases. **2021**, 145, 112265

7

- 462 Posttranslational modifications of TDP-43. **2022**, 45-79
- 461 Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion. **2020**, 2176, 185-208 ○
- 460 Linking amyotrophic lateral sclerosis and frontotemporal dementia. **2020**, 49-59
- 459 Drosophila Models to Study Long Noncoding RNAs Related to Neurological Disorders. **2020**, 405-430
- 458 Functional Characterisation of a GWAS Risk Locus Identifies GPX3 as a Lead Candidate Gene in ALS.
- 457 Antisense oligonucleotide drugs for neurological and neuromuscular disease. **2020**, 221-245
- 456 Recent Contributions of the Drosophila Eye to Unraveling the Basis of Neurodegeneration. **2020**, 293-309 ○
- 455 Diagnostische Verfahren. **2020**, 551-631
- 454 G4C2 repeat RNA mediates the disassembly of the nuclear pore complex in C9orf72 ALS/FTD. ○
- 453 Phase separation of toxic dipeptide repeat proteins related to C9orf72 ALS/FTD.
- 452 Linkage Analysis in Caribbean Hispanic Families with Puerto Rican Ancestry Identifies an Alzheimer Disease Locus on chromosome 9.
- 451 Cryo-EM structure of C9ORF72-SMCR8-WDR41 reveals the role as a GAP for Rab8a and Rab11a.
- 450 Proteostasis deregulation as a driver of C9ORF72 pathogenesis. **2021**, 159, 941 1
- 449 Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. **2021**, 2
- 448 Neurotrophic Therapy for ALS/MND. **2022**, 1-37
- 447 TDP-43 proteinopathy alters the ribosome association of multiple mRNAs including the glypican Dally-like protein (Dlp)/GPC6.
- 446 The clinical spectrum of frontotemporal dementia. **2018**, 69, 9-15
- 445 Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. **2020**, 26, 1323-1347 2

444	Multiple pathways of toxicity induced by C9orf72 dipeptide repeat aggregates and G4C2 RNA in a cellular model.	
443	Inducible expression of human C9ORF72 36x G4C2 hexanucleotide repeats is sufficient to cause RAN translation and rapid muscular atrophy in mice.	
442	NMJ-Analyser: high-throughput morphological screening of neuromuscular junctions identifies subtle changes in mouse neuromuscular disease models.	
441	Amyotrophic Lateral Sclerosis. 2021 , 759-781	
440	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 209-248	2
439	TARDBP mutations are not a frequent cause of ALS in Finnish patients. 2012 , 31, 134-8	8
438	C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. 2012 , 1, 107-18	31
437	Retinoid signaling alterations in amyotrophic lateral sclerosis. 2012 , 1, 130-45	19
436	Circulating progranulin as a biomarker for neurodegenerative diseases. 2012 , 1, 180-90	19
435	An Italian kindred with FALS due to c.149T>C mutation in the SOD1 gene: case report of an affected family member. 2013 , 32, 23-6	1
434	Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics. 2013 , 2, 276-86	11
433	C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. 2014 , 3, 1-18	20
432	An Iranian familial amyotrophic lateral sclerosis pedigree with p.Val48Phe causing mutation in SOD1: a genetic and clinical report. 2014 , 17, 735-9	2
431	Model systems of motor neuron diseases as a platform for studying pathogenic mechanisms and searching for therapeutic agents. 2015 , 7, 19-36	0
430	Observation of c.260A > G mutation in superoxide dismutase 1 that causes p.Asn86Ser in Iranian amyotrophic lateral sclerosis patient and absence of genotype/phenotype correlation. 2015 , 14, 152-7	3
429	Amyotrophic Lateral Sclerosis with Frontotemporal Dementia in the Presence of C9orf72 Repeat Expansion-A Case Report. 2016 , 13, 37-9	
428	Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. 2018 , 43, 25-28	32
427	Unravelling the mysteries of frontotemporal dementia. 2013 , 110, 411-6	

426	Management of amyotrophic lateral sclerosis. 2013 , 110, 417-21	4
425	Evaluation of Holistic Treatment for ALS Reveals Possible Mechanism and Therapeutic Potential. 2017 , 11, 348-374	3
424	Models and mechanisms of repeat expansion disorders: a worm's eye view. 2018 , 97, 665-677	3
423	Neuronal Transcriptome from Repeat Expanded Human Tissue is Associated with Loss of C9orf72 Function. 2020 , 1,	1
422	RNA-Based Therapies for Neurodegenerative Diseases. 2021 , 118, 340-345	
421	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage.. 2021 , 12, 743688	0
420	The Role of Nucleocytoplasmic Transport Defects in Amyotrophic Lateral Sclerosis. 2021 , 22,	3
419	Advances in Proteasome Enhancement by Small Molecules.. 2021 , 11,	1
418	Harnessing the Potential of Human Pluripotent Stem Cell-Derived Motor Neurons for Drug Discovery in Amyotrophic Lateral Sclerosis: From the Clinic to the Laboratory and Back to the Patient. 2021 , 1,	4
417	The Mutational Dynamics of Short Tandem Repeats in Large, Multigenerational Families.	0
416	Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. 2021 , 22,	6
415	Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review.. 2021 , 15, 790114	1
414	Mitochondria Dysfunction in Frontotemporal Dementia/Amyotrophic Lateral Sclerosis: Lessons From Models.. 2021 , 15, 786076	0
413	Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease mechanisms and current therapeutic approaches. 2021 ,	0
412	G-Quadruplexes in Neurobiology and Virology: Functional Roles and Potential Therapeutic Approaches.. 2021 , 1, 2146-2161	3
411	Epigenetic Small Molecules Rescue Nucleocytoplasmic Transport and DNA Damage Phenotypes in C9ORF72 ALS/FTD. 2021 , 11,	0
410	C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation. 2021 , e105026	0
409	Aggregation and the Intrinsic Structural Disorder of Dipeptide Repeat Peptides of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Characterized by NMR. 2021 , 125, 12446-12456	1

408	H, C and N resonance assignments and solution structures of the two RRM domains of Matrin-3. 2021 , 1	
407	The effects of molecular crowding and CpG hypermethylation on DNA G-quadruplexes formed by the C9orf72 nucleotide repeat expansion. 2021 , 11, 23213	0
406	Protein network analysis to prioritize key genes in amyotrophic lateral sclerosis.. 2022 , 12, 25-44	3
405	Antisense therapies in neurological diseases.. 2021 ,	0
404	MicroRNA biomarkers in frontotemporal dementia and to distinguish from Alzheimer's disease and amyotrophic lateral sclerosis.. 2022 , 17, 1412-1422	0
403	Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis.. 2022 , 43, 889	
402	Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation.. 2022 , 29, 11-35	6
401	RAN proteins in neurodegenerative disease: Repeating themes and unifying therapeutic strategies.. 2021 , 72, 160-170	0
400	Genetic architecture of motor neuron diseases.. 2021 , 434, 120099	2
399	Multiple system atrophy and C9orf72 hexanucleotide repeat expansions in a cohort of Italian patients.. 2021 , 112, 12-15	2
398	Pathological phase transitions in ALS-FTD impair dynamic RNA-protein granules. 2021 ,	1
397	A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.. 2022 , 12, e657	0
396	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia.. 2022 , 16, 758182	0
395	Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis.. 2022 , 8, e654	2
394	New antisense oligonucleotide therapies reach first base in ALS.. 2022 ,	0
393	Regulation of neuronal autophagy and the implications in neurodegenerative diseases. 2021 , 105582	3
392	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis.. 2022 , 7, 8	4
391	Possibilities and challenges of small molecule organic compounds for the treatment of repeat diseases.. 2022 , 98, 30-48	0

390	Cerebellar integrity and contributions to cognition in C9orf72-mediated frontotemporal dementia.. 2022 , 149, 73-84	
389	Inflammasome mediated neuronal-microglial crosstalk: a therapeutic substrate in C9orf72-FTD/ALS.	
388	Protein synthesis modulation as a therapeutic approach for amyotrophic lateral sclerosis and frontotemporal dementia.. 2022 , 17, 1423-1430	0
387	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis.. 2022 ,	1
386	Molecular Mechanisms in Pentanucleotide Repeat Diseases.. 2022 , 11,	0
385	Disruption of ER-mitochondria tethering and signalling in C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia.. 2022 , e13549	4
384	Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.. 2022 , 4, 2	3
383	C9orf72 hexanucleotide repeat expansion leads to altered neuronal and dendritic spine morphology and synaptic dysfunction.. 2021 , 162, 105584	0
382	Plasma Small Extracellular Vesicles with Complement Alterations in / and Sporadic Frontotemporal Lobar Degeneration.. 2022 , 11,	1
381	Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.. 2022 ,	2
380	Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis.. 2022 , 17, 11	5
379	Reduced mtDNA Copy Number in the Prefrontal Cortex of C9ORF72 Patients.. 2022 , 59, 1230	
378	The characteristics of early-stage research into human genes are substantially different from subsequent research.. 2022 , 20, e3001520	2
377	Comprehensive preclinical evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9ORF72 disease.	
376	Protein Arginine Methyltransferases in Neuromuscular Function and Diseases.. 2022 , 11,	1
375	Order controls disordered droplets: structure-function relationships in C9orf72-derived poly(PR).. 2021 ,	
374	Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS.. 2022 ,	4
373	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration.. 2022 , 34, 102954	0

372	The different autophagy degradation pathways and neurodegeneration.. <i>Neuron</i> , 2022 ,	13.9	9
371	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia.. 2022 , 23, 99		0
370	GIPC1 CGG repeat expansion is associated with movement disorders.. 2022 ,		0
369	Arginine-rich C9ORF72 ALS Proteins Stall Ribosomes in a Manner Distinct From a Canonical Ribosome-Associated Quality Control Substrate.		0
368	Involvement of molecular chaperone in protein-misfolding brain diseases.. 2022 , 147, 112647		2
367	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis.. 2022 , 216, 106681		0
366	Multimeric G-quadruplexes: A review on their biological roles and targeting.. 2022 ,		5
365	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. 2021 , 53, 1636-1648		19
364	Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide.. 2021 ,		6
363	Proteinopathies as Hallmarks of Impaired Gene Expression, Proteostasis and Mitochondrial Function in Amyotrophic Lateral Sclerosis.. 2021 , 15, 783624		1
362	Language impairment in primary progressive aphasia and other neurodegenerative diseases. 2019 , 98,		1
361	Measuring Repeat-Associated Non-AUG (RAN) Translation.. 2022 , 2428, 113-132		
360	Amyotrophic lateral sclerosis autosomal dominant due to a mutation in the TARDBP gene (ALS10). 2022 , 13, 1-6		
359	Protein Network Analysis Reveals a Functional Connectivity of Dysregulated Processes in ALS and SMA.. 2022 , 17, 26331055221087740		0
358	Biomarkers in Human Peripheral Blood Mononuclear Cells: The State of the Art in Amyotrophic Lateral Sclerosis.. 2022 , 23,		1
357	Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation.. 2022 , 10, 22		2
356	Novel Intronic Mutations of Promote Aberrant Splicing Modes in Amyotrophic Lateral Sclerosis.. 2022 , 15, 691534		0
355	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.. 2022 ,		0

354	Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics.. 2022 , 13,	6
353	Frontotemporal Dementia and Glucose Metabolism.. 2022 , 16, 812222	0
352	Trinucleotide CGG Repeat Diseases: An Expanding Field of Polyglycine Proteins?. 2022 , 13, 843014	2
351	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.. 2022 ,	2
350	Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes.. 2022 , 79, 189	0
349	C9orf72 dipeptides disrupt the nucleocytoplasmic transport machinery and cause TDP-43 mislocalisation to the cytoplasm.. 2022 , 12, 4799	0
348	Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3'UTR protect against ALS.. 2022 ,	1
347	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.. 2022 ,	0
346	Unique molecular features and cellular responses differentiate two populations of motor cortical layer 5b neurons in a preclinical model of ALS.. 2022 , 38, 110556	
345	ALS in Finland: Major Genetic Variants and Clinical Characteristics of Patients With and Without the Hexanucleotide Repeat Expansion.. 2022 , 8, e665	0
344	Machine-learning algorithm for identifying and predicting amyotrophic lateral sclerosis causal mutations.	
343	Poly-dipeptides produced from hexanucleotide repeats cause selective motor neuron hyperexcitability in ALS.. 2022 , 119, e2113813119	0
342	Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship.. 2022 , 12,	0
341	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.. 2022 ,	10
340	The translational landscape as regulated by the RNA helicase DDX3. 2022 , 55, 125-135	0
339	Modelling amyotrophic lateral sclerosis in rodents.. 2022 ,	1
338	Cerebrospinal fluid biomarkers and genetic factors associated with normal pressure hydrocephalus and Alzheimer's disease: a narrative review. 2022 , 23,	
337	Schizotypal traits across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: pathomechanistic insights.. 2022 , 1	

336	The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD.. 2022 , 17, 22	2
335	The motif composition of variable-number tandem repeats impacts gene expression.	0
334	A multimodal variational autoencoder for estimating progression scores from imaging and microRNA data in rare neurodegenerative diseases. 2022 ,	1
333	A mouse model with widespread expression of the C9orf72-linked glycine-arginine dipeptide displays non-lethal ALS/FTD-like phenotypes.. 2022 , 12, 5644	0
332	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for -associated frontotemporal dementia and amyotrophic lateral sclerosis.. 2022 ,	2
331	Formation of RNA G-wires by GC repeats associated with ALS and FTD.. 2022 , 610, 113-118	
330	Longitudinal surface-based spatial Bayesian GLM reveals complex trajectories of motor neurodegeneration in ALS.. 2022 , 119180	0
329	Lessons learned: next-generation sequencing applied to undiagnosed genetic diseases.. 2022 , 132,	0
328	RNA methylation influences TDP43 binding and disease pathogenesis in models of amyotrophic lateral sclerosis and frontotemporal dementia.	
327	Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo.. 2022 , 12, 5672	0
326	The expression discrepancy and characteristics of long non-coding RNAs in peripheral blood leukocytes from amyotrophic lateral sclerosis patients.. 2022 , 1	1
325	Disease Modeling of Rare Neurological Disorders in Zebrafish.. 2022 , 23,	0
324	Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia.. 2022 , 116, 67-79	0
323	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases.. 2022 , 155, 105307	1
322	Site-specific mitochondrial dysfunction in neurodegeneration.. 2022 ,	2
321	Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using <i>Caenorhabditis elegans</i> .. 2022 , 267, 111166	0
320	The molecular mechanisms that drive intracellular neutralization by the antibody-receptor and RING E3 ligase TRIM21. 2021 ,	0
319	Advancing genomic technologies and clinical awareness accelerates discovery of disease-associated tandem repeat sequences.. 2021 ,	2

- 318 Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis.. **2021**, 0
- 317 Shared brain transcriptomic signature in TDP-43 type A FTLN patients with or without GRN mutations.. **2021**, 0
- 316 Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.. **2021**, 14, 767041 3
- 315 Emerging Mechanisms Underpinning Neurophysiological Impairments in Repeat Expansion-Mediated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.. **2021**, 15, 784833 0
- 314 RNA-binding protein dysfunction in neurodegeneration.. **2021**, 1
- 313 Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions.. **2021**, 143, 383 0
- 312 Optineurin deficiency induces patchy hair loss but it is not sufficient to cause amyotrophic lateral sclerosis in mice.
- 311 Generation and analysis of innovative genomically humanized knockin , (TDP-43), and mouse models.. **2021**, 24, 103463 0
- 310 GC-rich repeat expansions: associated disorders and mechanisms. **2022**, 33, 325-335
- 309 Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.. **2022**, 1 0
- 308 Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of -associated ALS or FTD.. **2022**, 28, 558-570 0
- 307 Systematic generation and imaging of tandem repeats reveal multivalent base-pairing as a major determinant of RNA aggregation.
- 306 Multifaceted targeted protein degradation systems for different cellular compartments.. **2022**, e2200008 0
- 305 Methylome analysis of ALS patients and presymptomatic mutation carriers in blood cells.. **2022**, 116, 16-24 0
- 304 Cognitive Dysfunction in Repeat Expansion Diseases: A Review.. **2022**, 14, 841711
- 303 Image_1.TIF. **2018**,
- 302 Table_1.PDF. **2018**,
- 301 Table_2.PDF. **2018**,

300 Table_3.pdf. **2018**,

299 DataSheet_1.pdf. **2019**,

298 Table_1.DOCX. **2020**,

297 Table_2.DOCX. **2020**,

296 Data_Sheet_1.PDF. **2018**,

295 Data_Sheet_1.docx. **2020**,

294 Data_Sheet_1.docx. **2018**,

293 Data_Sheet_1.pdf. **2019**,

292 Image_1.JPEG. **2018**,

291 Image_2.JPEG. **2018**,

290 Image_3.jpg. **2018**,

289 Image_4.JPEG. **2018**,

288 Table_1.docx. **2018**,

287 DataSheet_1.docx. **2020**,

286 Data_Sheet_1.PDF. **2019**,

285 Data_Sheet_2.PDF. **2019**,

284 Image_1.TIFF. **2019**,

283 Table_1.DOC. **2019**,

282	Data_Sheet_1.docx. 2019,	
281	How can we interpret the relationship between liquid-liquid phase separation and amyotrophic lateral sclerosis?. 2022,	0
280	Defects of Nutrient Signaling and Autophagy in Neurodegeneration.. 2022, 10, 836196	1
279	The translational landscape as regulated by the RNA helicase DDX3.. 2022,	
278	Nuclear pore complexes - a doorway to neural injury in neurodegeneration.. 2022,	0
277	The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases.. 2022, 14, 872134	1
276	Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.. 2022, 23,	1
275	C-Jun N-terminal Kinase Promotes Stress Granule Assembly and Neurodegeneration in C9orf72-mediated ALS and FTD.	
274	Proteostasis Perturbations and Their Roles in Causing Sterile Inflammation and Autoinflammatory Diseases.. 2022, 11,	0
273	The Interplay Between Autophagy and RNA Homeostasis: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.. 2022, 10, 838402	
272	Singling out motor neurons in the age of single-cell transcriptomics.. 2022,	1
271	How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases.. 2022,	0
270	Characterization of RNA content in individual phase-separated coacervate microdroplets.. 2022, 13, 2626	1
269	Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers.. 2022, 12, e818	0
268	Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine.. 2022, 1-26	1
267	Ultrastructural and biochemical classification of pathogenic tau, β synuclein and TDP-43.. 2022, 143, 613-640	1
266	ATXN2 intermediate expansions in amyotrophic lateral sclerosis.. 2022,	1
265	RNA Helicases in Microsatellite Repeat Expansion Disorders and Neurodegeneration. 2022, 13,	

264	Macroautophagy in CNS health and disease.. 2022,	3
263	NEK1 and STMN2 short tandem repeat lengths are not associated with Australian amyotrophic lateral sclerosis risk. 2022,	
262	Molecular basis of C9orf72 poly-PR interference with the karyopherin family of nuclear transport receptors.	0
261	Lipid Metabolic Alterations in the ALS/FTD Spectrum of Disorders. 2022, 10, 1105	1
260	Physiological and Pathological Roles of the Cytohesin Family in Neurons.. 2022, 23,	0
259	The Clinical and Polynucleotide Repeat Expansion Analysis of ATXN2, NOP56, AR and C9orf72 in Patients With ALS From Mainland China. 2022, 13,	
258	Biological basis and psychiatric symptoms in frontotemporal dementia.. 2022,	0
257	Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids.	
256	Hyperexcitability in young iPSC-derived C9ORF72 mutant motor neurons is associated with increased intracellular calcium release.. 2022, 12, 7378	0
255	Modeling neurodegenerative disorders in zebrafish.. 2022, 104679	4
254	Advances in Treatment of Frontotemporal Dementia.. 2022, appineuropsych21060166	1
253	-derived poly-GA DPRs undergo endocytic uptake in iAstrocytes and spread to motor neurons.. 2022, 5,	0
252	Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer's Disease. 2022, 10, 1141	2
251	Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD.. 2022, 13, 2799	2
250	Ribosome inhibition by C9ORF72-ALS/FTD-associated poly-PR and poly-GR proteins revealed by cryo-EM.. 2022, 13, 2776	0
249	Identification and Monitoring of Nucleotide Repeat Expansions Using Southern Blotting in Drosophila Models of C9orf72 Motor Neuron Disease and Frontotemporal Dementia. 2022, 12,	
248	Progress in Amyotrophic Lateral Sclerosis Gene Discovery. 2022, 8, e669	2
247	Expanding Clinical Spectrum of C9ORF72-Related Disorders and Promising Therapeutic Strategies. 2022, 8, e670	0

- 246 Protein interaction networks in neurodegenerative diseases: from physiological function to aggregation. **2022**, 102062 1
- 245 Detecting Tandem Repeat Expansions Using Short-Read Sequencing for Clinical Use. **2022**, 15-42 0
- 244 Analysis of the Hexanucleotide Repeat Domain in the TAF1 SVA Retrotransposon in X-Linked Dystonia-Parkinsonism. **2022**, 139-153
- 243 Long-Read Sequencing and Analysis of Variable Number Tandem Repeats. **2022**, 79-94
- 242 ALS/FTD: Evolution, Aging, and Cellular Metabolic Exhaustion. **2022**, 13,
- 241 Recent Advances in Frontotemporal Dementia. 1-34
- 240 Two therapeutic CRISPR/Cas9 gene editing approaches revert FTD/ALS cellular pathology caused by a C9orf72 repeat expansion mutation in patient derived cells. 0
- 239 Targeting ER-Mitochondria Signaling as a Therapeutic Target for Frontotemporal Dementia and Related Amyotrophic Lateral Sclerosis. **2022**, 10, 1
- 238 How network-based approaches can complement gene identification studies in frontotemporal dementia. **2022**,
- 237 CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro.
- 236 A comparison of software for analysis of rare and common short tandem repeat (STR) variation using human genome sequences from clinical and population-based samples. 0
- 235 Antisense Oligonucleotides for the Study and Treatment of ALS. 1
- 234 Novel molecular targets and mechanisms for neuroprotective modulation in neurodegenerative disorders. **2022**, 22, 0
- 233 Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. 1
- 232 Telomere Attrition in Induced Pluripotent Stem Cell-Derived Neurons From ALS/FTD-Related C9ORF72 Repeat Expansion Carriers. 10, 0
- 231 Progress in biophysics and molecular biology proteostasis impairment and ALS. **2022**, 0
- 230 Behavioral Variant Frontotemporal Dementia. **2022**, 28, 702-725
- 229 Efficient Cloning and Sequence Validation of Repetitive and High GC-Content shRNAs.

228	Clinical and Electrophysiological Findings in C9ORF72 ALS.	0
227	Antisense, but not sense, repeat expanded RNAs activate PKR/eIF2 β -dependent integrated stress response in C9orf72 FTD/ALS.	0
226	Bioenergetic and Autophagic Characterization of Skin Fibroblasts from C9orf72 Patients. 2022 , 11, 1129	0
225	Early diagnosis of amyotrophic lateral sclerosis based on fasciculations in muscle ultrasonography: A machine learning approach. 2022 ,	0
224	Autophagy Dysfunction in ALS: from Transport to Protein Degradation.	0
223	C9orf72-Related Neurodegenerative Diseases: From Clinical Diagnosis to Therapeutic Strategies. 14,	0
222	C. elegans as an Animal Model to Study the Intersection of DNA Repair, Aging and Neurodegeneration. 3,	0
221	A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy.	1
220	Targeting pathogenic DNA and RNA repeats: a conceptual therapeutic way for repeat expansion diseases.	1
219	Drug screen in iPSC-Neurons identifies nucleoside analogs as inhibitors of (G4C2) _n expression in C9orf72 ALS/FTD. 2022 , 39, 110913	0
218	NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. 2022 , 13,	1
217	Major advances in neuromuscular disorders in the past two decades. 2022 , 21, 585-587	1
216	Improvement of amyotrophic lateral sclerosis symptoms using plant extracts. 2022 , 101-115	
215	Gene Therapy in Amyotrophic Lateral Sclerosis. 2022 , 11, 2066	2
214	Modifiable potential risk factors in familial and sporadic frontotemporal dementia.	
213	Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.	0
212	Therapeutic Strategies and Metal-Induced Oxidative Stress: Application of Synchrotron Radiation Microbeam to Amyotrophic Lateral Sclerosis in the Kii Peninsula of Japan. 13,	1
211	Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics [An AI-Enabled Biological Target Discovery Platform. 14,	1

- 210 Myelin loss in C9orf72 hexanucleotide expansion carriers. ○
- 209 Enhanced motor cortex output and disinhibition in asymptomatic female mice with C9orf72 genetic expansion. **2022**, 40, 111043 ○
- 208 Increased surface P2X4 receptors by mutant SOD1 proteins contribute to ALS pathogenesis in SOD1-G93A mice. **2022**, 79, ○
- 207 Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration. 10.1212/WNL.0000000000200860 ○
- 206 GLT8D1 mutations cause amyotrophic lateral sclerosis via disruption of neurotrophin signalling within membrane lipid rafts.
- 205 Amyotrophic Lateral Sclerosis Proteomic Signature And Treatment With Mesenchymal Stem Cell-derived Extracellular Vesicles.
- 204 Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations. 13, ○
- 203 Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. 13,
- 202 Regulating Phase Transition in Neurodegenerative Diseases by Nuclear Import Receptors. **2022**, 11, 1009 1
- 201 The Patterning and Proportion of Charged Residues in the Arginine-Rich Mixed-Charge Domain Determine the Membrane-Less Organelle Targeted by the Protein. **2022**, 23, 7658 ○
- 200 Brain structural and perfusion changes in amyotrophic lateral sclerosis-frontotemporal dementia patients with cognitive and motor onset: a preliminary study.
- 199 Hyperactivity of Purkinje cell and motor deficits in C9orf72 knockout mice. **2022**, 121, 103756 ○
- 198 The Role and Therapeutic Potential of the Integrated Stress Response in Amyotrophic Lateral Sclerosis. **2022**, 23, 7823 ○
- 197 Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid. **2022**, 172, 105813
- 196 Neuroimmune dysfunction in frontotemporal dementia: Insights from progranulin and C9orf72 deficiency. **2022**, 76, 102599
- 195 Amyotrophic lateral sclerosis. **2023**, 233-251
- 194 The role of inflammation in neurodegenerative diseases. **2023**, 403-421
- 193 Frontotemporal lobar degeneration. **2023**, 337-360

192	Cellular analysis of SOD1 protein-aggregation propensity and toxicity: a case of ALS with slow progression harboring homozygous SOD1-D92G mutation. 2022 , 12,	0
191	YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration. 2022 , 14,	0
190	An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD.	1
189	Comprehensive mapping of mutations in the C9ORF72 that affect folding and binding to SMCR8 protein. 2022 , 121, 312-321	1
188	Neuropathology and emerging biomarkers in corticobasal syndrome. 2022 , 93, 919-929	1
187	Radiogenomics of C9orf72 expansion carriers reveals global transposable element de-repression and enables prediction of thalamic atrophy and clinical impairment.	
186	Stress Granule Homeostasis, Aberrant Phase Transition, and Amyotrophic Lateral Sclerosis. 2022 , 13, 2356-2370	0
185	A nop56 Zebrafish Loss-of-Function Model Exhibits a Severe Neurodegenerative Phenotype. 2022 , 10, 1814	1
184	Exploring the phenotype of Italian patients with ALS with intermediate ATXN2 polyQ repeats. jnnp-2022-329376	
183	Exploring Links Between Psychosis and Frontotemporal Dementia Using Multimodal Machine Learning.	0
182	Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration. 2022 , 10,	
181	The repeat length of C9orf72 is associated with the survival of amyotrophic lateral sclerosis patients without C9orf72 pathological expansions. 13,	
180	Translation of dipeptide repeat proteins in C9ORF72-ALS/FTD through unique and redundant AUG initiation codons.	
179	The parallel tetrameric DNA G-quadruplex formed by the two-repeat C9orf72 GGGGCC sequence in solution. 2022 ,	
178	Identification of TARDBP Gly298Ser as a founder mutation for amyotrophic lateral sclerosis in Southern China. 2022 , 15,	1
177	Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects. 13,	1
176	Trends in global amyotrophic lateral sclerosis research from 2000 to 2022: A bibliometric analysis. 16,	0
175	The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review.	0

174	Rare and common variant analyses of amyotrophic lateral sclerosis in the French-Canadian genome.	
173	Defective axonal transport of endo-lysosomes and dense core vesicles in a <i>Drosophila</i> model of C9-ALS / FTD.	1
172	Non-canonical DNA structures: Diversity and disease association. 13,	1
171	Cyclin F, Neurodegeneration, and the Pathogenesis of ALS/FTD. 107385842211201	0
170	Approaches to Gene Modulation Therapy for ALS.	0
169	Oxytocin in Huntington's disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia. 15,	2
168	The genetic and molecular features of the intronic pentanucleotide repeat expansion in spinocerebellar ataxia type 10. 13,	0
167	Nuclear Export of mRNAs with Disease Pathogenesis and Therapeutic Implications. 2022 , 371-395	0
166	Disease progression score estimation from multimodal imaging and microRNA data using supervised variational autoencoders. 2022 , 1-12	1
165	Basic Concepts and Emergent Disease Mechanisms of Amyotrophic Lateral Sclerosis. 2022 ,	0
164	Small Molecules Targeting Repeat Sequences Causing Neurological Disorders. 2022 , 1-31	0
163	Emergencies in Motor Neuron Diseases. 2022 , 155-180	0
162	The contribution of proteasomal impairment to autophagy activation by C9orf72 poly-GA aggregates. 2022 , 79,	0
161	Enhancer RNAs step forward: new insights into enhancer function. 2022 , 149,	1
160	Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset. 2022 , 12,	0
159	Accurate measurement of microsatellite length by disrupting its tandem repeat structure.	0
158	The role of autophagy-lysosomal pathway in motor neuron diseases.	0
157	Huntington's disease phenocopy syndromes revisited: a clinical comparison and next-generation sequencing exploration.	0

156	ANXA11 mutations are associated with amyotrophic lateral sclerosisfrontotemporal dementia. 13,	0
155	Selective C9orf72 G-Quadruplex-Binding Small Molecules Ameliorate Pathological Signatures of ALS/FTD Models.	0
154	Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins. 2022 , 14,	1
153	The Potential Connection between Molecular Changes and Biomarkers Related to ALS and the Development and Regeneration of CNS. 2022 , 23, 11360	1
152	PolyGA targets the ER stress-adaptive response by impairing GRP75 function at the MAM in C9ORF72-ALS/FTD.	0
151	Chromosomes: Noncoding DNA (Including Satellite DNA). 1-18	0
150	Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2. 2022 , 23, 10491	1
149	Letter to the editor on a paper by Kaivola et al. (2020): carriership of two copies of C9orf72 hexanucleotide repeat intermediate-length alleles is not associated with amyotrophic lateral sclerosis or frontotemporal dementia. 2022 , 10,	0
148	Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18-Year Study.	0
147	Breakdown of the central synapses in C9orf72-linked ALS/FTD. 15,	0
146	Plasma Small Extracellular Vesicle Cathepsin D Dysregulation in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. 2022 , 23, 10693	1
145	Status of ALS Treatment, Insights into Therapeutic Challenges and Dilemmas. 2022 , 12, 1601	0
144	Dipeptide Repeat Pathology in C9orf72-ALS Is Associated with Redox, Mitochondrial and NRF2 Pathway Imbalance. 2022 , 11, 1897	0
143	A polymorphic transcriptional regulatory domain in the amyotrophic lateral sclerosis risk gene CFAP410 correlates with differential isoform expression. 15,	0
142	Nucleoporins are degraded via upregulation of ESCRT-III/Vps4 complex in Drosophila models of C9-ALS/FTD. 2022 , 40, 111379	0
141	Phase separation of low-complexity domains in cellular function and disease. 2022 , 54, 1412-1422	0
140	Optogenetic control of GGGGCC repeat-containing RNA phase transition. 2022 ,	0
139	The search for a link between autism spectrum disorder and neurodegenerative dementia. 2022 , 63,	0

- 138 Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease. 15, 1
- 137 Involvement of striatal motoric subregions in familial frontotemporal dementia with parkinsonism harboring the C9orf72 repeat expansions. **2022**, 8, 1
- 136 Not just neurological stamp collecting: when rare diagnoses lead to fundamental advances. pn-2022-003573 0
- 135 Expanding the spectrum of C9ORF72-related neurodegenerative disorders in the Greek population. **2022**, 120450 1
- 134 Clinical relevance of single-subject brain metabolism patterns in amyotrophic lateral sclerosis mutation carriers. **2022**, 103222 0
- 133 MITA/STING-mediated antiviral immunity and autoimmunity: the evolution, mechanism, and intervention. **2022**, 78, 102248 0
- 132 Kap β is a modifier of the C9orf72-linked glycine-arginine dipeptide neurotoxicity. 0
- 131 Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration. **2022**, 378, 94-99 1
- 130 Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors. **2022**, 442, 120439 0
- 129 Genomic Characterization of Prostatic Basal Cell Carcinoma. **2022**, 0
- 128 The PINK1 p.Asn521Thr Variant Is Associated with Earlier Disease Onset in GRN/C9orf72 Frontotemporal Lobar Degeneration. **2022**, 23, 12847 0
- 127 Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities. jmedgenet-2022-108477 0
- 126 Genome-wide RNA binding analysis of C9orf72poly(PR) dipeptides. 0
- 125 CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. **2022**, 13, 1
- 124 Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. **2022**, 12, 1747 0
- 123 iPSC Motor Neurons with Familial ALS Mutations Capture Gene Expression Changes in Postmortem Sporadic ALS Motor Neurons. 0
- 122 Cumulative genetic risk and C9orf72 repeat status independently associate with ALS status in two case-control studies. 0
- 121 MicroRNA signatures in genetic frontotemporal dementia and amyotrophic lateral sclerosis. 0

120	C9orf72 functions in the nucleus to regulate DNA damage repair.	0
119	Changing perspectives on frontotemporal dementia: A review.	1
118	Hexanucleotide repeat expansions in C9orf72 alter microglial responses and prevent a coordinated glial reaction in ALS.	0
117	Reversing lysosome-ribosome circuit dysregulation mitigates C9FTD/ALS neurodegeneration and behaviors.	0
116	FUS regulates RAN translation through modulating the G-quadruplex structure of GGGGCC repeat RNA in C9orf72-linked ALS/FTD.	0
115	A nascent peptide code for translational control of mRNA stability in human cells. 2022 , 13,	0
114	Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine. 2022 , 11,	0
113	Mutation spectrum of chinese amyotrophic lateral sclerosis patients with frontotemporal dementia. 2022 , 17,	0
112	Genome-wide contribution of common short-tandem repeats to Parkinson disease genetic risk.	0
111	Traumatic Brain Injury Associates with an Earlier Onset in Sporadic Frontotemporal Dementia. 2022 , 1-8	0
110	Longin domain GAP complexes in nutrient signaling, membrane traffic, and neurodegeneration.	1
109	Systematic generation and imaging of tandem repeats reveal base-pairing properties that promote RNA aggregation. 2022 , 100334	0
108	C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. 2022 , 175, 105927	1
107	Divergent impacts of C9orf72 repeat expansion on neurons and glia in ALS and FTD.	0
106	Distinct hypothalamic involvement in the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. 2023 , 37, 103281	0
105	The landscape of cognitive impairment in superoxide dismutase 1-amyotrophic lateral sclerosis. 2023 , 18, 1427	0
104	Generation of five induced pluripotent stem cells lines from four members of the same family carrying a C9orf72 repeat expansion and one wild-type member. 2023 , 66, 102998	0
103	Therapeutic and diagnostic potential of extracellular vesicles in amyotrophic lateral sclerosis. 2023 , 2, 100019	0

102	Targeting DNA Junctions with Small Molecules for Therapeutic Applications in Oncology. 2022 , 1-24	0
101	Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study.	0
100	Radiogenomics of C9orf72 expansion carriers reveals global transposable element de-repression and enables prediction of thalamic atrophy and clinical impairment. JN-RM-1448-22	0
99	Genetic landscape of ALS in Malta based on a quinquennial analysis. 2022 ,	0
98	Genome-Wide Gene-Set Analysis Approaches in Amyotrophic Lateral Sclerosis. 2022 , 12, 1932	1
97	TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?. 2022 , 23, 15755	0
96	Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes.	1
95	In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model.	0
94	Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation. 16,	0
93	Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation.	0
92	The mutational dynamics of short tandem repeats in large, multigenerational families. 2022 , 23,	0
91	The organization and function of the Golgi apparatus in dendrite development and neurological disorders. 2022 ,	1
90	Analysis of SOD1 and C9orf72 mutations in patients with amyotrophic lateral sclerosis in Antioquia, Colombia. 2022 , 42, 623-632	0
89	Molecular basis of C9orf72 poly-PR interference with the karyopherin family of nuclear transport receptors. 2022 , 12,	0
88	Arginine-rich C9ORF72 ALS proteins stall ribosomes in a manner distinct from a canonical ribosome-associated quality control substrate. 2022 , 102774	0
87	Altered Blood-Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis. 2022 , 14, 2803	0
86	The effect of the cyclic GMP-AMP synthase-stimulator of interferon genes signaling pathway on organ inflammatory injury and fibrosis. 13,	0
85	Neurocognitive patterns across genetic levels in behavioral variant frontotemporal dementia: a multiple single cases study. 2022 , 22,	0

84	Models of Neurodegenerative Diseases. 2023 , 179-209	0
83	Brain modulation by the gut microbiota: From disease to therapy. 2022 ,	1
82	Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches. 1-18	0
81	Impaired ribosome-associated quality control of C9orf72 arginine-rich dipeptide-repeat proteins.	0
80	Neurotrophic Therapy for ALS/MND. 2022 , 1893-1929	0
79	Neurotoxicity and ALS: Insights into Pathogenesis. 2022 , 1803-1821	0
78	Inflammasome mediated neuronal-microglial crosstalk: a therapeutic substrate of the familial C9orf72 variant of frontotemporal dementia/amyotrophic lateral sclerosis.	0
77	Advances in sequencing technologies for amyotrophic lateral sclerosis research. 2023 , 18,	0
76	Involvement of heterologous ubiquitination including linear ubiquitination in Alzheimer's disease and amyotrophic lateral sclerosis. 10,	0
75	Dorsomedial prefrontal hypoexcitability underlies lost empathy in frontotemporal dementia. 2023 ,	0
74	RNA methylation influences TDP43 binding and disease pathogenesis in models of amyotrophic lateral sclerosis and frontotemporal dementia. 2023 ,	1
73	How Villains are Made: The Translation of Dipeptide Repeat Proteins in C9ORF72-ALS/FTD. 2023 , 147167	0
72	Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales. jnnp-2022-330152	0
71	Therapeutic reduction of GGGGCC repeat RNA levels by hnRNP A3 suppresses neurodegeneration in Drosophila models of C9orf72-linked ALS/FTD.	0
70	Acid sphingomyelinase inhibition improves motor behavioral deficits and neuronal loss in an amyotrophic lateral sclerosis mouse model. 2022 , 55, 621-626	1
69	CLIP-Seq Analysis Enables the Design of Ribosomal RNA Bait Oligonucleotides That Protect Against C9ORF72ALS/FTD-Associated Poly-GR Pathophysiology.	0
68	Genetic correlation and gene-based pleiotropy analysis for four major neurodegenerative diseases with summary statistics. 2022 ,	0
67	Stress granule homeostasis is modulated by TRIM21-mediated ubiquitination of G3BP1 and autophagy-dependent elimination of stress granules. 1-18	0

- 66 Deficiency of RAB39B Activates ER Stress-Induced Pro-apoptotic Pathway and Causes Mitochondrial Dysfunction and Oxidative Stress in Dopaminergic Neurons by Impairing Autophagy and Upregulating β -Synuclein. ○
- 65 Frequency of C9orf72 and SOD1 mutations in 302 sporadic ALS patients from three German ALS centers. 1-6 ○
- 64 G-Quadruplexes in Repeat Expansion Disorders. **2023**, 24, 2375 ○
- 63 RNAi in Cell Nuclei: Potential for a new layer of biological regulation and a new strategy for therapeutic discovery. rna.079500.122 ○
- 62 UPF1 From mRNA Degradation to Human Disorders. **2023**, 12, 419 ○
- 61 A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. ○
- 60 STING trafficking as a new dimension of immune signaling. **2023**, 220, ○
- 59 Why should we care about astrocytes in a motor neuron disease?. 3, ○
- 58 C9orf72 ALS mutation carriers show extensive cortical and subcortical damage compared to matched wild-type ALS patients. **2023**, 38, 103400 ○
- 57 Comprehensive genetic screening of early-onset dementia patients in an Austrian Cohort-Suggesting new disease-contributing genes. ○
- 56 Increased Risk of Aging-Related Neurodegenerative Disease after Traumatic Brain Injury. **2023**, 11, 1154 ○
- 55 Non-coding RNAs as key players in the neurodegenerative diseases: Multi-platform strategies and approaches for exploring the Genome's dark matter. **2023**, 129, 102236 ○
- 54 Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression. **2023**, 181, 106108 ○
- 53 Survival in Huntington's disease and other young-onset dementias. **2023**, 38, ○
- 52 Excitotoxicity and Amyotrophic Lateral Sclerosis. **2022**, 1789-1802 ○
- 51 SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS. **2023**, 30, 171-187.e14 ○
- 50 Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies. ○
- 49 Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids. **2023**, 19, e1010606 2

- 48 Structures and conformational dynamics of DNA minidumbbells in pyrimidine-rich repeats associated with neurodegenerative diseases. **2023**, 21, 1584-1592 ○
- 47 C9ORF72 repeat expansion is not associated with atypical parkinsonism in the Serbian population. **2022**, 54, 1313-1330 ○
- 46 The mTORC2/AKT/VCP axis is associated with quality control of the stalled translation of poly(GR) dipeptide repeats in C9-ALS/FTD. **2023**, 299, 102995 ○
- 45 The genetic basis of multiple system atrophy. **2023**, 21, ○
- 44 Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors. ○
- 43 C9orf72poly(PR) mediated neurodegeneration is associated with nucleolar stress. ○
- 42 Amino acid sensing and lysosomal signaling complexes. **2023**, 79, 102544 ○
- 41 In vivo analysis of aggregation propensity of low levels of mislocalized TDP-43 on cytopathological and behavioral phenotype of ALS/FTLD. **2023**, ○
- 40 Negative regulation of TREM2-mediated C9orf72 poly-GA clearance by the NLRP3 inflammasome. **2023**, 42, 112133 ○
- 39 The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?. 3, ○
- 38 C9orf72 expansions are the most common cause of genetic frontotemporal dementia in a Southeast Asian cohort. **2023**, 10, 568-578 ○
- 37 Genome-Wide Gene-Set Analysis Identifies Molecular Mechanisms Associated with ALS. **2023**, 24, 4021 ○
- 36 Oxidative Stress and Antioxidants in Neurodegenerative Disorders. **2023**, 12, 517 2
- 35 DNA-initiated epigenetic cascades driven by C9orf72 hexanucleotide repeat. **2023**, 111, 1205-1221.e9 ○
- 34 Loss of C9orf72 perturbs the Ran-GTPase gradient and nucleocytoplasmic transport, generating compositionally diverse Importin β granules. **2023**, 42, 112134 ○
- 33 NOTCH2NLC GGC repeats are not expanded in Italian amyotrophic lateral sclerosis patients. **2023**, 13, ○
- 32 Synaptic Dysfunction and Plasticity in Amyotrophic Lateral Sclerosis. **2023**, 24, 4613 ○
- 31 C9orf72 hexanucleotide repeat allele tagging SNPs: Associations with ALS risk and longevity. 14, ○

- 30 A cell-penetrant peptide blocking C9ORF72 -repeat RNA nuclear export reduces the neurotoxic effects of dipeptide repeat proteins. **2023**, 15, ○
- 29 Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation. **2023**, 11, 750 1
- 28 *Caenorhabditis elegans* as a Model System to Study Human Neurodegenerative Disorders. **2023**, 13, 478 ○
- 27 Zfp106 binds to G-quadruplex RNAs and inhibits RAN translation and formation of RNA foci caused by G4C2 repeats. ○
- 26 Diagnostic Uncertainties: Chorea. **2023**, 43, 065-080 ○
- 25 Aberrant phase separation is a common killing strategy of positively charged peptides in biology and human disease. ○
- 24 The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis. **2023**, 24, 5240 ○
- 23 Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. 11, ○
- 22 Messenger RNA Translation Defects in Neurodegenerative Diseases. **2023**, 388, 1015-1030 ○
- 21 Downregulation of Hsp90 and the antimicrobial peptide Mtk suppresses poly(GR)-induced neurotoxicity in C9ORF72-ALS/FTD. **2023**, ○
- 20 Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology. 17, ○
- 19 Differences in Cerebral Glucose Metabolism in ALS Patients with and without C9orf72 and SOD1 Mutations. **2023**, 12, 933 ○
- 18 Motor neuron disorders. **2013**, 555-565 ○
- 17 Lost in local translation: TDP-43 and FUS in axonal/neuromuscular junction maintenance and dysregulation in amyotrophic lateral sclerosis. **2023**, ○
- 16 Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis. **2023**, 12, 971 1
- 15 Disease-modifying pharmacological treatments for amyotrophic lateral sclerosis/motor neuron disease: an overview of intervention reviews. **2023**, 2023, ○
- 14 Neuronal biomolecular condensates and their implications in neurodegenerative diseases. 15, ○
- 13 Targeting the NEDP1 enzyme to ameliorate ALS phenotypes through stress granule disassembly. **2023**, 9, ○

- 12 C9orf72-linked arginine-rich dipeptide repeats aggravate pathological phase separation of G3BP1. ○
- 11 Inflammasome-Mediated Neuronal-Microglial Crosstalk: a Therapeutic Substrate for the Familial C9orf72 Variant of Frontotemporal Dementia/Amyotrophic Lateral Sclerosis. ○
- 10 Enhanced Degradation of Mutant C9ORF72-Derived Toxic Dipeptide Repeat Proteins by 20S Proteasome Activation Results in Restoration of Proteostasis and Neuroprotection. ○
- 9 Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. ○
- 8 C9ORF72 suppresses JAK-STAT mediated inflammation. **2023**, 26, 106579 ○
- 7 Understanding neural development and diseases using CRISPR screens in human pluripotent stem cell-derived cultures. 11, ○
- 6 Reduced C9orf72 expression exacerbates polyGR toxicity in patient iPSC-derived motor neurons and a Type I protein arginine methyltransferase inhibitor reduces that toxicity. 17, ○
- 5 C9ORF72 knockdown triggers FTD-like symptoms and cell pathology in mice. 17, ○
- 4 The DAXX tax: C9orf72 DNA repeat expansions drive gain- and loss-of-function pathology in c9FTD/ALS. **2023**, 111, 1165-1167 ○
- 3 Modulation of the gutBrain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis. 14, ○
- 2 Vector enabled CRISPR gene editing \square A revolutionary strategy for targeting the diversity of brain pathologies. **2023**, 487, 215172 ○
- 1 Reversing Dysdynamism to Interrupt Mitochondrial Degeneration in Amyotrophic Lateral Sclerosis. **2023**, 12, 1188 ○